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Each year approximately 600,000 and 2.2 million bone graft procedures are performed
worldwide with 600,000 of them performed only in the United States. With a high success rate of
osteo-integration and limited activation of the immune response, autografts are currently
considered the gold standard for bone grafting. However, autografts are limited by the volume of
bone tissue that can be harvested and by the threat of donor site morbidity. Allografts are
alternatives to autografts since they are available in nearly unlimited supply and avoid donor-site
morbidity and pain. However, allografts have been shown to be less frequently osteoinductive
than autografts due to lack of biological factors, i.e., cells, growth factors. Limited
vascularization, new bone formation and remodeling associated with large allograft healing are
directly associated with clinical failure due to non-unions, late graft fractures and infections.
The objective of this thesis is to increase the functionality and subsequent incorporation
of allograft into host bone by applying a thin polymeric coating to allografts that would be
capable of carrying and delivering growth factors with quantitative precision in hopes of
increasing the ability of allografts to heal large scale bone defects. It is hypothesized that loading
the dual growth factors, bone morphogenetic protein-2 (BMP-2 ) and vascular endothelial
growth factor (VEGF), onto a polymeric coating with two different techniques will result in short
term and long term delivery kinetics. We also hypothesized that dual sequential delivery of
BMP-2 and VEGF will show enhanced bone repair over BMP-2 delivered alone. We introduced
a thin coating of poly(lactide-co-glycolide) (PLGA), that has been used for orthopaedic and
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musculoskeletal applications, to functionalize rat femoral allografts. Allografts was coated and
loaded with BMP-2 and VEGF independently and simultaneously using two different loading
techniques, surface adsorption and encapsulation, each with distinct delivery kinetics. The rapid
release of VEGF stimulated osteoclastogenesis and the sustained release of BMP-2 encouraged
osteogenesis. The bioactivity of the growth factors, BMP-2 and VEGF was evaluated through
different bioassays using Human Mesenchymal Stem Cells (hMSCs) and Bone Marrow
Macrophages (BMMs), respectively. Healing of rat femoral segmental defect was assessed after
4 and 8 weeks to determine the effect of controlled release of VEGF and BMP-2.
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1. INTRODUCTION

1.1. Biology of Bone

Bone is a metabolically active and highly organized connective tissue which constitutes
an internal support for all higher vertebrates. The main functions of bone are: a) it is a major
organ for calcium homeostasis and a significant store of phosphate, magnesium, potassium, and
bicarbonate; b) bones provide mechanical support for the soft tissues; c) it provides protection of
internal vital organs; and d) bone is the major site of hematopoiesis in the human adult. By mass,
bone is 8% water, 22% protein, and 70% mineral [1]. The organic portion of bone is primarily
type I collagen while the inorganic portion is mainly calcium phosphate. Like other connective
tissues, the structural organization of bone is a robust ECM coupled with a relatively sparse
distribution of cells. Bone cells have the ability to form and deposit calcium phosphate within
their extracellular matrixes.

1.1.1. Overview and Structure of Bone

The adult human skeleton has about 213 bones, excluding the sesamoid bones. The
appendicular skeleton has 126 bones, axial skeleton 74 bones, and auditory ossicles six bones
[2]. Each bone constantly undergoes remodeling during life to help it adapt to changing
biomechanical forces, as well as remodeling to remove old, micro-damaged bone and replace it
with new, mechanically stronger bone to help preserve bone strength. Cells penetrate throughout
the mineralized tissue constantly facilitate new bone formation through the process of
apposition, in which cells deposit new matrix on existing bone surfaces that eventually becomes
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mineralized. At the same time, a distinctly different class of cell resorbs the old bone matrix to
make the way for the fresh bone.
The four general categories of bones are long bones, short bones, flat bones, and irregular
bones. Long bones include the clavicles, humeri, radii, ulnae, metacarpals, femurs, tibiae,
fibulae, metatarsals, and phalanges. Short bones include the carpal and tarsal bones, patellae, and
sesamoid bones. Flat bones include the skull, mandible, scapulae, sternum, and ribs. Irregular
bones include the vertebrae, sacrum, coccyx, and hyoid bone. The adult human skeleton is
composed of 80% cortical bone and 20% trabecular bone overall. Cortical bone, the outer, denser
envelope of most bones, plays a major role in the support function and trabecular or cancellous
bone, which is metabolically more active and is highly vascular and is responsible for blood cell
production.
The long bones are composed of a hollow shaft, or diaphysis; flared, cone-shaped
metaphyses below the growth plates; and rounded epiphyses above the growth plates (figure
1.1.1.1). The diaphysis is composed primarily of dense cortical bone, whereas the metaphysis
and epiphysis are composed of trabecular meshwork bone surrounded by a relatively thin shell of
dense cortical bone. The diaphysis contains the medullary cavity filled with bone marrow.
Cortical bone is a very dense material with 5% to 10% porosity. Trabecular bone, commonly
found in the end of long bones is highly porous with 50-90% porosity. The periosteum is a
fibrous connective tissue sheath that surrounds the outer cortical surface of bone, contains blood
vessels, nerve fibers, and osteoblasts and osteoclasts. Periosteum bone formation remains active
during our lifespan. In case of bone fracture, periosteum promotes formation of cartilaginous
callus, followed by ossification. It also provides vascular and nerve supply to bones and serves as
attachment sites for surrounding tendons and muscles. The endosteum is a membranous structure
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covering the inner surface of cortical bone, trabecular bone, and the blood vessel canals
(Volkman’s canals) present in bone. The endosteum is in contact with the bone marrow space,
trabecular bone, and blood vessel canals and contains blood vessels, osteoblasts, and osteoclasts.
Both cortical and trabecular bones are composed of osteons [3].

Figure 1.1.1.1 : Diagrams of cortical and trabecular bones in long bone and bone matrix arranged in the form of concentric rings,
lamellae, centered around Harversian canals to form osteons [3].

In cortical bone the osteons are known as Haversian systems. In cortical bone, 3-8 lamellae of
continuous collagen fibril (50-500 nm) arrange in a concentric manner around a central
harversian canal to form osteon or harversian systems. These canals are occupied by blood
vessels to supply nutrients.
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1.1.2. Bone cells and their functions

Mature bone tissue consists of three primary cell types: osteoblasts, osteocytes, and
osteoclasts (figure 1.1.2.1).

Figure 1.1.2.1: Bone cell types and organizations. Osteoblasts, osteoclasts and bone lining cells
reside on the surface of the bone whereas osteocytes are in the interior matrix of the bone.
Mesenchymal stem cells differentiate into osteoblasts whereas osteoclast stem from
hematopoietic cells [4].

Osteoblasts and osteoclasts are present on the surfaces of bone, while osteocytes permeate the
mineralized interior. Osteoblasts are fully differentiated bone cells, present on bone forming
surfaces and are responsible for synthesis and regulation of matrix mineralization. Osteocytes are
terminally differentiated osteoblasts that are incased by the mineralized matrix and support
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overall bone structure. Osteoclasts are large, multinucleated cells that are derived from different
cellular precursors (hematopoietic stem cells), and are responsible for bone resorption. Mature
bone cells, lacking the ability to divide and proliferate, are formed from proliferative
mesenchymal stem cells. During embryonic development, three germ layers are formed; the
ectoderm, the mesoderm, and the endoderm. The mesoderm is the middle germ layer consisting
of multipotent mesenchymal stem cells that eventually give rise to (among other things) the
entire vascular and lymphatic systems and all connective tissue. Several classes of mesodermderived stem cells exist and are distinguished according to the types of cells they may become.
Mesenchymal stem cells found in the bone marrow or periosteum are capable of being induced
to differentiate into osteoprogenitors that can then become osteoblasts, osteocytes, and bone
lining cells, whereas osteoclasts originate from the hematopoietic stem cells in blood [5].

1.1.2.1.

Osteoblast

Osteoblasts are cuboidal cells that are located along the bone surface comprising 4–6% of
the total resident bone cells and are largely known for their bone forming function. Osteoblasts
are derived from mesenchymal stem cells (MSC). The commitment of MSC towards the
osteoprogenitor lineage requires the expression of specific genes, following timely programmed
steps, including the synthesis of bone morphogenetic proteins (BMPs) and members of the
Wingless (Wnt) pathways. The expressions of Runt related transcription factors 2 (RUNX2),
Distal-less homeobox 5 (Dlx5), and osterix (Osx) are crucial for osteoblast differentiation.
Additionally, Runx2 is a master gene of osteoblast differentiation, as demonstrated by the fact
that Runx2-null mice are devoid of osteoblasts. Runx2 has demonstrated to upregulate
osteoblast-related genes such as ColIA1, ALP, BSP, BGLAP, and OCN. Once a pool of
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osteoblast progenitors expressing Runx2 and ColIA1 has been established during osteoblast
differentiation, there is a proliferation phase. In this phase, osteoblast progenitors show alkaline
phosphatase (ALP) activity, and are considered preosteoblasts. The transition of preosteoblasts to
mature osteoblasts is characterized by an increase in the expression of Osx and in the secretion of
bone matrix proteins such as osteocalcin (OCN), bone sialoprotein (BSP) I/II, and collagen type
I. Moreover, the osteoblasts undergo morphological changes, becoming large and cuboidal cells.
The synthesis of bone matrix by osteoblasts occurs in two main steps: deposition of organic
matrix and its subsequent mineralization. Osteoblasts are very rich in ALP, which participates in
the mineralization process. Osteoblasts deposit about ~0.5 μm of matrix per day and their
forming period lasts about 100 days [6-8]. Some of the osteoblasts are then entrapped within the
matrix which they formed and are called osteocytes; others become flattened cells on the surface
of the bone, and are called lining cells.

1.1.2.2.

Osteoclast

Osteoclasts are terminally differentiated multinucleated cells, which originate from
mononuclear cells of the hematopoietic stem cell lineage, under the influence of several factors.
Among these factors the macrophage colony-stimulating factor (M-CSF), secreted by
osteoprogenitor mesenchymal cells and osteoblasts, and RANK ligand, secreted by osteoblasts,
osteocytes, and stromal cells, are included. Together, these factors promote the activation of
transcription factors and gene expression in osteoclasts. M-CSF binds to its receptor (cFMS)
present in osteoclast precursors, which stimulates their proliferation and inhibits their apoptosis.
RANKL is a crucial factor for osteoclastogenesis and is expressed by osteoblasts, osteocytes, and
stromal cells. When it binds to its receptor RANK in osteoclast precursors, osteoclast formation
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is induced. On the other hand, another factor called osteoprotegerin (OPG), which is produced by
a wide range of cells including osteoblasts, stromal cells, and gingival and periodontal
fibroblasts, binds to RANKL, preventing the RANK/RANKL interaction and, consequently,
inhibiting the osteoclastogenesis. Thus, the RANKL/RANK/OPG system is a key mediator of
osteoclastogenesis. Parathyroid hormone (PTH) inhibits OPG and thus helps in enhancing
RANKL expression (Figure 1.1.2.2.1).

Figure 1.1.2.2.1: Mechanisms of osteoclast formation and bone resorption. Stromal cells and
osteoblasts express RANKL and M-CSF, which are up-regulated by osteoclastogenic molecules
such as PTH. RANKL and M-CSF, interacting with their receptors on monocyte/macrophage cells,
induce osteoclast formation. As these osteoclasts mature and form ruffled membrane, they
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acidifies an extracellular microenvironment. Cathepsin K, a lysosome protease cause the
degradation of demineralized organic matrix [9].
Osteoclasts are bone dissolving cells that carry out the resorption of mineralized tissue.
During bone resorption, osteoclasts attach to the active site of bone surface. They have two distinct
plasma membrane regions: a ruffled border where the active resorption occurs and a clear or
sealing zone that attaches the osteoclasts to the underlying matrix. Binding of osteoclasts to bone
matrix causes them to become polarized, with the bone resorbing surface developing a ruffled
border that forms when acidified vesicles that contain matrix metalloproteinases and cathepsin K
are transported via microtubules to fuse with the membrane. The ruffled border secretes H+ ions
via H+ -ATPase and chloride channels and causes exocytosis of cathepsin K and other enzymes in
the acidified vesicles. The sealing zone surrounds the ruffled border and forms the resorption
lacuna. In the sealing zone, the osteoclasts secrete hydrochloric acid to acidify and dissolve the
hydroxyapatite crystals which constitute the mineral portion of extracellular matrix. The matrix
degradation products ae removed from the resorption lacuna and transported into the extracellular
space through the basolateral membrane of the osteoclasts. It has recently been demonstrated that
the osteoclastogenic potential may differ depending on the bone site considered. It has been
reported that osteoclasts from long bone marrow are formed faster than in the jaw. This different
dynamic of osteoclastogenesis possibly could be, due to the cellular composition of the bone-site
specific marrow [10, 11].

1.1.2.3.

Osteocytes

Osteocytes, which comprise 90–95% of the total bone cells, are the most abundant and
long-lived cells, with a lifespan of up to 25 years [12, 13]. The morphology of embedded
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osteocytes differs depending on the bone type. For instance, osteocytes from trabecular bone are
more rounded than osteocytes from cortical bone, which display an elongated morphology.
Osteocytes are derived from MSCs lineage through osteoblast differentiation. In this process,
four recognizable stages have been proposed: osteoid-osteocyte, preosteocyte, young osteocyte,
and mature osteocyte. At the end of a bone formation cycle, a subpopulation of osteoblasts
becomes osteocytes incorporated into the bone matrix. Once the stage of mature osteocyte totally
entrapped within mineralized bone matrix is accomplished, several of the previously expressed
osteoblast markers such as OCN, BSPII, collagen type I, and ALP are downregulated. On the
other hand, osteocyte markers including dentine matrix protein 1 (DMP1) and sclerostin are
highly expressed. Within the matrix, osteocytes residing in lacunae provide the communication
network between adjacent osteocytes, osteoblasts and bone lining cells on the external surfaces
of bone by extending out processes within the canaliculi and establishing contact to adjacent
cells via gap junctions. Such an extensive network of canaliculi also allows the diffusion of
nutrients and metabolites through the mineralized matrix and blood vessels. Moreover, osteocyte
apoptosis has been recognized as a chemotactic signal to osteoclastic bone resorption. In
agreement, it has been shown that during bone resorption, apoptotic osteocytes are engulfed by
osteoclasts. In addition, osteocytes act as mechanosensors in bone. Osteocytes can sense and
signal transport functions and promote the translation of mechanical stimuli into biochemical
signals to initiate formation or resorption responses [14].

1.1.2.4.

Bone lining cells

Bone lining cells are thin, flat and elongated inactive cells that line with bone surfaces.
They are originated from osteoblasts but have fewer cytoplasm and organelles. Recent studies
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have shown that bone lining cells are able to communicate with the entrapped osteocytes and
contribute to the anchorage of hematopoietic stem cells and their subsequent differentiation into
osteoclasts. These lining cells secrete matrix metalloproteinase to remove the thin layer of
osteoid covering the bone matrix and aid in the attachment of osteoclasts to specific bind sites
and initiate bone resorption. After remodeling, a collagen layer is secreted by the bone lining
cells to cover the bone surfaces [12].

1.1.3. Bone Matrix and Markers

Bone matrix is composed of both organic (35%) and inorganic components
(65%). The inorganic material of bone consists predominantly of phosphate and calcium ions;
however, significant amounts of bicarbonate, sodium, potassium, citrate, magnesium, carbonate,
fluorite, zinc, barium, and strontium are also present. Calcium and phosphate ions nucleate to
form the hydroxyapatite crystals, which are represented by the chemical formula
Ca10(PO4)6(OH)2. Together with collagen, the non-collagenous matrix proteins form a scaffold
for hydroxyapatite deposition and such association is responsible for the typical stiffness and
resistance of bone tissue. The inorganic phase is comprised of 65% of the bone matrix and play
important roles in conferring compression resistance. The non-collagenous proteins contribute to
the regulation of hydroxyapatite crystal size, orientation and mineral deposition by binding to
calcium or releasing phosphate ion [16, 17,18].
The organic phase is primarily consisted of type I collagen (90% of organic phase). The noncollagenous proteins (10% of organic phase) include: glycoproteins (osteonectin, osteopontin,
bone morphogenetic proteins and bone sialoprotein), proteoglycans (hyaluronan, decorin,
biglycan and chondroitin sulfate) and a few protein with γ-carboxyglutamic acid (Gla)
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(osteocalcin). These proteins regulate the cell differentiation and matrix mineralization via
temporal and spatial expression. Figure 1.1.3.1 shows the cellular production of various
osteoblastic markers including calcium, osteocalcin (OCN), osteopontin (OPN), alkaline
phosphatase (ALP), and collagen type I (collagen I) relative to culture time and their effect on
osteoblastic differentiation, proliferation and matrix mineralization.

Figure 1.1.3.1: Expression of osteoblast markers shown relative to culture time and their
contribution in different phases of f bone matrix formation [15].
Osteopontin (OPN) is a secreted glycoprotein that was originally found in osteoblasts. It
is produced by a variety of cells, including preosteoblasts, osteoblasts, osteocytes, endothelial
cells, and macrophages, and its synthesis is stimulated by vitamin D3. The role of OPN in
mineralization process attributes to 1) inhibition on apatite formation and growth; 2) regulation
on the shape of hydroxyapatite crystal. It is also believed that OPN is important in recruiting
osteoclast precursors and binding them to the mineralized bone matrix.
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Osteocalcin (OCN) is a calcium-binding protein that is the most abundant noncollagenous protein in bone tissue. It is known to have a role in the process of bone
mineralization, during which it binds to calcium phosphate in the ECM of osteoblasts. It is
primarily synthesized during the matrix mineralization stage of osteoblastic development, but
may be marginally produced at earlier stages of matrix maturation. It has been suggested that
OCN acts as a chemoattractant for osteoblasts, osteoclasts, and blood monocytes. Most of an
organism’s OCN is localized within the bone cell matrices, however, when osteoblasts are
producing large amounts of OCN during the mineralization phase of osteoblastic development,
some OCN is also emitted into the blood. It is for this reason that serum levels of OCN are
considered to be indicative of new bone formation.
Alkaline phosphatase (ALP) is an enzyme that is associated with cell plasma membrane.
ALP is found in several other non-mineralized tissues including liver, kidney, intestine and
placenta. ALP gene expression generally begins when a cell transitions from the proliferative to
the matrix maturation stage, peaks during matrix maturation, and then decreases upon entrance
of the osteoblastic mineralization stage. The role of ALP in mineralization can be summarized:
1) ALP hydrolyzes phosphate ester and results in the increase of local phosphate concentrate
ultimately promoting bone mineral formation; 2)ALP hydrolyzes pyrophosphate, a calcification
inhibitor, into phosphate molecules; 3) ALP transfers phosphate groups from the extracellular
fluid and binds calcium to facilitate calcium phosphate precipitation [16,17].
Bone resorption markers include an enzyme, tartrate resistant acid phosphatase (TRAP),
and products of bone breakdown, which include calcium and bone matrix degradation products
such as hydroxyproline, pyridinium cross-links, and telopeptides [16].
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1.1.4. Bone Fracture and Repair

There are two different mechanisms of ossification in normal bone healing:
intramembranous and endochondral ossification. In either case, mesenchymal cellular
condensation first occurs and serves as a template for the subsequent bone formation.
Intramembranous bone formation involves mesenchymal progenitor cells differentiating directly
into osteoblasts, and the subsequent development of parts of the mandible and clavicle, and many
cranial bones. Most bones in the body (i.e., all long bones and vertebrae), however, are formed
through endochondral bone formation. This process involves mesenchymal progenitor cells first
differentiating into chondrocytes, which are responsible for depositing a cartilaginous template
that is later, mineralized and replaced by bone.
Fractured cortical bone is repaired by a callus formation mechanism, in which new bone
(callus) composed of fibrous tissue, blood vessels, cartilage, and bone forms in order to bridge
the gap between the two fractured bone fragments. This fracture healing process involves four
sequential stages: hematoma formation (inflammation), soft callus formation, hard callus
formation and bone remodeling (figure 1.1.4.1). These stages often overlap with each other
temporally [18,19].
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Figure 1.1.4.1: A four-stage model of fracture repair. (A) Histological images of fracture healing
showing soft callus is systematically remodeled; (B) Repair of fractures by callus production
occurs in four overlapping phases; (C) Cellular contribution to the fracture healing process
[18,19].

1.1.4.1.

Inflammation

The first stage of cortical bone healing is inflammation. Following the fracture, disruption
of blood vessels and normal vascular function causes the activation of non-specific wound
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healing pathways. The bleeding results in formation of hematoma between fractured fragments.
Degranulated platelets, macrophages, and other inflammatory cells (granulocytes, lymphocytes,
and monocytes) infiltrate the hematoma between the fractured fragments and combat infection,
secrete cytokines and growth factors, and advance clotting into a fibrinous thrombus. Over time,
capillaries grow into the clot, which is reorganized into granulation tissue. Macrophages, giant
cells and other phagocytic cells clear degenerated cells and other debris. Eventually, hemostasis
is achieved within the hematoma as platelets bind to the fibrillar collagen that forms throughout
the site. These platelets release various vasoactive mediators and growth factors in order to
influence cell migration, proliferation, and differentiation. New blood vessels are formed from
preexisting ones through the process of angiogenesis within the hematoma as inflammatory cells,
fibroblasts, and preosteoblasts are recruited by growth factors and cytokines that are released by
the inflammatory response. The increased cellular proliferation throughout the injury site is seen
within the first 8 hours of post injury and reaches its maximum around 24 hours. In the next few
days, the cellular activity subsides and confines to the fracture area. This stage can last up to a
month.

1.1.4.2.

Soft Callus Formation

The second stage of cortical bone healing is soft (or primary) callus formation, in which a
fibrocartilagous callus forms. In this stage, chondrocytes and fibroblasts produce a semi-rigid
soft callus that is able to provide mechanical support to the fracture, as well as act as a template
for the bony callus that will later supersede it. The growth of the separated cartilaginous regions
continues until they unite to generate a big fibrocartilaginous callus bridging the fracture.
Finally, chondrocytes become hypertrophic and mineralize the cartilaginous matrix. At the same
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time, intramembranous ossification occurs at the periosteum and an external callus is created
along the periphery of the fracture.

1.1.4.3.

Hard Callus Formation

This stage of bone healing is also known as primary bone formation stage, which is the
most active osteogenesis period. It is characterized by high levels of osteoblast activity and the
formation of mineralized bone matrix, which arises directly in the peripheral callus. In order for
bridging new hard callus to form, the insecure soft callus is gradually removed, followed by
revascularization. The new bone is known as the hard callus and it is typically irregular and
under-remodeled. However, it has an increased diameter compared to the original cortex and
thus provides sufficient stability to the defect site. In summary, the primary bone formation
phase displays the most rapid osteogenesis, involving (1) bone cell recruitment and woven bone
formation; (2) chondrocyte apoptosis, osteoclast recruitment, and mineralized cartilage
resorption; and (3) continued neo-angiogenesis.

1.1.4.4.

Bone Remodeling

In the final stage of bone remodeling (over 12 weeks), the woven bone hard callus is
gradually remodeled to lamellar bone and the size of the callus is decreased to that of preexisting bone. During this renewal process small pockets of old bone are replaced by new bone.
It has been estimated that in humans, as much as 25% of trabecular bone and 3% of cortical bone
is resorbed and replaced each year [20]. A remodeling site is initiated by the appearance of
osteoclasts (and precursors) following any of several humoral or local stimuli to resorption. The
osteoclasts proceed to resorb an amount of bone which produces a small resorption pit
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(Howship’s lacuna), following which, they move to another site. This resorptive phase is
followed by an active reversal phase when the cement line is deposited. During the subsequent
formative phase, actively synthesizing cuboidal osteoblasts appear and begin to deposit
uncalcified matrix (osteoid) which is later mineralized. Resorption and formation always occur
successively in the same location and always in the same order [21]. This sequence of resorption
and formation has been referred to as a basic multicellular unit of bone turnover (BMU) as
illustrated in figure 1.1.4.4.1. The process of bone resorption followed by an equal amount of
formation has been termed coupling. This remodeling phase may take 3 months to several years
to complete [20].

Figure 1.1.4.4.1: The remodeling cycle in bone. Representation of Bone Multicellular Units
(BMUs) showing the various stages of cellular activity including resorption of old bone by
osteoclasts and the subsequent formation of new bone by osteoblasts. For simplicity of
illustration, the cartoon shows remodeling in only two dimensions, whereas in vivo it occurs in
three dimensions, with osteoclasts continuing to enlarge the cavity at one end and osteoblasts
beginning to fill it in at the other end [22].
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1.2. Growth Factors Associated with Healing Process

A cell receives information from a growth factor through the binding of the factor to its
receptor, which is integrated in the cell’s plasma membrane. Each factor is associated with a
specific receptor to which it binds with a high affinity in order to stimulate an intercellular
response. The signal from the factor-binding may be transmitted to the cell in several different
ways, depending on the specific factor-receptor pair. Many growth factors have been purified
and their amino acids sequenced, enabling researchers to isolate the corresponding human
cDNA. With the cDNA sequences, it is possible to achieve recombinant growth factor
expression in pharmaceutical amounts.
As discussed in the previous section bone healing is a very intricate phenomenon that
involves many different steps and components throughout its process. Following a fracture, a
blood clot is formed at the injury site, causing platelets to release granules to transform the clot
into a hematoma. The ECM created allows for inflammatory cells such as neutrophils,
monocytes, and lymphocytes to access the hematoma. Along with these inflammatory cells,
mesenchymal stem cells (MSC’s) are recruited within a couple hours of the fracture. This
cellular response is coordinated by and involves the secretion of a range of cytokines and growth
factors including transforming growth factor-β(TGF-β), platelet-derived growth factor (PDGF),
fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), macrophage
colony stimulating factor (MCSF), interleukins-1 and -6 (IL-1 and -6), bone morphogenetic
proteins (BMPs), and tumor necrosis factor-α(TNF-α). These factors facilitate the recruitment of
additional inflammatory cells in a positive feedback loop, and also the migration and invasion of
multipotent mesenchymal stem cells. In the second stage of healing, the differentiation of these
MSC’s into chondrocytes causes the formation of cartilage. Fibroblast proliferation and
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chondrocyte proliferation/ differentiation are stimulated by the coordinated expression of growth
factors including TGF-β2 and -β3, PDGF, fibroblast growth factor-1 (FGF-1), and insulin-like
growth factor (IGF). Additionally, members of the BMP family assist in promoting cell
proliferation and chondrogenesis. Invasion of the soft callus by vascular endothelial cells,
angiogenesis, and capillary in-growth is stimulated by pro-angiogenic factors including VEGF,
BMPs, FGF-1 and TGF-β. In addition, angiopoietin I and II regulate vascular morphogenesis of
larger vessels and development of collateral branches from existent vessels. In the primary bone
phase formation, there’s an increase in TNF-α, receptor activator of nuclear factor kappa B
ligand (RANKL) and macrophage colony-stimulating factor (MCSF), associated with
mineralized cartilage resorption, the recruitment of mesenchymal stem cells and induces
apoptosis of hypertrophic chondrocytes. Activity of BMP-3, BMP-4, BMP-7, and BMP-8
increase in association with the resorption of calcified cartilage and promote recruitment of cells
in the osteoblastic lineage. VEGFs are upregulated to stimulate neo-angiogenesis. In the
remodeling phase, osteoblasts and osteoclasts work in combination to create secondary bone and
through the process of remodeling restore the bone to its original size, shape, and structure.
During this stage the activity of IL-1 and IL-6 increase, whereas RANKL, MCSF, and TGF-β
activity slowly diminish. This cascade of events is caused by the presence and activation of
different growth factors and cytokines at specific time points. A list of the major growth factors
during the different stages of bone healing is shown in table 1.2.1 [23, 24]:
Table 1.2.1: Growth factors associated with fracture healing [23, 24]
Cytokines/Growth

Bone healing stages

Overall action

Factors


IL-1, 6



1.Inflammation
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Hematoma



TNFα



Inflammation



PDGFs



MSCs recruitment



GDF-8



RANKL, M-



Chondrogenesis



Endochondral

CSF


OPG



VEGFs

2.Soft callus



BMPs

(fibrocartilagous



TGFβs

callus) Formation



Angiopoietin



FGF-I

precursors



IGF

recruitment



ossification




VEGFs

3.Cartilage resorption



BMP-2, 7

and primary bone



RANKL and M-

formation



Vascular ingrowth



New angiogenesis



Chondrocyte
apoptosis

CSF




Osteoblast/Osteoclast



Cartilage resorption



Osteoblast/Osteoclast
precursors

Angiopoietin

differentiation


Woven bone
formation
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IL-1, IL-6

4.Secondary bone



RANKL and MCSF





Bone remodeling

formation and



Osteoblast activity

remodeling



Marrow
establishment

1.2.1. Bone Morphogenetic Protein-2 (BMP-2)
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor β
(TGFβ) family. They are involved in numerous mechanisms of organogenesis, notably in
skeletogenesis. Thus far, around 20 different proteins have been named BMP in humans, but not
all members are truly osteogenic. The bone-inducing BMPs can be divided into several
subgroups, according to homology of their amino acid sequences. BMP-2 and BMP-4 comprise
one subgroup; the second group consists of BMP-5, BMP-6, BMP-7 and BMP-8, while BMP-9
and BMP-10 form the third osteogenic group. The other members of the BMP family do not
possess osteogenic properties. BMP-1 is actually a metalloprotease and not a member of the
superfamily, whereas BMP-3 and BMP-13 function as BMP antagonists/inhibitors rather than as
BMPs [25]. In bone, BMPs are produced by osteoprogenitor cells, osteoblasts, chondrocytes and
platelets. After their release, the extracellular matrix functions as a temporary storage for BMPs.
The regulatory effects of BMPs depend upon the target cell type, its differentiation stage, the
local concentration of BMPs, as well as the interactions with other secreted proteins. BMPs
induce a sequential cascade of events leading to chondrogenesis, osteogenesis, angiogenesis and
controlled synthesis of extracellular matrix. Of all BMPs, BMP-2 is essential for fracture healing.
The BMP-2 signal transduction pathway is complex, but in brief, once BMP-2 has bound to its
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receptor complex, a signaling cascade is activated in which the Type II receptor kinase
phosphorylates the Type I receptor, which then phosphorylates the intracytoplasmic signaling
molecules, Smads 1, 5, and 8. Smads 1, 5, and 8 bind to Smad 4 and then translocate into the
nucleus of the cell to activate transcriptional factors for certain osteoblastic genes [26]. Activated
transcription factors enhance the expression of the osteoblastic mRNA and ultimately lead to
increased production of proteins such as osteocalcin and alkaline phosphatase required for
osteoblastic phenotype development, bone remodeling and mineralization. BMP-2 has shown
strong osteoinductive activity both in vitro and in vivo. In vitro effects of BMPs are observed at
very low dosages (5-20 ng/mL). Normal bone has been estimated to contain about 0.002 mg of
BMP per kilogram of pulverized bone. However, current commercially available rhBMPs are
used in large dosages (up to 40 mg of some products), probably because of their intense
proteolytic consumption during the early stages of post-surgical repair, especially for orthopedic
spinal fusion procedures [27]. Animal studies have shown a half-life of 7-16 min systemically,
and up to 8 days locally when implanted on a collagen sponge [28]. The possible negative side
effects for patients due these high doses of BMP-2 may result in vertebral osteolysis, ectopic
bone formation, radiculitis and cervical soft tissue swelling [30].

1.2.2. Vascular Endothelial Growth Factor (VEGF)

Vascular endothelial growth factor (VEGF) is a potent mitogen, which increases the
number of capillaries in a given network and is essential for angiogenesis, the mechanism to
remodel initial vascular network. VEGF acts as a chemotactic factor for the proliferation of
endothelial cells. Under hypoxic conditions, VEGF is upregulated by HIF-1, which stimulates
vessel permeability, proliferation/survival, migration and differentiation into mature blood
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vessels [30, 31]. It is well known that VEGF is required for effective coupling of angiogenesis to
endochondral and membranous bone formation during skeletal development. VEGF plays
significant role in osteoblast functionality. Studies have shown that VEGF has dose-dependent
chemoattractive effect on primary human osteoblasts and human mesenchymal progenitor cells.
Human-derived mesenchymal cells express VEGF and VEGFR-1, a VEGF receptor, during their
differentiation and VEGF increases ALP activity in primary human osteoblastic cells [32, 33]. In
endochondral ossification, an essential process for formation and growth of long bones, VEGF is
responsible for regulating blood vessel invasion (neovascularization) into hypertrophic cartilage.
The entering blood vessels bring undifferentiated mesenchymal cells into the mineralization
front and later differentiate into osteoblasts and engage in osteogenesis. VEGF also plays a vital
role in osteoclast differentiation and bone resorption. Studies showed that VEGF can directly
enhance osteoclastic bone resorption. Nakagawa et al., demonstrated VEGF caused a dose- and
time-dependent increase in the area of bone resorption pits excavated by the purified rabbit
mature osteoclast. They detected two distinct VEGF receptors, KDR/Flk- 1 and Flt-1, in
osteoclasts at the gene and protein levels, and VEGF induced tyrosine phosphorylation of
proteins in osteoclasts. Thus, osteoclastic function and angiogenesis are upregulated by a
common mediator, VEGF [34]. Yang et al. also reported that VEGF regulates survival of mature
osteoclasts via VEGFR-2 signaling [35]. Liu et al. showed in a recent in vivo study with mutant
mice that VEGF can stimulate osteoclast differentiation [36]. They suggested VEGF stimulates
osteoclast formation in a paracrine mechanism. Helmrich et al. investigated a cell-based gene
therapy approach to generate osteogenic grafts with an increased vascularization potential in an
ectopic nude rat model in vivo. The study showed that the expression VEGF in the defect site not
only improved vascularization but also increased the recruitment of the TRAP and Cathepsin K23

positive osteoclasts [37]. Henriksen et al. conducted a combination of ex vivo bone culture and
in vitro cell migration assays to study the role of Receptor activator of nuclear factor kappa-B
ligand (RANKL) and VEGF in osteoclast recruitment through chemotactic properties during
bone regeneration. Results demonstrated that RANKL and VEGF stimulate osteoclast
recruitment and induce bone resorption through a signaling pathway different from M-CSF, a
well characterized chemoattractant for osteoclasts. Addition of the antagonists of RANKL and
VEGF led to reduced recruitment of osteoclasts in ex vivo cultures of embryonic bones [38].
When introduced intravenously, VEGF has a half-life of less than 30 minutes, requiring many
doses or massive amounts of growth factor, which can lead to detrimental vessel formation in
non-target areas [39]. It is essential to deliver the proper dosage of the growth factor to grow
quality neo-vasculature.

1.3. Bone Grafts and bone graft substitutes

A bone graft is surgery to place new bone or bone substitutes into spaces around a broken
bone or bone defects. Currently, the United States, as well as other countries worldwide, are
experiencing an exceedingly high demand for functional bone grafts, as the statistics have risen
above half a million recipient patients and costing over $2.5 billion annually in the United States.
This figure not only doubles on a global basis, but is also expected to double by 2020 due to a
variety of factors, including the growing baby boomer population and increased life expectancy
[40]. Bone grafts are utilized in a wide array of clinical settings to augment bone repair and
regeneration. There are four broad clinical situations in which bone grafting is performed: (1) to
stimulate healing of fractures, either fresh fractures or fractures that have failed to heal after an
initial treatment attempt; (2) to stimulate healing between two bones across a diseased joint. This
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situation is called “arthrodesis” or “fusion”; (3) to regenerate bone which is lost or missing as a
result of trauma, infection, or disease. Settings requiring reconstruction or repair of missing bone
can vary from filling small cavities to replacing large segments of bone up to 12 inches in length;
(4) to improve the bone healing response and regeneration of bone tissue around surgically
implanted devices, such as artificial joints replacements (e.g. total hip replacement or total knee
replacement) or plates and screws used to hold bone alignment [41]. Autografts are considered as
the gold standard for bone graft procedure as they contain osteogenic bone cells, marrow cells,
and an osteoconductive collagen matrix suitable for new and existing bone cell attachment and
migration, as well as osteoinductive proteins and factors endogenous to bone. However, the
autograft requires a second surgery at the tissue harvest site, which increases post-operative pain
and the possibility of surgical complications at the site. The best alternative to autograft is
allograft, tissue taken from a donor or cadaver. Although secondary surgery or donor site
morbidity is less of a problem, there is a minimal but real risk of disease transmission from donor
to recipient with allografts [42, 43], and there have been reports of additional allograft-associated
complications in which as many as 30%-60% of allograft implants encounter some complication
when evaluated at the 10-year mark. Bone graft substitutes have been proposed as alternatives to
allografts but they have also shown limited tissue ingrowth. Traditional scaffold design supports
bone formation through intramembranous ossification with limited to no vascularization leading
to graft core necrosis and, thus, poor bone formation. Therefore there is a need to develop a
biocompatible scaffold that (i) closely mimics the natural bone extracellular matrix niche, (ii)
recruit osteogenic cells to lay down the bone tissue matrix, (iii) contain morphogenic signals to
help direct the cells to the phenotypically desirable type, and (iv) allow sufficient vascularization
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to meet the growing tissue nutrient supply and clearance needs. Table 1.3.1 demonstrates various
bone grafts and graft substitutes and their advantages and limitations [44].
Table 1.3.1: List of graft options for bone repair [44]
Bone Graft

Structural
Strength

Osteoconduction

Osteoinduction

Osteogenesis

+++
++

+++
++

+++
++

No
+++

++
+

+
+

No
No

No

+

+

No

+
No
+++
No
+

++
+
++
+
++

No
No
No
+
++

No
No
No
+
++

+

++

No

+

Autograft
Cancellous
Cortical

No
+++
Allograft

Cancellous
Cortical
De-mineralized Bone Matrix
(DBM)

Bone graft substitutes
Coralline HA
Collagen-based matrices
Calcium phosphate
Calcium sulfate
Bioactive silicate
Biodegradable Polymers (e.g.,
PLGA)

1.3.1. Autograft

Autografts are currently the gold standard method of bone grafting in which the donor
tissue is harvested from the recipient’s own body. As autografts intrinsically possess optimal
biocompatibility, three-dimensional pore structure, and biological components, they represent the
most ideal bone grafting option and boast an 80-90% success rate. In short, the autograft
possesses all the requirements for an ideal bone substitute; osteoconductivity, osteogenicity, and
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osteoinductivity. However, although the grafted tissue may be optimal at the defect site, the
threat of donor-site morbidity and the limited supply of donor tissue impose restrictions on
autograft procedures. In fact, there are relatively few bones in the human body that can be
harvested without incurring significant morbidity, for example the iliac crest, rib, and fibula. A
retrospective study by Silber et al followed the healing of 187 patients who had undergone
autologous anterior iliac crest bone graft harvest for anterior cervical discectomy and fusion
procedures, all of which were performed by the same surgeon. Patients were interviewed an
average of 48 months post-surgery, and reported that although there was a 92.5% degree of
satisfaction with the cosmetic result, 26.1% of the patients reported pain at the donor site [45].
Recovery time depends on the injury or defect being treated and the size of the bone graft.
Patient recovery may take 2 weeks to 3 months. The bone graft itself will take up to 3 months or
longer to heal.

1.3.2. Allograft

Allograft procedures, in which the grafting tissue is harvested from a cadaver, are
common alternatives to autografts. The advantages of using structural allografts are: (1) the
patient does not have to donate the bone graft, so the surgery is shorter, and there may be less
postoperative pain (2) biologic constructs (3) mechanically strong (e.g., cortical allograft) (3)
simple to use; grafts can be customized in operating room (4) easily available and inexpensive
(vs. synthetic spinal devices) (5) easy radiographic fusion assessment (vs. radiopaque devices).
Allograft, removed from organ donor is usually kept in bone banks. The bone bank follows
procedures intended to sterilize the bone graft and perform tests on the bone for diseases such as
hepatitis and AIDS. The earliest collections of allograft tissue, or bone banks, were established in
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the beginning of the 20th century when Bauer refrigerated bone samples for 3 weeks and then
implanted them in dogs [44]. Allografts were prepared for storage at this point by chilling or
heating, but it was soon determined that boiling the bone samples rendered them inferior in
healing to autografts because the endogenous proteins and factors were undoubtedly destroyed
during heating. The big leap forward in bone banking came during World War II when new
methods of bone storage preparation were studied, including freezing, freeze-drying,
deproteinating, irradiating, autoclaving, demineralizing, and chemically treating the harvested
bone [46]. The challenge that exists with allografts is to ensure their sterility while imparting
appropriate biologic and biomechanical properties to the defect. In order to provide disease-free
bone grafts that will not elicit an immune response in the host, the donor tissue must be
processed with treatment solutions and/or radiation methods in order to remove cellular and viral
components. As a result of sterilization process allograft, void of osteoinductive components
show decreased revascularization and graft incorporation. Therefore, an allograft does not
always heal as well or as quickly as an autograft. In addition to the loss of osteoinductivity,
processing techniques may also alter the mechanical properties of the allograft. Studies have
shown the compressive modulus of allographic bone to decrease by 30% after undergoing
lyophilization and 10-20% after exposure to gamma radiation [47]. The allograft also carries a
risk of transferring infectious diseases, although it is rigidly tested.
Demineralized bone matrix (DBM) is a commonly used allographic form in which
donated tissue is morcellized and exposed to a demineralizing agent such as hydrochloric acid in
order to remove the mineral content of the bone. This process makes DBM much safer than
mineralized allographic tissue, which is more likely to retain viral components in the intact blood
spaces such as the marrow and blood vessels. After the decalcification step, all blood elements
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are removed from the DBM with subsequent treatment solutions. Depending on the type of
demineralizing agent used, DBM has the potential to retain osteoinductive properties from native
extracellular matrix that induce cellular differentiation. Morcellized allograft tissue and
demineralized allograft tissue (demineralized bone matrix or DBM) have demonstrated better or
faster incorporation than intact large allograft bone but neither of these tissue types is loadbearing, considerably reducing their indications and applications [48].

1.3.3. Bone Graft Substitutes

Synthetic bone graft substitutes offer alternative grafting methods that avoid the
difficulties associated with conventional autografts and allografts. A variety of commercial
implants approved by the U.S. Food and Drug Administration are currently available for clinical
use. Materials used to construct synthetic bone grafts range from natural (collagen) and synthetic
(poly(lactide-co-glycolide)) polymers to ceramics such as calcium phosphates and sulfates and
may be used alone or in combination. Although synthetic bone graft options offer virtually
unlimited supply and minimal disease transmission possibilities, they do not incorporate every
component of the ideal autologous bone graft. A list of commercially available bone grafts is
shown in table 1.3.3.1 [49].
Table 1.3.3.1: List of bone graft substitutes that are commercially available [49]

Company

DePuy Spine

Commercially
available
product
HEALOS®

Composition

Commercially
available form

Claimed mechanisms of
action

Mineralized
collagen matrix

Variety of strip
sizes

• Osteoconduction
• Creeping substitution
• Osteoinduction
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• Osteogenesis when
mixed
with bone marrow
aspirate
DBM suspended
in a
hydrogel carrier
Optecure®

Integra
Orthobiologics

Integra
MozaikTM

80% highly
purified
b-TCP/
20% highly
purified Type-1
collagen

Dry mix kit
delivered
with buffered
saline

Strip and putty

INFUSE®
Bone Graft

on an absorbable

NovaBone

Biomet
Osteobiologics

Synthes

Stryker Biotech

NovaBone®

ProOsteon®
500R

Calceon® 6

OP-1®
Implant

Multiple kit
sizes

collagen sponge

Bioactive silicate

Coralline-derived

Particulate,
putty and
Morsels
Granular or
block

HA/CC
composite
Calcium sulfate
rhBMP-7 with
Type-1
bone collagen
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• Bioresorbable
• Osteoinduction
• Osteogenesis when
mixed with autogenous
bone graft
• Osteoconduction
• Bioresorbable

• Bioresorbable carrier

rhBMP-2 protein
Medtronic Spinal
& Biologics

• Osteoconduction

• Osteoinduction
• Chemotaxis of
stem cells; indirect
Osteogenesis
• Osteoconduction
• Bioresorbable
• Osteostimulation
• Osteoconduction
• Bioresorbable
• Osteoconduction

Pellets
Lyophilized
powder
reconstituted
with
saline to form
wet
sand-like
consistency

• Bioresorbable
• Bioresorbable scaffold
• Osteoinduction

1.3.4. Challenges Associated with Allograft Healing

Massive bone allografts have been used primarily for limb salvage in orthopaedic
oncology and remain an option for reconstructing large bony defects. The primary function of
the structural allograft is to provide immediate structural support. Implanted bone allograft can
transmit disease, therefore, safety is a prime consideration in the use of allograft transplant. It is
reported that fresh allograft can be immunogenic. From least to most immunogenic, rank order
is, freeze-dried allograft, fresh- frozen allografts, fresh non vascularized allograft and fresh
vascularized allograft. It is necessary to inactivate and remove any harmful agents from the bone
to reduce the risk of disease transmission, since only unprocessed, fresh-frozen allografts have
been documented as sources of viral infection in recipients of bone grafts. Procedures designed
to ensure the supply of safe bone include guidelines on donor selection, tissue quarantine and
tissue processing. Long bones are procured under sterile conditions in the operating theatre after
organ ex-plantation. The mechanical properties of the bone are excellent as the donors are young.
Bone allograft tissue can be processed under strict aseptic conditions or be sterilized at the final
stage, usually with irradiation. Some of the processing techniques include demineralization,
freeze- drying, fresh- freezing, cryopreservation, and sterilization. Ethanol, acetone and ether are
often used, as they have been shown to inactivate coated viruses such as HIV and the hepatitis
viruses [50]. Large intact allograft are usually procured sterile from organ donors and stored at 80˚C. All these tissue processing steps eliminates cellular and viral components, growth factors
and proteins that were present in the native allograft tissue. As a result, the graft become very
desirable for immunity but undesirable for bone repair. The graft completely loses its ability to
make bone because of the absence of viable osteogenic cells.
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An allograft serve primarily as a spacer that allows osteoconduction of the host cells into
its mass, resulting in progressive incorporation of the graft into the host bone. Five-year followup studies have demonstrated substantial concerns with allograft incorporation into host bone
particularly with intact allograft tissue [51, 52]. Incorporation is a series of events leading to
gradual replacement of the old necrotic bone by living new bone as a result of creeping
substitution, a mechanism of osteoclastic resorption followed by deposition of new bone. A bone
graft is considered to be incorporated when there is no abrupt histological change between the
host bone and the graft. Stevenson et al defined successful incorporation as the graft uniting with
the host, with the graft-host bone construct able to tolerate physiological loads without fracture
or pain. From the perspective of basic science, the complete incorporation is defined as rapid
vascularization and substitution of original graft bone with new host bone without substantial
loss of strength. The process of bone graft incorporation involves an initial hemorrhage and
hematoma within and around the graft that serves to nourish the graft until distinct capillaries
and vasculature develops. With the initial injury from surgery, there is an inflammatory response,
resulting in granulation tissue ingrowth into the graft. This process of tissue ingrowth will serve
to revascularize the tissue and bring osteoprogenitor cells into the graft. Once revascularization is
complete, viable cells within the graft and the recipient osteoprogenitor cells will begin to resorb
the old bone and form new bone via creeping substitution [53]. After new bone is formed, it is
mineralized and remodeled. In cortical bone, or cortical-cancellous grafts for that matter, the
revascularization and resorption process follows along peripheral haversian canals. Unlike
cancellous grafts that incorporate by creeping substitution initiated by osteoblasts, cortical graft
incorporation is initiated by osteoclast resorption in a process often called reverse creeping
substitution. Extensive resorption occurs as early as 2 weeks and increases up to 6 weeks,
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resulting in relative weakness that can persist for 6 to 12 months [54]. Incorporation of the
cortical bone begins at the graft/recipient junction and proceeds to the center of the graft.
However, this intricate process of incorporation is very limited in large segmental allograft and
there remains a final bulk of dead bone that has been poorly substituted by new bone. Efforts
have been made to overcome this limited substitution by improving the revascularisation of the
bone via perforation and the introduction of stem cells and growth factors. Despite this, no major
progress in clinical series using massive allografts has been accomplished so far. This reduced
incorporation has secondary manifestations that influence the overall healing capacity of the
defect site such as poor mechanical integrity at the interface, poor mechanical properties of the
allograft. Intact allografts exhibit limited creeping substitution, delayed non-union of the host
allograft/implant interface, bone callus bridging of the allograft/implant segment, and limited
bone remodeling with increased frequency of fatigue fracture. Each secondary manifestation may
lead to failure of the structural allograft and does so as often as 60% of the time according to ten
year follow-up studies [55]. Cortical allografts remain significantly weaker than cortical
autografts for considerable time after surgery. Given enough time and a weight bearing, stable
construct, most segmental cortical allografts eventually resemble autografts biomechanically and
structurally, although significantly more un-remodeled necrotic bone remain present in
allografts. In autograft healing, both graft and host bones contribute toward healing whereas,
large allografts do not contain living cells, therefore, graft incorporation relies only on host cells
and tissues. In summary the complications associated with intact allograft healing are: (1)
inadequate vascularization; (2) micro-fractures occur in graft areas in which no bony apposition
is found and in areas of bone without subchondral resorption; (3) lack of creeping substitution,
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osteoclastic resorption of dead bone from the allograft and its replacement by new living bone
made by osteoblasts from the host.

1.4. Bone Tissue Engineering

Tissue engineering (TE) aims to replace or facilitate the regrowth of damaged or diseased
tissue by utilizing biomaterials, cells, and bioactive molecules alone or in combination with one
another. The need for TE stems from the limited availability of autologous tissue and the potential
for immunorejection of allogeneic sources and is bolstered by the numerous and growing
availability of advanced material fabrication methods of novel biocompatible biomaterials. The
strategies involved in designing and building engineered scaffolds are diverse but often focus on
the biomaterial as a synthetic extracellular environment to organize cells into a three-dimensional
architecture and to present stimuli that can direct the growth and formation of a desired tissue. The
promise of TE would empower scientists to grow tissues and organs in the laboratory and safely
implant them when the host body is incapable of self-healing. This possibly offers an alternative
to organ transplantation, which, although an important clinical tool, has its limitations. The goals
of TE integrate so well with the goals of regenerative medicine that as each field progresses, the
distinction between them becomes ever less clear.
Recently, a new field has evolved that seeks to unite TE and regenerative medicine with
an additional focus on the integration of stem cells, developmental biology, and advanced materials
science. This field, termed ‘regenerative engineering’, seeks to integrate these fields in pursuit of
the current clinical challenge of complex tissue regeneration where more than one tissue type,
often in direct proximity to another distinct tissue type, is regenerated [56]. The complexity of
regenerating neighboring tissues with distinct structural and chemical requirements cannot be
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underestimated, and mandates a renewed focus on these specific challenges. Regenerative
engineering seeks to build on what has been accomplished thus far in TE and regenerative
medicine, and move the field forward towards true clinical implementation.
A key moment in organ transplant history was in 1954 with the first successful kidney
transplant. Development in the field continued into the 1960s with successful pancreas–kidney,
liver, and later in the 1980s with heart–lung, single lung, double lung, and living-donor liver
transplants [57]. Despite the utility of organ transplantation there is a real mismatch in supply and
demand in respect of organs and tissues available for transplantation. Data published by United
Network for Organ Sharing (UNOS) listed only 11,579 people receiving transplants from January
2013 to May 2013, while 76,223 people were recorded as waiting-list candidates (Figure 1.4.1)
[126]. While the simple hope of TE is that discrepancies like this would be obviated, its potential
full impact is far broader than this: in addition to reducing the need for organ replacement TE, and
now with advanced biomaterials science, developmental biology, and a focus on stem cell
integration, regenerative engineering could, for instance, greatly accelerate the development of
new drug delivery systems that may reduce the need for transplantation through novel drug
delivery applications and other novel treatments.
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Figure 1.4.1: UNOS organ transplant statistics for 2002 to 2012 [126].

TE approach involves three main components: biomaterials to form a substrate onto which
cells and biological molecules can reside; proteins and/or peptides that function to influence cell
behavior; and, the cells to build the tissue (Figure 1.4.2). Designing the substrate or scaffold (the
first of the three components) onto which new tissue may grow has become a critical part of the
development process. Although some scaffolds simply involve the injection of a material into the
defect site, those that are designed to provide structural support with a specific architecture require
additional preparation prior to implantation. For instance, often the tissue engineer chooses to
incorporate biological molecules (the second of the three components) like growth factors or
peptides into the scaffold to control proliferation and/or differentiation of progenitor cells to
increase the rate of tissue healing. The choice of cells (the third component) that are seeded onto
the scaffold to supplement the process of cell migration from the host and therefore accelerate the
overall tissue formation can greatly influence the success of the overall repair. These three
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components – the design of the scaffolds, the use of growth factors and other biological molecules,
and the cells chosen to seed onto the scaffold – are reviewed in depth below. This is not meant as
an exhaustive survey of the field as that is beyond the scope of this chapter, but an update on select
approaches to tissue regeneration. It will be noted that these three components exist neither alone
nor always in combination toward whole tissue regeneration, but rather as a combination of one,
two, or three elements.

Figure 1.4.2: Tissue engineering paradigm. Cells isolated from donor/source.; seed cells in
combination with appropriate growth factors onto scaffold; implant the engineered scaffold in
the defect site [126].

Natural biomaterials are widely available in nature and derived from natural sources,
mostly from plants, animals, and microorganisms. Recent research has been focused on
polysaccharide-derived polymers such as chitin and chitosan, hyaluronic acid (HA), alginate,
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starch, and cellulose-based polymers for the development of scaffolds for bone, cartilage, and skin
regeneration [58]. Native collagens form the main structural components of the ECM of many
tissues, such as bone, skin, teeth, tendons, cartilage, and ligaments. Twenty-seven types of
collagens have been identified to date, but collagen type I is the most abundant and widely
investigated. A broad range of collagen-based scaffolds have been developed and commercialized
in recent times. For example, bi-layered collagen gels seeded with human fibroblasts in the upper
layer and keratinocytes in the upper layer have been used as the dermal matrix, an artificial skin
product commercialized by Organogenesis in the USA under the name of Apligraf in 1998 [59].
Collagen sponges have been used as an osteoconductive carrier of bone morphogenetic protein
(BMP-2) for spinal fusion marketed by Medtronic in the USA [60] Collagraft, commercialized by
Angiotech Pharmaceuticals, Inc., Canada, is a mixture of porous hydroxyapatite and tricalcium
phosphate and animal derived collagen I, and has been used clinically for the treatment of long
bone fractures for more than a decade. Healos Bone Graft Replacement by DePuy Orthopedics,
USA, is an osteoconductive matrix constructed of crosslinked collagen fibers that are fully coated
with hydroxyapatite. It has been approved recently for clinical use as a bone graft substitute in
spinal fusions [62].
The application and use of synthetic polymers in tissue regeneration is relatively recent
compared to natural polymers. In the past 50 years with the synthesis of novel synthetic
biomaterials, scientists have been able to simulate many key aspects of the extracellular
microenvironment [63]. Scaffolds can be produced from a variety of materials, including metals,
ceramics, and polymers. Metallic alloys are popular for both dental and bone implants [64] while
ceramics with good osteoconductivity have been used for bone tissue engineering [65]. However,
both metals and ceramics have significant drawbacks. Metals are not biodegradable and do not
38

provide a biomimetic matrix for cell growth and tissue formation. Ceramics, meanwhile, also have
limited biodegradability and are difficult to process into highly porous structures due to their
brittleness. In contrast, polymers have great processing flexibility and their biodegradability can
be imparted through molecular design. Therefore, polymers are the dominant scaffolding materials
used in TE. In the process of developing scaffolds, synthetic polymers hold numerous advantages
over natural materials. Key among those advantages is the ability to tailor mechanical properties
and degradation kinetics for various applications. Synthetic polymers can be engineered into
various shapes with optimum pore sizes and surface textures, conducive to tissue formation.
Furthermore, polymers can be designed with chemical functional groups that can induce tissue
ingrowth. Aliphatic polyesters, including poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and
their copolymer poly[(lactic acid)-co-(glycolic acid)] (PLGA) are the most widely used synthetic
polymeric materials in TE. These polymers are well characterized and have gained FDA approval
for certain clinical application (e.g., sutures). PGA is a rigid thermoplastic material with high
crystallinity making it less soluble in most organic solvents; a troublesome property if trying to
form scaffolds. PGA is widely used in medical application as resorbable sutures (dexon, American
Cyanamide Co). The degradation process of the material occurs in two stages: the first stage
involves the diffusion of water into the amorphous (non-crystalline solid) regions of the matrix
followed by the degradation of the crystalline structure of the polymer. The rapid degradation rate
of PGA causes the weak mechanical integrity of the scaffolds [66]. Poly(lactic acid) (PLA) is more
hydrophobic and stable against hydrolysis than PGA. PLA degrades to form lactic acid, naturally
present in the body. No significant amounts of accumulation of harmful degradation products of
PLA have been reported. Both in vitro and in vivo studies have been carried out to determine the
biocompatibility of PLA and PGA. Many studies suggest that these polymers are sufficiently
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biocompatible [67, 68]. Poly(lactide-co-glycolide) (PLGA), copolymer of PLA and PGA, has been
used in many biomedical applications, for example, sutures, drug delivery devices, and TE
scaffolds. Due to its good biodegradability, biocompatibility, and process ability, PLGA has been
considered for many TE applications, such as the skeletal muscle [69], bone [70], cartilage [71],
ligament/tendon [72], and nerve [73]. Synthetic polymers, such as Polycaprolactone (PCL) a
semicrystalline polyester shows very low in vivo degradation rate up to 3–4 years. Therefore, it is
used in long-term implant delivery devices. PCL films modified with arginine-glycine-aspartate
(RGD) peptide (which promotes cell adhesion by acting as a binding site for integrins) served to
promote the attachment and spreading of mesenchymal stem cells (MSCs) [74]. Other synthetic
biodegradable polymers, including poly(3-hydroxybutyrate) (PHB) [75], polyurethanes (PU) [76],
polycarbonate (PC) [77], poly(ortho ester) (POE) [78], poly(propylene fumarate) (PPF) [79], and
polyphosphazenes (PP) [80] have also been used as scaffolding biomaterials. Biodegradable
bioceramics are designed to aid in the self-repair processes of the living organism, and are
subsequently resorbed. Tricalcium phosphates, calcium sulfates, HA, and certain compositions of
glasses and glass-ceramics have been recently investigated as biodegradable bioceramics.
Hydrogels can be used as space-filling scaffolds, for cell delivery, and for bioactive
molecule delivery [81]. Gilbert et al. demonstrated how adult muscle stem cells on engineered
hydrogel substrates can be proliferated in vitro with higher efficiency, leading to better host tissue
integration. These stem cells would normally lose their pluripotency and undergo massive cell
death within the first weeks of culture on rigid plastic culture dishes. However, when cultured on
chemically crosslinked bioactive poly(ethylene glycol) (PEG) hydrogels, the cells showed signs
of self-renewal and were engrafted with substantially better integration in a muscle implant model
[82]. Hydrogel-based products have been made available for patient care in the recent years. For
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example, soft contact lenses are typically made from poly(hydroxyethylmethacrylic) acid
[poly(HEMA)] while biological adhesives routinely used in surgical procedures have been made
from reconstituted fibrin or albumin. Hydrogels are currently extensively investigated for bone,
cartilage, intervertebral, and cardiac regeneration. Moreover, ‘smart’ hydrogels are raising
significant interest due to their ability to change shapes. They can dynamically shrink, swell, or
degrade based on exposure to changing stimuli such as pH, temperature, and other activators. They
are often used for vascular applications, since their smart capabilities allow them to be maneuvered
through small, tight pathways [83].
One of the most important aspects of regenerative engineering is to have cells that are able
to differentiate and proliferate based not only on the cell type, but also the environment that
surrounds them. The scaffold acts similarly to an ECM, creating an environment that is conducive
to integration, differentiation, and cell growth. With that in mind, it is extremely important to select
a cell source that not only matches the overall goal of the implantation, but that also integrates well
with compatible scaffolding. Obtaining cells that are able to differentiate and proliferate to the
correct degree is imperative in successful tissue regeneration, as many damaged tissues are not
able to regenerate the native tissue to an acceptable extent. The most common types of stem cell
used are progenitor stem cells. These cells, while having undergone some degree of differentiation,
are still able to differentiate into multiple lineages. They can also be isolated, cultured and
differentiated into the appropriate lineage before being transplanted into the patient. Human
mesenchymal stem cells (MSCs) are of particular interest due to their multilineage potential, being
able to differentiate into many different cell types like osteogenic, adipogenic, and chondrogenic
[84]. They are used for vastly different functionalities, treating hundreds of symptoms from a wide
spectrum of ailments [85]. Neural stem cells (NSCs) are used for differentiation into almost all
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types of neural lineages, but there a large amount of difficulty has been encountered in creating
the desired type and number of cells when expanding the NSCs. Epithelial stem cells have been
used for skin grafts, as well as things such as ocular regeneration. Considerable research efforts
have been directed toward human induced pluripotent stem cells (hiPSCs) that are able to
differentiate into many lineages, acting very similarly to ESCs [86]. These hiPSCs are capable of
different functionalities and are also procured much more easily than most other stem cell types.
They are created by inducing a forced expression of specific genes in order to cause a specific
expression. Cells are often taken from bone marrow, hair keratinocytes, or skin fibroblasts to create
an array of functions, as noted by Streckfuss-Bomeke et al [87]. Somewhat similar to MSCs, it has
also been found that it is possible to extract stem cells from the amnion and amniotic fluid that
have similar capabilities. Corradetti et al. showed that MSCs from the amniotic fluid are capable
of many different functions from their original lineages [88]. With so many different types of stem
cells to choose from for tissue regeneration procedures, steps must be taken to ensure the correct
cell type is selected. Grompe et al. created a tracing system in order to show the differentiation
process of stem cell systems [89]. This allowed for better selection of different cells for different
functions. In order to harvest the stem cells for implantation, they must first be isolated and
expanded in culture. Because it is difficult to harvest a large number of stem cells, expansion is
important in order to have a viable level of cells for transplantation. The environment and methods
to culture the stem cells is of particular importance, as it can result in changes to the growth rate
and extent of the expansion.
Growth factors are therapeutic agents for tissue regeneration. Different growth factors are
used in order to create differentiation of cells towards a specific phenotype. The following are
some of the more commonly used growth factors given their efficacy and the tissue types they
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have been found to repair and regenerate effectively: nerve growth factor (NGF), epidermal growth
factor (EGF), vascular endothelial growth factor (VEGF), and bone morphogenetic proteins
(BMPs). Nerve growth factor is normally used to help with nerve damage and neurodegenerative
disorders. NGF is used to maintain neuronal survival and promote axonal elongation. It has also
been used to treat disorders such as Alzheimer’s disease or Huntington’s disease [90]. By
promoting neuronal growth, NGF can be used for brain and spinal cord injuries. Bone
morphogenetic proteins are used extensively and have been called the gold standard for enhancing
bone formation and cell proliferation [91]. Due to their extensive osteoinductive properties and
ability to stimulate osteoblast proliferation, BMPs are able to help form new bone, as well as help
it continue to grow. They are applicable for bone defects almost anywhere within the body.
Vascular endothelial growth factor is a growth factor that is used to form blood vessels. Its job is
to not only induce endothelialization of existing vessels, but also to promote angiogenesis (the
process of forming new blood vessels from pre-existing tissue). VEGF can also recruit endothelial
cells to migrate to where they are needed. Epidermal growth factor is a growth factor used for
skin injuries such as incisions and burns. It supports epidermal cell growth, proliferation, and
migration. It is also able to catalyze the creation of collagen to help with wound healing. It is used
to engineer new skin, as well as heal existing skin [92]. Using these (or similar) growth factors,
many different cell types can be proliferated and differentiated. Tissue engineered scaffolds
incorporate these growth factors to ensure that the correct type of cells are created to treat the
defect. In order to do this, it is important to know how the growth factor will react with the
extracellular matrix of the scaffold, as well as to the material of the scaffold itself.
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1.5. Poly(lactide-co-glycolide) (PLGA) and its Application in Tissue Engineering
Poly (lactide-co-glycolide) (PLGA) is the copolymer of poly-(lactic acid)/polylactide
(PLA) and poly-(glycolic acid)/polyglycolide (PGA). Poly lactic acid contains an asymmetric αcarbon which is typically described as the D or L form in classical stereochemical terms and
sometimes as R and S form, respectively. The enantiomeric forms of the polymer PLA are poly
D-lactic acid (PDLA) and poly L-lactic acid (PLLA). PLGA is generally an acronym for poly
D,L-lactic-co-glycolic acid where D- and L- lactic acid forms are in equal ratio (figure 1.5.1)
[93]

Figure 1.5.1: Chemical formula of poly(lactide-co-glycolide) (PLGA) [93]
PGA has highly crystalline structure and higher hydrophilicity and faster degradation rate,
whereas PLA has less crystalline structure and shows poor hydrophilicity and slow degradation
rate. Crystalline PGA, when co-polymerized with PLA, reduces the degree of crystallinity of
PLGA and as a result increase the rate of hydration and hydrolysis. PLGA copolymers are
amorphous in nature with glass transition temperature between 45 and 55°C. Higher content of
PGA leads to quicker rates of degradation with an exception of 50:50 ratio of PLA/PGA, which
exhibits the fastest degradation, with higher PGA content leading to increased degradation
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interval below 50%. For instance, PLGA 50:50 degrades at a faster rate as compared with PLGA
85:15 due to the higher hydrophobic lactide content of the latter. PLGA undergoes hydrolytic
degradation in aqueous environment where ester linkages present along the polymer backbone
are randomly hydrolyzed to lactic and glycolic acids that are finally broken down to form energy,
carbon dioxide and water by the normal metabolic pathways of the body. The degradation of
PLGA copolymer is the collective process of bulk diffusion, surface diffusion, bulk erosion and
surface erosion. The degradation time of the frequently used PLGA family of polymers ranges
from 1 to 2 months for completely amorphous PLGA 50:50 and up to 1–2 years for the semicrystalline poly L-lactide (PLLA). As a drug delivery vehicle PLGA shows biphasic release
pattern. The initial burst release of drug occurs as water penetrates into polymer matrix, causes
random scission of PLGA and drug on surface of the polymer release through desorption. The
sustain release of drug occur when the polymer breaks down by hydrolysis into soluble
oligomeric and monomeric products and creates a passage for drug to be released by diffusion
and erosion until complete polymer dissolved [94]. PLGA polymers are easy to process as they
are soluble in wide range of solvents such as dichloromethane, tetrahydrofuran, ethyl acetate,
chloroform, hexafluoroisopropanol, acetone and benzyl alcohol. Table 1.5.1 shows physical and
chemical properties of PLGA, PLA and PGA [95].
Table 1.5.1: Physical and Chemical properties of PLGA compositions [95]

Polymer

Inherent
viscosity
(dl/g)

50:50 DL-PLG
65:35 DL-PLG
75:25 DL-PLG

0.55–0.75
0.55–0.75
0.55–0.75

Density
(g/ml)

Crystalline
melt
transition
(°C)

Glass
transition
temp (°C)

Solubility
(at 5% w/w)

Approx.
degradation
(months)

1.34
1.30
1.30

Amorphous
Amorphous
Amorphous

45–50
45–50
50–55

123456
123456
123456

1–2
3–4
4–5

45

85:15 DL-PLG 0.55–0.75
1.27
Amorphous
50–55
123456
DL-PLA
0.55–0.75
1.25
Amorphous
50-60
123456
L-PLA
0.90-1.20
1.24
173–178
60-65
145
PGA
1.40-1.80
1.53
225–230
35-40
5
Solvents: 1 = dichloromethane; 2 = tetrahydrofuran; 3 = ethyl acetate; 4 = chloroform; 5 =
hexafluoroisopropanol; 6 = acetone.

5–6
12–16
>24
6–12

1.6. Growth-Factor Loading Techniques

Incorporating growth factors to bone grafts/ substitutes can encourage osteoinductivity in
the defect site. The growth factors are expected to be delivered to cells seeded on the scaffold or
localized at the defect site and stimulate the differentiation of osteoprogenitors down the
osteoblastic lineage. The choice of which growth factor to load depends on the inductive effects
that one hopes to impart on the targeted cells. For example, growth factors such as insulin-like
growth factor-1 (IGF-1), bone morphogenetic protein-2 (BMP-2), and vascular endothelial
growth factor (VEGF) induce cellular differentiation towards adipose, osteoblast, and endothelial
lineages, respectively. With the appropriate growth factor selected, the loading method is next to
be considered. As proteins, the activity of growth factors depends on their conformation and
ability to interact with their cellular receptors. Growth factors may be denatured if exposed to
extremes in temperature or pH and must therefore be loaded under appropriate conditions.
Therefore, while loading the protein it is imperative to consider that the loading method doesn’t
denature the protein conformation and also maintains a sufficient concentration of the growth
factors that mimics the physiological range for bone regeneration. In order to do this, the growth
factor must be bound to the system in such a way that causes the desired release kinetics. The
timing and duration of release, as well as how it is administered, are very important to optimize
healing. Growth factors in vivo degrade due to denaturation, oxidation, or proteolysis. These
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challenges must be controlled if the factors are to be delivered from an implanted construct to
achieve a release profile that can mimic that of the natural healing process.

1.6.1. Non-Covalent Growth Factor Immobilization

Strategies for non-covalent binding of growth factors into carrier matrix include physical
encapsulation and surface adsorption. Growth factors can be physically entrapped into scaffolds
by dispersing the proteins into the scaffold material prior to scaffold construction. Scaffolds used
for physical encapsulation can be designed to have specific mechanical properties, degradation
rates, and porosity to elicit desired cellular responses. These types of growth factor delivery
systems can be created using techniques such as phase separation, solvent casting and particulate
leaching, melt molding, freeze drying, phase emulsion, and gas foaming. There are many
different fabrication methods for physical encapsulation, all with different benefits and
drawbacks that make them effective in certain applications. The table below outlines the most
common techniques, along with their advantages and disadvantages.
Table 1.6.1.1: Growth Factor Encapsulation Techniques [39]
Technique

Advantages

potential disadvantages

solvent

residual solvents and porogen

casting/particulate
leaching

control over porosity, pore sizes
and crystallinity; high porosity

materials; limited mechanical
properties

freeze drying

high porosity and
interconnectivity

limited pore sizes range (15–
35 µm)

high porosity

limited pore sizes, residual
solvents (1–10 µm)

phase separation
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Technique

Advantages

potential disadvantages

melt moulding

control over macrogeometry,
porosity and pore size; free of
harsh organic solvents

high temperatures

high internal-phase
emulsion

control over porosity, pore size
and interconnectivity

limited polymer types and
mechanical properties

injectable; control over

residual monomers and crosslinking agents, limited

in situ polymerization

mechanical properties

porosity

gas foaming

free of organic solvents; control
over porosity

pore interconnectivity

Both natural and synthetic biomaterials can be to design three- dimensional scaffolds to
load and deliver growth factors for bone regeneration. Synthetic polymers such as aliphatic
polyesters, including poly (glycolic acid) (PGA), poly(lactic acid) (PLA), and their copolymer
poly[(lactic acid)-co-(glycolic acid)] (PLGA), poly(ε-caprolactone) (PCL) and its copolymer are
the most widely used for encapsulating growth factors into polymeric delivery systems. These
scaffolds can be engineered into different shapes such as sphere, cylinder, thin-films etc.
depending on the parameters necessary for the specific experiment. Gelatin, silk fibroin,
cellulose, chitin and chitosan, hyaluronic acid (HA), alginate, and collagen are natural carrier
materials that have been used for delivering bone growth factors due to their protein affinity,
biocompatible byproducts, and mild processing conditions. Being fully encapsulated, the loading
and release kinetics of the growth factors are controlled largely by the physical, chemical and
biological properties of the polymers. In PLGA, polymer composition is the most important
factor in hydrophilicity and degradation of the polymer and hence in controlling release rate of
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the protein. PLGA 65:35 shows higher degradation than PLGA 75:25. Presence of higher ratio of
highly crystalline PGA makes PLGA polymer more hydrophilic and thus exhibits faster
degradation and drug release rate [94].
The approach of loading proteins on pre-made scaffolds presents an attractive option for
tissue engineered growth factor delivery. Furthermore, the surface area that the growth factor
contacts is the same as that which cells eventually approach, making the proteins more accessible
to the cells than if they were hidden within the material. Depending on the protein’s
hydrophilicity, they tend to desorb from the scaffold too quickly upon implantation in a “burst”
effect. Deluca et al. have reported a series of experiments in which they loaded BMP-2 on porous
PLGA microspheres by soaking the spheres in the BMP-2 concentrated solution. Deluca et al.
defined “bound” (adsorbed to the surface of the PLGA microsphere) and “free” (physically
entrapped within the pores of the microsphere) proteins [96,97]. They reported that increasing
NaCl and buffer concentrations decreased the amount of protein adsorbed to PLGA. It was
suggested that relative to the pI of the BMP-2 (~9) and the pKa of the PLGA (~3), there exists an
intermediate pH range in which the positively charged protein and the negatively charged
carboxylic acid end groups on the polymer interact via isoelectric bonding. Increased number of
ionic species in the buffer was determined to have caused charge shielding, which resulted in the
decrease of attractive forces between the polymer and protein. A subsequent study by the Deluca
group investigated the effect of different properties of the polymer on protein-loading [98].
Microspheres made from a range of hydrophilic and hydrophobic PLGA were constructed by
varying the molecular weight (MW), polydispersity, and acid number of the polymer and BMP-2
was incorporated. PLGA with various degrees of end-capping were used in order to adjust the
polymer acid number of the microspheres, which was directly related to the number of free
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carboxylic acid functionalities. Higher acid values showed an increase in BMP-2 binding. Also,
hydrophilic PLGA, which had greater acid numbers and therefore greater ionic reactivity than
the hydrophobic form, exhibited the greatest protein adsorption capacity. By increasing the
polymer acid number, the group effectively provided more negative moieties per unit of scaffold
surface area on which the positively charged protein could adsorb. The MW of the polymer is
also linearly correlated with the protein binding.

1.6.2. Covalent Growth Factor Immobilization

Covalent tethering of growth factors is another way of incorporating growth factor to
scaffolds. This method allows prolong availability of growth factors, spatial control of growth
factors and reduce the required doses of growth factors, subsequently reduce the cost and the
efficacy of growth factor based devices. In order to load growth factor using the tethering
method reactive groups need to be available both in the growth factors and substrates. Utilizing
crosslinkers such as water-soluble carbodiimide (e.g., EDC), monoacrylated PEG-succinimidyl
ester, and photo-immobilization to functionalize growth factors and then bind to polymers are
commonly used methods for covalent immobilization of growth factors. Sulfosuccinimidyl- 4(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) is a heterobifunctional
crosslinker that has been used to tether VEGF to agarose, collagen, PEG-dA hydrogel [99, 100]
as well as PDGF-BB to demineralized bone [101] and BMP-2 to PCL, chitosan and collagen
[102,103 ]. Scaffolds modified with immobilized VEGF and BMP-2 showed improved
neovascularization and mature bone formation, respectively, in vivo [104].

1.6.3. Growth Factor Loading and Delivery Systems
50

Bone healing is a complex process where multiple growth factors play important role in
concert. Therefore, it is imperative to obtain a delivery system that can maintain inherent ECM
structure of bone as well as load and deliver multiple growth factors mimicking natural bone
healing. To this end, Kolambkar et al. designed a growth factor delivery system consists of an
electrospun nanofiber mesh tube for guiding bone regeneration combined with peptide-modified
alginate hydrogel injected inside the tube for sustained rhBMP-2 release [105]. Kempen et al.
fabricated a composite scaffold consisting of PLGA microsphere loaded with BMP-2 embedded
in a poly(propylene) scaffold surrounded by a gelatin hydrogel loaded with VEGF to obtain
sequential delivery of growth factors[106]. Following the same trend, dual release of TGF-b1
and IGF-1 through gelatin-loaded microspheres incorporated in oligo(poly (ethylene
glycol)fumarate) (OPF) hydrogels was evaluated for cartilage repair [107]. Richardson et al.
engineered a PLG microsphere based system where PDGF were encapsulated into the polymer
with lyophilized VEGF to promote angiogenesis in bone healing [108].
Release kinetics of growth factors depend on the way protein is loaded on the scaffold, as
well as on the environmental factors of the release medium. If a factor is released too quickly, it
may diffuse away from the target site and not have enough time to interact with local cells. A
burst release might even induce a toxic result if the protein is immediately presented to cells in
too high of a concentration. Contrariwise, an overly slow release of growth factors may cause
denaturation of the proteins. Since healing of bone is a complex multidimensional process,
researchers are investigating scaffold systems that are capable of delivering multiple growth
factors in a temporal and spatial manner. However, controlling the rate and dosage of growth
factors is not a standardized procedure. In general, factor delivery is most important during the
first few weeks following graft implantation. Reconstituted recombinant growth factors are most
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active during this time, as their stabilities tend to decrease when exposed to temperatures above 70°C. Furthermore, the first few weeks of healing are also the critical time for seeded precursor
cells to differentiate towards the osteoblastic lineage. Drug release from 3D matrices is mostly
driven by a pure diffusion mechanism, where free solutes very rapidly escape to the surrounding
solution. Protein release can be also activated by external stimuli, including temperature changes,
magnetism, ultrasound, electrical effect and irradiation. The size of the protein molecules also
affects the release kinetics. Larger molecules may release more slowly from being bound to the
surface by virtue of its larger physical size [109].

1.6.4. Design Criteria for Growth Factors Delivery Systems

A growth factor delivery system engineered for bone healing should be a combination of
osteoinductive and osteoconductive properties, that way in the presence of an adequately porous
shape 3D- matrix and biological stimulus cells can migrate, proliferate and differentiate and lead
to the generation of ECM and vascular network osteo-integration. The materials for growth
factor based delivery devices should be biocompatible, non-cytotoxic to the body. The device
should degrade at a rate of few weeks to months according to the rate of tissue regeneration
while maintaining appropriate release dose and profile of the incorporated growth factors. The
delivery system should also be able to retain the bioactivity of the proteins during incorporation
of the growth factors into the delivery systems and also over extended period of delivery time.
The delivery system should have mechanical properties that are similar to those of the native
bone. A weak scaffold may not have sufficient load-bearing capabilities, while an overly strong
one may result in stress shielding that could lead to the resorption of the newly forming bone.
Additionally, the delivery device should hold high loading protein efficiency and several growth
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factors may be released sequentially in a manner that mimics the temporal profile of the healing
process in vivo [110,111,112].

1.6.5. Release Kinetics of Growth Factors: In Vitro and In Vivo

Release kinetic is a function of the ability of the growth factors to diffuse out of the
scaffold. In a purely diffusion-based system, release profile is often characterized by an
initial burst; growth factors attached to the scaffold diffuse out to the defect site following
concentration gradient. If the release of the growth factors is governed by the degradation of
the scaffold, release profile depends on the molecular weight, concentration and
hydrophobicity of the base polymer, degree of crosslinking and swelling, and the mode of
degradation.
The healing cascade of bone is administrated by temporally and spatially available
growth factors which are produced by the cells and ECM at the defect site. However, in a
non-union defect site the spatiotemporal action of the biological and mechanical cues is
perturbed. Hence, it is imperative to achieve spatiotemporal release profile of growth factors
to heal bone efficiently. Literatures indicate that simultaneous delivery of low doses of two
growth factors, BMP-2 and TGF-β3 can induce more bone formation over single factor
delivery [113,114]. It is important to consider the synergistic effect of the growth factors
while designing a multiple delivery system. The growth factors should be able to maintain
their respective bioactivity and work in concert. Selection of growth factors is also crucial. If
not appropriately chose, the combination of growth factors can inhibit/stimulate the activity
of each growth factor and affect overall healing. For instance, in a rabbit tibia model
simultaneous delivery of osteogenic BMP-2 and angiogenic basic fibroblast growth factor
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(bFGF) resulted in decreased bone formation [115]. However, sequential of BMP-2 and
angiogenic VEGF is widely studied and have shown increased bone formation and
regeneration [116,117]. Lee et al. evaluated knee meniscus repair upon spatially released
human connective tissue growth factor (CTGF) and transforming growth factor–β3 (TGFβ3)
from a three-dimensional (3D)–printed biomaterial. The group treated with CTGF followed
by TGFβ3 delivered to the cell culture media showed fibrochondrogenic differentiation of
human MSCs whereas the cells treated with combination/simultaneous delivery of CTGF and
TGFβ3 failed to yield a substantial number of fibrochondrocyte-like cells [118]. Temporal
control over the release kinetics can be obtained in different ways: designing hybrid scaffolds
with polymers degrade at different rate, utilizing hydrogels as a layer in a polymeric scaffold,
embedding multiple growth factors in charged mesh/film on scaffolds using layer-by-layer
technology are explored by researchers. Delivering growth factors in a temporally controlled
environment is beneficial as this allows to achieve desired cellular activity over the course of
healing time without the need for repeated dosing of the proteins.
Spatial control over growth factor release is an important issue in bone interfaces.
Interfaces between bone and other tissues such as cartilage, ligament and tendon express
various gene expressions which are tightly controlled in space. Mechanical and biochemical
gradients are present at these interfaces. Releasing growth factors in a spatially controlled
manner may influence cell phenotype, differentiation state and ECM production and
organization which may have effect in tissue mechanical properties, mimicking those seen in
vivo. A wide variety of technologies have been engineered to regulate the spatial organization
of bioactive factors, and many of these have been applied for bone regeneration.
Microcontact printing, non-contact technique, 2-D irradiation-based patterning, 3-D scaffolds
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with microchannel, UV laser light treatment are widely studies techniques to create pattern
on the scaffold to obtain spatially controlled growth factor release [119-121].

1.6.6. Dose Response of Growth Factors: In Vitro and In Vivo

Selecting the appropriate growth factors to regenerate the target tissue is only part of the
solution of regenerative engineering. Optimal growth factor dose, carrier vehicle, and release
kinetics all have to be assessed prior to the tissue scaffold implantation. Growth factors such as
BMP-2 are considered to be dose dependent in vitro; that is the larger the dose of growth factor,
the more bone tissue regeneration is observed. In vitro doses of BMP-2 at 1μg and larger were
able to successfully bridge the defect site gap, with increasing doses resulting in an increase of
bone formation, while doses at 0.5μg or lower were unable to sufficiently fill in the defect site
[122]. The release of these doses in vitro often follows the pattern of a short burst release for the
first week, followed by a more gradual increase, eventually leveling off after approximately 42
days [106]. However, the dose-dependence of growth factors changes once evaluated in vivo.
While the in vitro studies concluded that doses of 1μg and larger were able to bridge the defect
site and regenerate bone, in vivo dose-dependence increased with the dose, but started to
decrease after quantities of 1μg [122]. This had been hypothesized to be due to the saturation of
BMP-2 receptors, or the fact that at higher doses, new bone formation has already filled the
defect site. In vivo implantation must also take more careful consideration of the doses present,
due to the physiological side effects of high doses. While it is important to maintain a dose
significant enough to bridge the defect gap and regenerate new tissue, it is also important to
ensure that the dose is not large enough to cause cell toxicity, an immune response, or excess
bone or tissue formation.
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1.7. Dual and Sequential Delivery of VEGF and BMP-2 in Fracture Healing

It has been observed that a combination of growth factors can result in a synergistic effect
on the wound healing process, and lead to more advanced tissue regeneration. One of the more
prevalent and understood growth factor combinations involves the delivery of both angiogenetic
and osteogenic agents, which work together to establish vascularization and new bone formation
respectively. Perhaps the most commonly used combination involves vascular endothelial
growth factor (VEGF) and bone morphogenetic protein 2 (BMP-2). The synergy of these two
growth factors is notable, as VEGF plays multiple roles in bone formation when combined with
BMP-2. VEGF is known for ability to induce new blood vessel formation. Blood vessel
formation is a key component in bone formation, as the blood vessels will transport blood,
oxygen, cytokines, and other healing agents to the wound site, enhancing and sustaining the new
bone formation. Additionally, VEGF also plays a role in ossification, further improving its
synergistic effects with BMP-2. Peng et al., for instance, have shown that VEGF antagonists
reduce the induction capacity BMP-2 to form bone, while BMP-2 in the presence of VEGF
showed enhanced bone formation [117]. Further, the degree of bone formation after exposure to
both factors was partially dependent on the ratio of one to the other, with higher amounts of
BMP-2 compared to VEGF eliciting more bone formation than the reverse. In another study of
co-release of VEGF and BMP-2 examining the chemotactic role of each molecule, Ramazanoglu
et al. examined expressions of collagen type I, Osteocalcin, and Osteopontin. Increased collagen
I from VEGF+BMP-2 groups confirmed the chemotactic migration behavior elicited by VEGF
on osteoblasts. At week 4, the VEGF+BMP-2 group showed higher osteopontin expression.
Since osteopontin regulates bone remodeling by helping osteoclasts bind to bone, an increase in
its expression was interpreted as an indication of bone remodeling [123]. Studies have been
56

reported where VEGF and VEGF receptor, VEGFR-1 have been expressed by human
mesenchymal stem cells during their differentiation and that VEGF has increased the ALP
activity in primary human osteoblastic cells. In intramembranous ossification during
angiogenesis VEGF direct the surrounding blood vessels to invade the mesenchymal
condensation and in endochondral ossification it helps to recruit the endothelial cells associated
vasculature to invade the ischemic cartilaginous region. Invading vasculature allows the
recruitment of osteoclasts, which subsequently remove the cartilaginous matrix and allow for
osteoprogenitor cells to migrate and synthesize bone matrix. Furthermore, in addition to
osteoblast formation, VEGF has been shown to stimulate osteoclast formation as well, due to its
increase of RANKL expression in osteoclast precursor cells. By upregulating RANKL
expression in these cells, VEGF aids in the differentiation of these precursor cells in to
osteoclasts [34, 35].These additional benefits have made the VEGF and BMP synergy a
favorable combination of growth factors to use in bone healing, because they address new bone
formation from multiple different pathways in the healing process.
The BMP family and VEGF is widely and commonly used, but other growth factors can
also affect bone healing from multiple pathways. One example of such a growth factor is the
fibroblast growth factor (FGF). FGF effects the bone regeneration process in a related way to
VEGF, by increasing the differentiation and proliferation of precursor cells into osteoblasts, and
it has also been observed to express type 1 collagen and osteoclast differentiation. Additionally,
in vitro studies have shown that FGF directs endothelial cell migration as well as promotes
VEGF expression, meaning FGF also has the potential to express both angiogenetic and
osteogenic properties [125]. Platelet derived growth factor (PDFG) is another growth factor that
is thought to effect both the angiogenetic and osteogenic pathways in wound healing. PDFG
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plays a role in osteogenesis by inducing the formation of cartilage and other connective tissue by
stimulating fibroblasts and chondrocytes. Similar to FGF, PDGF can increase VEGF expression,
therefore making it an angiogenetic factor as well [125]. In fact, a small number of other growth
factors have been shown to play a role in both osteogenesis and angiogenesis, including TGF-β,
IGF and HGF, and perhaps the right combination of these growth factors with each other or other
growth factors can prove to be as effective as the BMP-2 and VEGF synergy.
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2. PROJECT OVERVIEW AND SPECIFIC AIMS
The objective of this thesis is to outline studies evaluating the efficacy of PLGA-coated
cortical allografts capable of delivering both BMP-2 and VEGF, individually and simultaneously
to enhance bone allograft incorporation and overall defect healing. We anticipate that our
modified polymer coated- growth factor loaded allograft will demonstrate osteoinductive
capacity and adequate remodeling during healing process. Coating will be applied to allografts to
both maximize available surface area for coating and to retain the pore structure to support bone
implant integration and growth factors will be loaded utilizing two different loading schemes to
obtain short and long term delivery kinetics. The study is organized into the specific aims,
detailed below.
2.1. Specific Aim I: To optimize and characterize continuous coating on allografts using PLGA,
an FDA polymer and examine the loading and delivery kinetics of VEGF and BMP-2 alone
and simultaneously released from PLGA coated allografts.
It is hypothesized that PLGA can be used to create a continuous coating of polymer on both
the periosteal and intramedullary surfaces of the allograft while maintaining the native
macroporous structure for host bone. It is further hypothesized that coated allografts will be
capable of adsorbing and delivering growth factors in a controlled fashion.

2.2. Specific Aim II: To determine the bioactivity of BMP-2 both in vitro and in vivo.
It is hypothesized that loading and delivering the growth factors will not impact the
bioactivity of the BMP-2. To test the bioactivity of the released BMP-2, differentiation
ability of hMSCs into mature osteoblast will be assessed using hMSCs in the presence BMP2, released from PLGA coated allografts. Using a transwell, BMP-2 loaded, polymer coated
73

allografts will be cultured with human mesenchymal stem cells to determine the functionality
of released BMP-2 from the allografts in supporting osteoblast differentiation.
We also hypothesize that PLGA coated and BMP-2 loaded allograft will show more bone
formation and osteointegration over coated allograft in a critical size rat femoral segmental
defect.

2.3. Specific Aim III: To investigate the role of VEGF in osteoclastogenesis in virto.
We hypothesize that VEGF delivered will be viable to the extent that it can stimulate
osteoclast differentiation. Using a transwell PLGA coated-VEGF loaded allograft will be
cultured with Raw 267.4 cells and Bone Marrow derived Macrophages (BMM) cells and the
ability of released VEGF to stimulate functional osteoclast differentiation will be evaluated.

2.4. Specific Aim IV: To evaluate the ability of PLGA coated and growth factors loaded
allografts to repair large scale segmental defects in vivo.
It is hypothesized that delivery of both VEGF and BMP-2 in a controlled way will increase
healing over BMP-2 alone and uncoated-unloaded allografts. Specifically, given the nature
of the bone defect to be used, segmental defects, it is anticipated that bone repair will occur
via endochondral ossification as opposed to intramembranous. For this reason it is
anticipated that an initial release of VEGF, followed by a more sustained release of BMP-2
will result in more vascularization, better bone remodeling and overall healing.

74

3. LOADING AND DELIVERY OF BMP-2 AND VEGF FROM PLGA COATED
ALLOGRAFT
3.1. INTRODUCTION

Bulk allograft incorporation has been limited by a number of factors including diminished
mechanical properties of the allograft, lack of remodeling of the allograft over time, fracture
non-unions, and scant allograft vascularization. This has led to high failure rates which has
been as high as 60% in ten-year follow-up studies.1 Intact allografts, however, are the only
subgroup suitable for load-bearing applications and indications, underscoring their importance
in the clinical realm.

Given their importance clinically and their well-documented

shortcomings enhancing allograft healing has become a well-studied topic. Researchers are
investigating several ways of improving allograft healing outcomes by combining them with
cells, factors, proteins, and/or adenoviruses to revitalize the otherwise largely inert implant
material,2-10 although for the most part these strategies have not investigated the nature with
which these additives are delivered to the defect site nor sought to design delivery kinetics.
Studies on growth factors and bone repair have clarified the importance of controlling not
only which factors to administer to a bone defect site but also the relative quantities and the
temporal expression of factors as well. Our hypothesis was that allografts could be made
biologically active by combining the allograft with growth factors such as vascular
endothelial growth factor (VEGF) and bone morphogenetic protein-2 (BMP-2).11 Our
ultimate goal is to quantitatively and temporally control the delivery of these growth factors
which has the potential to enhance the nature and extent of bone-allograft incorporation
toward bone healing. To accomplish this we introduced a thin coating of a biodegradable
polymer to functionalize the exposed surface of the allograft as a delivery vehicle for the
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growth factors, with the intention of delivering them simultaneously with short-term and
long-term kinetics. The primary aim of this study was to develop a methodology to apply a
polymer coating onto the surface of the allograft thin enough to maintain its native
architecture, specifically its inherent pore structure that facilitates new bone ingrowth, and to
use the coating as a factor delivery modulator in which two growth factors, VEGF and BMP2, can be released from coated allograft in such a way that the VEGF is released rapidly, and
prior to, the release of BMP-2.

3.2. MATERIALS AND METHODS
3.2.1. Allograft Harvest and Preparation

For allograft samples, tibial and femoral bone samples were harvested from male and female
Sprague-Dawley retired breeder rats (300-600g). The samples were cleaned of soft tissue and the
bone marrow was aspirated. The bone segments were agitated in a chloroform solution overnight
to reduce the residual fatty tissue and subsequently trimmed to 5 mm longitudinal segments. After
a brief ethanol rinse, the allograft segments were autoclaved (121°C and 15 PSI for 30 minutes) to
devitalize biological remnants.

3.2.2. Allograft Coating with PLGA
Polymer coating of sterilized allografts was based on prior studies12. Briefly, 50:50 PLGA
(Lakeshore Biomaterials, Inc. Birmingham, AL) was dissolved in 1:8 (w/v) concentration of
tetrahydrofuran (Fisher Scientific, Pittsburgh, PA). Each allograft was placed in the cylinder
portion of a 3cc syringe and the polymer solution was drawn into the syringe by pulling the plunger
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to fully submerge the allograft with the polymer and coat it through its endosteal and periosteal
surfaces. This process was repeated by moving the plunger up and down to effectively rinse the
allograft with the polymer. The pressure applied to the plunger in each direction was to force the
polymer solution through the small pores found at the ends of the long bones to fully coat all
surfaces. Once coated the allografts were then lyophilized to remove any residual solvent.

3.2.3. Coating Characterization of PLGA –coated Allograft

Polymer coating was evaluated qualitatively using scanning electron microscopy (SEM) and
microcomputed tomography (microCT). SEM images were taken of allografts sputter-coated
with gold using a JEOL 6700 scanning electron microscope (JEOL USA, Peabody MA) operated
at 5.0 kV. SEM was then performed to analyze the outer surface, as well as the cross section of
the allograft. Allografts were positioned on the SEM sample platform and sputter coated with a
gold-palladium (Au-Pd) solution before being inserted into the SEM. Images were taken to
assess the thickness of the polymer coating.
Additional images were taken with micro-focus X-ray computed tomography CT scans
(µCT40; Scanco Medical AG, Bruttisellen, Switzerland) in 5 mm segments of the coated allograft
to assess the volume of polymer coating. Serial tomographic images were acquired at 45 kV and
114 µA, collecting 1,000 projections per rotation at 300 msec integration time. Three-dimensional
16-bit grayscale images were reconstructed using standard convolution back projection algorithms
with Shepp and Logan filtering, and rendered at a discrete density of 244,141 voxels/mm 3
(isometric16-µm voxels). Betadine was integrated into the polymer coating on the allografts to
enhance contrast between the polymer coating and background. Polymer coating volume was
quantified by analyzing the microCT images.
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3.2.4. Surface Adsorption of Growth Factor

The growth factor VEGF was loaded onto the bone graft using surface adsorption.
VEGF was purchased from Sigma Aldrich in 5 µg vials and stored in a -20ᵒ C freezer. The
VEGF was reconstituted using with 1 ml of deionized (DI) water to create a VEGF concentration
of 5 µg/ml13. Allografts were coated with 1g/8ml (w/v) concentration of PLGA. . After
allografts were coated with the polymer solution and lyophilized, they were submerged in 500 µl
of the VEGF solution with a concentration 5µg/ml. The allografts were allowed to soak in the
VEGF solution at room temperature for 15 minutes before the samples were frozen in a -20ᵒ C
freezer. Once frozen, they were lyophilized for 24 hours. Control samples were created using
the same procedure, being submerged in pure DI water instead of the reconstituted VEGF
solution. Studies were completed with a sample size of n = 6.
Surface adsorption of BMP-2 was conducted following similar protocol as VEGF.
Recombinant human BMP-2 was procured from Genscript Inc., NJ as a lyophilized powder in
500 µg vials and stored at a temperature of -20ᵒ C before use. Allografts were coated with a
polymer solution containing a PLGA concentration of 1g/8ml. Acetic acid was diluted with DI
water to create a solution of 20 mM acetic acid. 1 ml of the solution was added to the 500 µg
vial of BMP-2 to create a BMP-2 concentration of 500µg/ml13. Coated allografts were
submerged in 500 µl of the BMP-2 solution and incubated for 15 minutes at room temperature.
The samples were then placed in a -20ᵒ C freezer until the BMP-2 solution had completely
solidified. The samples were then lyophilized for 24 hours. Control samples were submerged in
20 mM acetic acid rather than the BMP-2 solution. A sample size of n = 6 was used.
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3.2.5. Encapsulation of Growth Factor

Release of BMP-2 was also tested using encapsulation of the protein in the polymer coating.
PLGA was dissolved in THF at a concentration of 1g/8ml. A 500 µg vial of BMP-2 from
Genscript was reconstituted with 500 µl of 20 mM acetic acid. This reconstituted solution was
slowly mixed into the polymer solution until homogenized. Allografts were then coated and
lyophilized using the coating method stated previously.

3.2.6. Incorporation of Multiple Growth Factors

BMP-2 and VEGF were both loaded onto one coated allograft sample using one of two
methods to obtain short-term and long-term release kinetics. Recombinant human BMP-2
(Genscript, NJ) was loaded into polymer-coated allografts through encapsulation within the polymer
coating and recombinant mouse VEGF (sigma Aldrich, MO) was loaded onto the same allograft
sample through surface adsorption onto the polymer coating. For factor encapsulation, 50:50 PLGA
(Lakeshore Biomaterials, Inc. Birmingham, AL) was dissolved in 1:8 (w/v) concentration of
tetrahydrofuran (Fisher Scientific, Pittsburgh, PA). BMP-2 was then added to the polymer solution
(500μg/ml) prior to allograft coating. Each allograft was then placed in the barrel of a 3cc syringe
and the polymer solution was drawn into the syringe by pulling the plunger to fully coat the allograft
across its endosteal and periosteal surfaces. This process was repeated by moving the plunger up
and down to effectively rinse the allograft with the polymer. The allografts were then placed in a
rotator at 40C overnight to achieve an even, continuous coating, followed by lyophilization to
remove residual solvent. After lyophilization VEGF was adsorbed to the surface of the same coated
allografts by placing them into a concentrated VEGF solution (5μg/ml) for a period of 15 minutes
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to allow the protein to adsorb to the coating. Coated allografts were subsequently frozen at -20°C
for 20 hours, lyophilized for an additional 24 hours, and stored at -20°C until use.

3.2.7. Release Protocols of Growth Factors

Release kinetics of the growth factors were determined by placing the growth-factorloaded allografts in phosphate buffered saline (PBS) at 37°C under constant agitation for 42
days. Samples were placed in well plates and submerged in 800 ul of phosphate-buffered saline
(PBS). Ion concentrations and osmolarity of PBS were equivalent to that of the human body,
making it more similar to the environment of the body when the allograft is implanted. The well
plates were wrapped in parafilm and placed in a 37ᵒ C room to simulate the internal temperature
of the human body. Samples were taken by extracting the supernatant fluid in each well and
freezing it in a -20ᵒ C freezer until it was ready to be analyzed. The allografts were shifted to a
new well at each time point and re-submerged in 800 ul of PBS. 800µl samples of buffer were
taken at specific intervals: 2, 4, 6, 8, 12, and 24 hours, and 3, 5, 7, 10, 14, 21, 28, and 42 days.

3.2.8. Growth factor Release Kinetics

Protein release was analyzed using the enzyme-linked immunosorbent assay (ELISA) (R&D
systems, Minneapolis, MN). To quantify the release of VEGF and BMP-2, 50 µl of each sample
was added to an individual well, followed by 50 µl of Assay Diluent. Two standard curves were
also made using reconstituted VEGF diluted with PBS, as well as VEGF standards provided in
the ELISA kit. The well plate was covered with an adhesive strip and placed on a Thermo
Scientific rocker to incubate for 2 hours with slight agitation at room temperature. The wells
were aspirated and washed with wash buffer 5 times before adding 100 µl of Mouse VEGF
80

conjugate to each well. The well plate was then covered and incubated on the rocker for another
2 hours. The washing step was repeated, followed by 100 µl of Substrate Solution being added
to each well. The plate was covered in aluminum foil to protect from light and incubated on the
rocker for 30 minutes. 100 µl of Stop Solution was then added to the Substrate Solution in each
well. The optical density of each well was read using a Biotek Synergy HT plate reader at 450
nm and correction wavelength was set to 540 nm. Using the optical densities of the wells, the
concentration of VEGF in each sample was calculated, and cumulative release kinetics of the
VEGF were calculated.

3.2.9. Statistical Analysis
A student’s t-test (to compare two groups) or one-way analysis of variance with Tukey
post-hoc testing, (for multiple group comparisons) was used to determine statistical significance
with p<0.05. Sample size for all protein release in vitro analysis was n=6.

3.3. RESULTS
3.3.1. Mass Analysis of Coating

The weight of the allograft with and without factor-loaded polymer was measured and
recorded (n=6) to quantify the extent of polymer coating. The mean recorded weight for
uncoated allograft was 126.50 mg (± 38.88 mg) and the mean recorded weight for the coated and
factor-loaded allograft was 158.16 (± 38.99 mg), a statistically significant mass increase of 27%
(± 10.84%) (p<0.05, figure. 3.3.1.1).
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Figure 3.3.1.1: Measurements of average weight of samples before and after polymer coating and
protein loading (encapsulation scheme). Addition of growth factor and coating increased the
mass of the allograft (p<0.05).
3.3.2. Coating Thickness

Scanning electron micrographs confirmed an even, continuous coating both on the
endosteal and periosteal surface (figure. 3.3.2.1) that was between 30-100µm in thickness, thin
enough to maintain open pores as small as 200µm but thick enough to minimally but evenly coat
the entire surface area of the allograft.
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Figure 3.3.2.1: SEM micrograph of the coated allograft at low magnification (right, 27X) and high
magnification (left, 170X) represents 40 µm thick coating on the periosteal surface. Coating
thickness ranged from approximately 30µm-100µm.
3.3.3. Coating Volume and Pore Size

MicroCT analysis of the coated allografts confirmed an even continuous coating that
maintained the small trabecular pore structure evident at the proximal and distal aspects of the
allograft samples (figure 3.3.3.1) and demonstrated a trend toward a greater volume of coating on
the periosteal surface of the allograft than the endosteal surface (figure 3.3.3.2). It was anticipated
that the periosteal surface would have a greater volume of polymer coating than the endosteal
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surface given the overall uniformity of the coating along the allograft and the greater inherent
surface area of the periosteal surface than endosteal surface.

Figure 3.3.3.1: MicroCT image of allograft coating alone, with allograft removed from image (left)
showing thin, continuous polymer coating on both the endosteal and periosteal surfaces. Scale bar
=1 mm
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Figure 3.3.3.2: Distribution of polymer coating between periosteal and endosteal surfaces indicates
a trend but no significant differences in volume.
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Figure 3.3.3.3: Pore size measurement of allografts. No significant difference in pore size was
depicted before and after coating

3.3.4. Release of BMP-2 and VEGF (Single Release)

To determine the release kinetics of the single release of growth factors, one growth
factor either BMP-2 or VEGF was loaded on one coated allograft.

3.3.4.1.

Release Kinetics Profile

In vitro factor release studies examining the rate at which the growth factors were
released from the coated allografts (n=6) indicated that the implants with BMP-2 adsorbed to the
surface of the polymer coating exhibited a burst release of 91.10% (± 24.16%) during the first 24
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hours, followed by a more gradual release and eventual plateau over the next 7 days. Almost the
entire payload had been released within the first 7 days (figure 3.3.4.1.1). For the BMP-2
encapsulated within the polymer coating a more sustained release profile was noted (fig.
3.3.4.1.1) with no initial growth factor burst release but rather a more sustained release over the
entire study.

Figure 3.3.4.1.1: Growth factor release profiles from polymer-coated allografts containing either
surface adsorbed (black line) or encapsulated (grey line) BMP-2 show the rapid release of
surface adsorption and the more sustained release of encapsulation.

The release profile of surface adsorbed VEGF depicted similar release kinetics as the
surface adsorbed BMP-2, suggesting the burst release profile due to surface adsorption was
independent of the molecule being released. VEGF release was most prominent within the first
few days with 60% VEGF released within the first 24 hours and 82% released by day 7 (fig.
3.3.4.1.2).
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Figure 3.3.4.1.2: Growth factor release profiles from polymer-coated allografts containing VEGF
(surface adsorbed). Release profiles indicate a rapid burst release of VEGF from the surface of
the coated allograft. This demonstrates the versatility of delivering of multiple growth factors
from coated allograft with temporal control.
3.3.4.2.

Cumulative Protein Release

In total, 52 µg/ml of BMP-2 was released from the surface of the allograft coating, with no
further release after day 7 (Fig. 3.3.4.2.1) while 550ng/ml of BMP-2 was released from within
the polymer coating over the 42-day release study (Fig. 3.3.4.2.2). In total, 170 ng/ml of VEGF
was released from the surface of the allograft coating, with no further release after day 10 (Fig
3.3.4.2.3). The surface adsorption of BMP-2 showed higher release of payload than VEGF
because of the higher loading concentration in surface adsorbed BMP-2 (500 µg/ml) than surface
adsorbed VEGF (5 ug/ml).
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Figure 3.3.4.2.1: In vitro cumulative concentration of BMP-2 released from coated allograft
constructs in phosphate buffered saline at 37 0C. BMP-2 was surface adsorbed onto the polymer
coated allograft. Data are mean ±SD, n=6 independent experiments.

89

Encapsulated BMP-2 released over 42 days

Figure 3.3.4.2.2: In vitro cumulative concentration of encapsulated BMP-2 released from coated
allograft constructs in phosphate buffered saline at 37 0C. Data are mean ±SD, n=6 independent
experiments.
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Surface Adsorbed VEGF released over 28 days

Figure 3.3.4.2.3: In vitro cumulative concentration of VEGF released from coated allograft
constructs in phosphate buffered saline at 37 0C. VEGF was surface adsorbed onto the polymer
coated allograft. Data are mean ±SD, n=6 independent experiments.
3.3.5. Release of Simultaneous Delivery of BMP-2 and VEGF

To determine release kinetics of simultaneous delivery of the growth factors, two growth
factors were loaded concurrently on one coated allograft.
3.3.5.1.

Release Kinetics Profile

In vitro factor release studies showed the rate at which the growth factors were released
from the coated allografts when VEGF was surface adsorbed onto the polymer coating and BMP2 was encapsulated within the coating of the coated/loaded allograft. The simultaneous release of
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the two growth factors exhibited a sequential release pattern where VEGF release was predominant
at the earliest time points with 96.8% of the VEGF payload eluted between days 1 and 14 (Fig.

Figure 3.3.5.1.1: Growth factor release profiles from polymer-coated allografts containing both VEGF (surface
adsorbed) and BMP-2 (encapsulated) simultaneously. Release profiles indicate a rapid burst release of VEGF from
the surface of the coated allograft and a more sustained, longer-term release profile of BMP-2 from the polymer
coating. This demonstrates the feasibility of delivering two growth factors from one coated allograft with temporal
control.

3.3.5.1.1 grey line), while the BMP-2 release followed a more sustained profile with less of an
initial burst release over the entire study (Fig. 2 black line).

3.3.5.2

Cumulative Protein Release

In total, 145 ng/ml of VEGF was released from the surface of the allograft coating, with no
measurable release after day 28 (Fig. 3.3.5.2.1) while 368ng/ml of BMP-2 was released from
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within the polymer coating over the 42-day release study (Fig.3.3.5.2.2) Overall, this result
demonstrated the ability to elicit short-term and long-term delivery kinetics with one growth factor
released prior to another from the same construct by using surface adsorption and encapsulation,
respectively.

Figure 3.3.5.2.1: In vitro cumulative concentration of VEGF released from BMP-2+ VEGF loaded
and PLGA coated allograft constructs in phosphate buffered saline at 37 0C. VEGF was surface
adsorbed onto the polymer coated allograft. Data are mean ±SD, n=6 independent experiments.
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Figure 3.3.5.2.2: In vitro cumulative concentration of encapsulated BMP-2 released from
VEGF+BMP-2 loaded and PLGA coated allograft constructs in phosphate buffered saline at 37
0
C. Data are mean ±SD, n=6 independent experiments.
3.4. DISCUSSION

Based on 5- and 10-year clinical follow-up studies large-scale bone allografts have a high
failure rate from infection, fracture, and non-union associated with the poor healing and integration
with host bone.14 Retrieval studies done by Wheeler and Enneking showed as much as a 50%
decline in mechanical properties over time, which correlated with increased microfractures and
decreased allograft bone mineral density.5 Data suggests that the allograft is less an active part of
the repair process once implanted, a factor that most likely contributes to the overall failure of the
allografts in the long term. Given this, we imagined a system through which defect repair would
be facilitated better by a functionalized allograft that delivers multiple bone growth factors with
temporal precision rather than relying on it as a purely mechanical support. Our strategy was to
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apply a microscale thick coating of degradable polymer to all surfaces of the allograft to act as a
delivery vehicle for multiple growth factors known to be relevant to bone healing (VEGF and
BMP-2). Further, we sought to evaluate whether the release kinetics of the loaded growth factors
could be controlled to allow one to be delivered rapidly (VEGF) while the other remained
sequestered and ultimately delivered over a more sustained period of time (BMP-2).
A study by Schrier et al. showed that the binding capacity of PLGA is affected by the
molecular weight of the polymer, as well as the acid number of the polymer, which correlates to
the hydrophilic/hydrophobic nature of the polymer. It also showed that molecular weight linearly
related to binding capacity, and hydrophobic PLGA showed a greater affinity for surface
adsorption binding of proteins. The release of proteins from PLGA is biphasic, with an initial burst,
as well as an extended release as the polymer degrades. The burst release is caused by protein on
the surface of the coating interacting with the medium surrounding it. The extended release occurs
through hydrolysis of the polymer to allow for drug release through diffusion and erosion. The
drug release is affected by the drug type and concentration, as well as the hydrophobicity and
molecular weight of the polymer15. PLGA is very useful when creating drug delivery systems due
to the way in which it is able to load and release growth factors. Its biphasic release makes it an
optimal polymer to deliver multiple growth factors due to the fact that it is capable of causing a
burst effect or an extended release. Using surface adsorption and encapsulation, it is able to exhibit
a wide range of release kinetics. Properties of PLGA can also be changed in order to optimize a
system for specific applications. PLGA, being a copolymer containing PLA and PGA, can be
procured in many different variations, including molecular weight and ratio of the two polymers.
PGA has been shown to be more hydrophobic than PLA, and a higher level of PGA also correlates
to a faster degradation rate of the polymer. Therefore, PLGA can be procured in different forms
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depending on the specific binding and release properties that are needed. BMPs have been
administered to bone defects in a variety of ways; as a reconstituted protein that is dripped into the
defect site, loaded into degradable structures that release the payload as they degrade, and directly
onto allograft, both morcellized and intact, to assist with incorporation and healing to surrounding
bone. Baas et al. used morcellized canine allograft as both a mechanical strut and delivery vehicle
by drip-coating the rhBMP-2 onto allograft chips and implanting them with titanium screws. No
means were taken to measure or control the rate of release of BMP-2 from the allograft chips, and
healing was noted to have been hindered because the rhBMP-2 stimulated elevated metabolic
activity of the surrounding cells. The allograft chips were completely resorbed prior to healing,
leaving the implant site unstable. Therefore this was not a failure of rhBMP-2 as a healing agent,
but was an indication that this approach may not be suitable for small allograft samples.16 Indeed,
Lieberman et al. authored the only clinical study of its kind investigating the utility of coating
intact structural allograft with partially purified human BMP as both a mechanical strut and
delivery vehicle in osteonecrotic femoral heads.17 BMP was coated on the surface of fibula
allograft samples and lyophilized, and implanted with a gelatin capsule containing BMP. Positive
results indicated the potential value and utility of delivering BMP from an allograft to treat human
osteonecrosis, but little was known about the uptake and release kinetics of BMP.

Others have sought to improve allograft healing by adding an external coating to try to
recreate the periosteum by adding a cell layer to allografts via a submucosal membrane-coating,1821

or by adding a porous polymeric outer textured layer to increase osteoconductivity of the

implanted allograft.22,23 While successful to an extent, these strategies presented additional
challenges when considering long-term storage since they would require an environment capable
of sustaining living cells. Adding growth factors to a stable polymeric layer would not have the
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same storage limitations. Further, as these alternative approaches sought to coat the periosteal
portion of an allograft it is unclear how endosteal surfaces would remodel and contribute to repair.
The coating process described in this manuscript does not occlude any pore structure larger than
100µm along the endosteal, periosteal, and cross-sectional regions of an implanted allograft while
adding biofunctionality by delivering growth factors determined to be beneficial to new bone
ingrowth.
Bone growth and repair has been attributed to many different growth factors including
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth
factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), to name a few. BMP-2 and
VEGF, two of the more commonly studied growth factors in bone repair, are critically important
on their own but also have interconnected roles in the healing process. VEGF has been shown to
be involved in the conversion of soft callus to hard callus,24 contributes to cartilage resorption and
subsequent ossification,25 and has also been found at very early stages of angiogenesis within the
fracture hematoma after injury. BMP-2 has been shown to stimulate osteoblast migration and
differentiation,26 and its function has been intimately tied to the presence or absence of VEGF.24
The function and timing of growth factor expression in bone repair has also been evaluated. Street
et al. have uncovered subtle but measureable differences between intramembranous and
endochondral ossification, where early angiogenesis may be required for the latter to convert
chondrocytes to hypertrophic chondrocytes, stimulating their apoptosis and subsequent
replacement with hard tissue. Peng et al. have evaluated the response of BMP-2-mediated bone
repair in the absence and presence of VEGF. Their findings showed that BMP-2 in the presence
of VEGF antagonists was reduced in its capacity to form bone, while BMP-2 in the presence of
VEGF showed enhanced bone formation.27
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Our strategy was to be able to release one growth factor, VEGF, rapidly and prior to the
release of another growth factor, BMP-2, over several weeks to mimic the sequence of release
suggested by the literature. Using surface adsorption and encapsulation techniques, respectively,
we were able to achieve this effect. Evaluating the surface adsorption release kinetics of both
BMP-2 and VEGF allowed us to determine if surface adsorption-mediated burst release was
simply a function of the loading process or was also dependent on the molecule released. It was
found that while surface adsorption led to an overall burst release regardless of the molecule there
were some slight differences in the kinetics of the burst release. Each growth factor, VEGF and
BMP-2, released over 90% of the payload within 7-10 days but about 70% of the BMP-2 had
released within 24 hours while only 60% of the VEGF was released in the same time frame. There
are several factors that could explain the subtle difference like the hydrophobicity of the surface
of the polymer, the 3-dimensional structure of the scaffold, the pKa and isoelectric point of the
molecule,29,30 and the molecular weight of the polymer30. Since the scaffold material and structure
were the same for each growth factor those parameters were not relevant. Both BMP-2 and VEGF
have pI values of 8.5-9 so that is unlikely to have had a large impact. Molecular weight, however,
of BMP-2 is 26 kDa while VEGF is 45 kDa. The larger size may have impacted the release of the
VEGF from the surface since surface adsorbed proteins can either be considered free or bound,
where the free molecules are dependent on the concentration of the molecule in solution and the
bound molecules are physically entrapped within small pores on the surface of the microsphere2830

. The larger VEGF molecule may have released more slowly from being bound to the surface

by virtue of its larger physical size.
The simultaneous and sequential delivery of VEGF and BMP-2 from the same
coated allograft exhibited that surface adsorbed VEGF is released rapidly from the double loaded
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allograft, with over 96% coming off in the first four days. While BMP-2 release also begins in the
short term its release is more gradual and extends over a longer period of time than the VEGF,
with more than 50% of its payload still bound to the allograft after VEGF is almost completely
eluted. This demonstrates that we can deliver both VEGF and BMP-2 from the same construct,
and preferentially have the vast majority of the VEGF elute first, a temporal specificity that has
been shown in the literature to be important for bone repair and regeneration 31,32. While the two
growth factors do elute simultaneously at the earliest time points, VEGF elutes at 3x-5x that of
BMP-2. At later time points BMP-2 continues to elute after the entire VEGF payload has been
released. So while not perfectly sequential, the release is dominated in the earliest time points by
VEGF and at the later time points by BMP-2.

3.5. CONCLUSIONS & FUTURE DIRECTIONS

Studies on factors and bone repair have clarified the importance of controlling not only
which factors to administer to a bone defect site but also the relative quantities and the temporal
expression of factors as well. In response, this study was an attempt to address each of these needs
by modifying existing large scale bone allografts with a thin polymeric coating that would act as
a delivery vehicle for growth factors in a temporal pattern designed to maximize bone-allograft
incorporation. In this study we have demonstrated the dual release of VEGF and BMP-2 with
temporal precision from one polymer-coated cortical allograft. Burst release of VEGF was
confined to the first week while BMP-2 release was extended over several weeks of elution. Our
studies have resulted in a microscale thin polymer coating of PLGA capable of retaining and
delivering growth factors, VEGF, and BMP-2 and releasing them in such a way that it is available
at the defect site initially by a burst release or by a longer-term exposure.
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Further refinement of release kinetics for each growth factor is possible by functionalizing
the surface of the polymer to modify its hydrophobicity, varying the polymer used (more slowly
degrading materials may sustain long term release for longer periods of time) or by adding other
materials like calcium phosphate to the coating, which may allow for a more sustained release of
the surface adsorbed VEGF if desired. Further, we should develop protocol to measure the total
amount of growth factors loaded onto the coated allograft. This will give us an indication of the
total amount of proteins that will be released in vivo as the allografts break down and eventually
proteins that are embedded within the bone matrix will be eluded. Additionally, this approach is
not limited to VEGF and BMP-2. Antibiotics, which may need to be released in a bolus after
implantation could be surface adsorbed to provide both acute and chronic delivery.
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4. INVESTIGATION OF BIOACTIVITY OF RELEASED BMP-2: IN VITRO & IN
VIVO EVALUATION
4.1. INTRODUCTION

Encapsulation of proteins or peptides within biodegradable and biocompatible polymers is
a successful and well-documented method for their sustained or controlled-release. The benefits
of sustained or controlled-release protein delivery systems include avoidance of resistance in
bacteria [1–4] and pulsatile administration of vaccines to enhance immune response, etc [5, 6]. In
general, during the protein encapsulation process an aqueous solution of the protein, or of protein
and an additive, is added to an organic solution of the polymer of choice to form an emulsion.
Because proteins are large hydrophilic molecules and difficult to encapsulate within hydrophobic
polymers, a high rate of mixing is employed to entrap the protein into pockets of water solution
inside the polymer, followed by freeze-drying. As discussed in the previous section the
encapsulation of BMP-2 into the PLGA coated allograft showed sustained release of payload over
42 days, which can be beneficial to mimic the healing of native bone. However, this method results
in direct exposure of the protein molecule to water–oil interfaces, which can often result in protein
denaturation. [2] Therefore the primary goal of this study is to confirm that the coating applied to
the allograft did not diminish nor remove the bioactivity of the delivered proteins. To this end the
released growth factor bioactivity was assessed by both in vitro and in vivo studies. We performed
in vitro cell studies with human mesenchymal stem cells (hMSCs) to test the osteoinductivity of
the released BMP-2. A pilot in vivo study was also conducted to further verify the bioactivity of
released BMP-2 to heal a critical sized defect.
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4.2. MATERIALS AND METHODS

4.2.1. Cell Culture
To study the bioactivity of the released BMP-2, human mesenchymal stem cells (hMSCs)
isolated from human bone marrow, cell culture growth medium, and cell culture osteogenic
medium were obtained from Lonza (Lonza Walkersville Inc, Maryland). hMSCs were expanded
per vendor protocols in growth medium, after which they were trypsinized and seeded into 24 well
culture plates at a seeding density of 50,000 cells/well and maintained in osteogenic medium.
Cellular viability and phenotypic expression was evaluated after 7, 14, and 21 days (and 28 for
mineralization studies). Three different groups were tested for the in vitro study: 1) Test Group:
Cells were treated with BMP-2 that was released from polymer-coated and growth-factor-loaded
(coated-loaded) allografts that were placed into transwell inserts so the seeded cells would be
exposed to released BMP-2 but not the allograft itself, 2) Positive Control: cells were cultured as
above but without the coated-loaded allografts added. Rather 1.5l of a stock solution of
reconstituted rhBMP-2 (100g/ml) was added directly to wells every three days for a final
concentration of 100ng/ml, and 3) Negative Control: cells were cultured as the control group but
vehicle (reconstitution solution with no BMP-2) was added every three days.

4.2.1.1.

Cytotoxicity Assay

Potential cytotoxicity of the released BMP-2 was assessed using an MTS assay (CellTiter
96® Aqueous One Solution, Promega Corp, WI) at specific intervals (7, 14 and 21 days). For
MTS assay study the cells were treated with basal media. Assays were performed by adding a
small amount of the CellTiter 96® AQueous One Solution Reagent directly to culture wells at
designated time points ( 7, 14 and 21 days), incubating for 2 hours and then recording the
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absorbance at 490nm with a micro plate reader. The absorbance values were normalized to the
background readings. A standard curve relating cell number to MTS activity was plotted for the
specific hMSCs used in the current study.

4.2.1.2.

Alkaline Phosphatase (ALP) Activity

Alkaline phosphatase (ALP) activity was analyzed using an Alkaline Phosphatase
Substrate kit (Bio-Rad Laboratories, Inc., Hercules, CA), which measured the catalytic activity
of ALP via the conversion of p-nitrophenyl phosphate to p-nitrophenol + phosphate and assumed
that the rate of reaction was proportional to the enzyme activity. Prior to conducting the ALP
activity assay, cells were rinsed with PBS and lysed with 1% Triton X-100. Next, 100 μL of each
cell lysate sample was incubated with 100 μL of the working ALP substrate solution (pnitrophenyl phosphate tablets dissolved in 1X diethanolamine buffer) for 30 minutes at 37°C. 0.4
N NaOH was then added to each sample to stop the ALP-catalyzed reaction. Finally, the
absorbance of each sample was immediately measured at a wavelength of λ = 405 nm using a
SpectraFluor Plus Tecan plate reader (Männedorf, Switzerland). ALP data was normalized to cell
number by BCA protein assay.

4.2.1.3.

Mineralized Matrix Production

Alizarin red was used to stain calcium deposits to measure the capacity and extent of
mineralization of the cell cultures. At each culture time point (7, 14, 21 and 28 days) cells were
fixed with 70% ethanol. Following fixation, cells were stained with 40 mM alizarin red (pH 4.23)
for 10 minutes and then thoroughly rinsed with ddH2O until all excess stain was removed. Stain
was quantified (562 nM) after solubilizing in 10% cetylpyridinium chloride (10 mM sodium
phosphate, pH 7.0). Mineralization data was normalized to cell number by BCA protein assay.
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4.2.2. In Vivo Femoral Critical-Sized Defect
Allografts were placed in critical size segmental femoral defects in 14 week-old male
Lewis rats (n=1). Two groups were evaluated; one of which received BMP-2 loaded allografts
(both surface adsorbed and encapsulated) and one of which received polymer coated but nonfactor-loaded allografts. All procedures were done in accordance with approved Institutional
Animal Care and Use Committee guidelines. Briefly, the femur was approached anterolaterally,
the periosteum incised, and then removed circumferentially. A small plate was fixed to the femur
with four Kirschner wires and two surgical steel cerclage wires and a 6mm critical-sized fullthickness defect was created in the central third of the diaphysis. The allografts were shaped to
final size intraoperatively and placed into the defects to achieve a press-fit, and maintained in place
using a single 4-0 Vicryl (Ethicon, Somerville, NJ) cerclage stitch that was tied around the graft
and plate. A three-layered closure of the muscle, subcutaneous tissue, and skin was performed
with 4-0 Vicryl.

4.2.2.1.

Radiological Analysis

Bone formation on rat femur was analyzed at 26 kV for 6 seconds using the Faxitron Xray machine, and the Faxitron DX-Beta SR v1.4 software. Radiographic images were taken at 1,
2, 4, and 8 weeks after surgery to track bone formation as indicated by radiographic opacity.

4.2.2.2.

Microcomputed Tomography (MicroCT)

MicroCT provides an efficient method to measure the distribution and density of
mineralized tissue throughout the scaffold. Limbs harvested at week 12 were imaged using cone
beam micro-focus X-ray computed tomography to render three-dimensional models for direct
quantitation of sample bone density and volume, and to provide a three-dimensional
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reconstruction of the defect (μCT40, Scanco Medical AG, Bassersdorf, Switzerland).
Segmentation of bone and allograft provided direct volumetric quantification of new bone
formation

4.2.2.3.

Histological Analysis

Limbs were embedded in methyl methacrylate using a plastic methylmethacrylate
processing, infiltration and embedding techniques as described by Kecena et al., [7] and then
was sectioned as undecalcified, and mounted onto glass slides. These sections were then be
stained with hematoxylin and eosin to evaluate cellular events, and with Masson’s Trichrome to
evaluate the osteoid, or new unmineralized bone being deposited at bone forming sites. All
staining was performed according to protocols described by Kecena et al. [7].

4.2.3. Statistical Analysis
A student’s t-test (to compare two groups) or one-way analysis of variance with Tukey
post-hoc testing, (for multiple group comparisons) was used to determine statistical significance
with p<0.05. Sample size for in vitro cell culture analysis was n=3.

4.3. RESULTS
4.3.1. Cell Viability

The cell viability assay showed significant increase in cell number over the 21 days
(Figure 4.3.1.1) where the cells were treated with BMP-2 released from the loaded-coated
allografts (n=3). The result shows that the released dose of BMP-2 and the byproducts of the
scaffold are not toxic to the cultured hMSCs.
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A

B

MTS reading of cells treated with
released BMP-2

Figure 4.3.1.1: Effect of released BMP-2 dose on human mesenchymal stem cell viability
determined by MTS mitogenic assay. (A) There is no significant difference between the groups
in each time point. (B)Increasing cell numbers in the group treated with released BMP-2 over 21
days confirm the biocompatible released dose of the protein. Significance between groups is
designated with * = p<0.05.
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4.3.2. ALP Activity: Bioactivity of Released BMP-2

Alkaline Phosphatase (ALP) activity, well know osteoblastic phenotype marker was
assessed in cells treated with BMP-2 released from allografts. The control for this study was cells
treated in osteogenic media without any added BMP-2. Due to the presence of osteogenic
component in the media the cells with no BMP-2 showed some ALP activity in the early stage of
the time point, however as time progressed and the allograft started to release BMP-2, the group
with BMP-2 showed significant increase in ALP activity over the control group (Figure
4.3.2.13.1).

Figure 4.3.2.1: ALP activity on cells treated with released BMP-2 and cell alone over a period of
28 days (A). Significant increase in the cellular ALP activity at day 21 and 28 between cells
exposed to released BMP-2 compared to cells not exposed to BMP-2 confirms the intact
bioactivity of the protein (B). Significance between groups is designated with (*)= p<0.05.
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4.3.3. Mineralization: Bioactivity of Released BMP-2

The quantitative results of the alizarin red calcium staining assay, an indicator that the cells
are differentiating into mature osteoblasts, showed that at day 28 there was a significant increase
in cellular mineralization from cells not exposed to released BMP-2 to cells exposed to released
BMP-2 (Figure 4.3.3.11). The positive control where BMP-2 solution was added manually to the
culture also demonstrated similar trend as the experimental group (n=3). The data revealed that
the BMP-2 released from the scaffold aids in differentiation of hMSCs into osteoblasts and is as
effective when loaded and released as it is when added directly to culture wells.
A
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B

Mineralization at day 28

Figure 4.3.3.1: Alizarin red staining on cells treated with released BMP-2, added BMP-2 and cell
alone over a period of 28 days (A). Significant increase in the cellular mineralization activity at
day 28 between cells exposed to released BMP-2 compared to cells not exposed to BMP-2
confirms the intact bioactivity of the protein (B). Significance between groups is designated with
(*)= p<0.05.
4.3.4. In Vivo Bone Formation

Radiograph, microCT and histological analysis revealed robust bone formation over an 8week period. Evidence of mineralized callus was first evident by day 14 radiographs of allografts
loaded with BMP-2 and continued to develop over the 8-week period as compared to polymercoated allograft without growth factors (see fig. 4.3.5.1). MicroCT detected total volume through
Defect Region as 76.0787 mm 3 and new bone volume through defect region as 41.3817 mm3.
BV/TV was calculated as 54.4 % (fig. 4.3.5.2). Histological sections performed 8 weeks after the
procedure confirm the healing noted in radiographs. Coated allografts with no BMP-2 loading
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show evidence of osteoid formation along the length of the allograft but no mineralized tissue, and
incomplete bridging surrounding the implant (figure 4.3.5.3 A, B). The coated and BMP-2 loaded
allograft, however, showed dramatically different results at the same time interval. Dense,
organized bone was formed along the length of the allograft, fully encapsulating the coated
allograft.

Figure 4.3.4.1: In vivo analysis bioactivity of the released BMP-2 utilizing critical size segmental femoral defects in (2) 14 weekold male Lewis rats, one of which received BMP-2 loaded allografts (both surface adsorbed and encapsulated) and one of which
received polymer coated BMP-2 loaded allografts (both surface adsorbed and encapsulated) and one of which received polymer
coated but non-factor-loaded allografts. Representative radiographs of the rat femoral segmental defect at 1, 2, 4, and 8 weeks.
Continuing formation of the mineralized callus observed in the BMP-2 loaded coated allograft, confirm the bioactivity of the
released protein and bone union at the host site.
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A

B

Figure 4.3.4.2: MicroCT analysis of femoral bone defect 8 weeks post-implantation. Representative longitudinal section
images, cross section images and three-dimensional reconstructed images are shown for control (A) and experimental group
(B). No evidence of new bone growth was detected through the defect site in the control group (A), whereas new bone
formation was identified around the BMP-2 loaded coated allograft. Scale bar = 5 mm.
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Figure 4.3.4.3 : Longitudinal histological sections of allograft and surrounding femoral bone and
tissue after 8 weeks of healing. Masson’s trichrome stain (A,C) and Hematoxylin and Eosin
stain (B,D) show limited healing around polymer coated/unloaded allograft indicated as “ca” in
the figures (A,B). Figure A shows evidence of unmineralized osteoid within the defect site,
peripheral to the allograft while Figure C shows mineralized bone bridging the defect and
surrounding the coated/BMP-2 loaded allograft.

4.4. DISCUSSION

BMP-2 released from polymer coated allograft showed Human mesenchymal stem cells
exposed to BMP-2 released from polymer-coated allografts were noted to show no reduced
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metabolic activity over 21 days of culture, and to produce mineralization at levels exceeding
those of hMSCs exposed to osteogenic media with no BMP-2, and at levels comparable to BMP2 added directly to culture media (vs released from scaffolds), suggesting the enhanced
osteoinductive effect of BMP-2 was neither eliminated nor reduced as a consequence of being
encapsulated within the polymeric layer. Enhanced Alkaline Phosphatase (ALP) expression in
the group treated with released BMP-2 at day 21 and 28, indicates matrix maturation [12]. In
clinical studies high doses of BMP2 were needed to be effective (1.5–2.0 mg/mL) [13-15],
raising concerns about bone overgrowth and the potential subsequent risks of neural compression
and oncogenic effects. High concentrations also make these treatments expensive. Therefore,
more specific and controlled strategies for administration of BMP-2 for bone reconstruction is
necessary. Human bone marrow–derived mesenchymal stem cells (hMSCs) have long been
considered promising candidates for bone regeneration due to their capability to differentiate into
osteoblasts when appropriately induced in vitro, allowing the use of these cells for engineering of
implantable bone constructs [16,17]. BMP-2 has been shown to stimulate the osteogenic activity
in rodent cell cultures, [18–20] whereas the osteogenic effects are less pronounced in human
cells. Some studies indicated that continuous stimulation with BMP2 (0.1–800 ng/mL) affects
the differentiation but not the proliferation of hMSCs [21–25] whereas other studies did not
demonstrate an osteogenic effect of 100 ng/mL BMP-2 [26, 27]. It is noted that in our study we
developed a delivery system that can release sustain payload of BMP-2 significantly lower (300
ng/ml from dual release) than what is currently being used clinically (1.5–2.0 mg/mL). This
work suggests that delivering BMP-2 from coated allograft can promote osteoinduction of
hMSCs in vitro and can serve as controlled delivery vehicle for new bone formation utilizing a
reduced dose of BMP-2.
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Our pilot in vivo study has shown feasibility of this approach for enhancing allograft
repair. The robust bone formation was a strong indication that the BMP-2 that was loaded and
subsequently delivered was bioactive and resulted in enhanced bone/allograft incorporation when
compared to the control, coated allografts containing no BMP-2. Allograft fracture do not initiate
the repair processes seen in normal fracture healing. Under normal circumstances, growth factors
released from freshly injured bone send stimuli to the osteoprecursor cells in the periosteum and
endosteum and induce formation of osteoblast which eventually cause callus formation. In
devitalized allograft healing process the host bone only contribute to the healing process as the
devitalized allograft doesn’t contain any biological factors. Numerous growth factors are
responsible for orchestrating cellular proliferation, differentiation, chondrogenesis, and
osteogenesis have been identified. BMP-2 is well recognized for its osteoinduction ability. In our
study the robust bone formation and union at the host-graft junction occur due to BMP-2
released from the allograft stimulate osteoinductive signaling and regulation of a number of
gene-expression pathways involving the recruitment and differentiation of host mesenchymal
progenitor cells into osteoblasts and eventually callus formation around the defect zone.
Literature supports our findings that a burst release followed by sustained release
promotes enhanced new bone formation [28, 29]. The burst release of BMP-2 triggers early and
fast cellular response and initiates the fracture healing cascade, also enhanced the recruitment of
osteoprogenitor cells into the allograft [30], whereas, the sustained delivery of BMP-2 enhances
bone regeneration, which has been attributed to by stimulating a larger population of
osteoprogenitor cells at the fracture site at later stages following the original injury [31-33], as
well as its role in promoting vasculogenesis [34]. Overall, an appropriate growth factor dose,
timing and sequence of growth factor delivery, and the physical–chemical and three-dimensional
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attributes of the scaffold are crucial to mimic the physiological repair process in bone.
Interestingly in both the allograft implant with and without BMP-2 the allograft remained largely
intact suggesting that, while BMP-2 delivery results in robust bone formation, it does not
necessarily aid in the resorption of the allograft itself.

4.5. CONCLUSIONS & FUTURE DIRECTIONS
The in vitro and preliminary in vivo data strongly suggests the utility of a growth factorloaded polymeric coating on massive allografts to enhance bone repair. These biologically active
structural allografts may be effective in treating fracture non-unions and revision total joint
arthroplasties with large bone defects [35]. There is great potential for the coated allograft as an
“off-the-shelf” option for treating bone defects given that once the coating and growth factors are
applied they are somewhat stable if stored appropriately. That is to say there is no requirement for
rehydration or special storage as there can be for hydrogel-based or cell-based bone graft
substitutes.
Future in vivo studies will include the delivery of VEGF (along with BMP-2) to determine its
role in allograft resorption, a key component in complete allograft healing. These studies confirm
the ability to deliver growth factors essential for bone repair from polymer-coated allografts
without modifying the general physical structure of the allograft itself. Implications of this work
are great as many other proteins and pharmaceuticals could seemingly be delivered in a similar
manner, depending on the particular need.
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5. IN VITRO CELLULAR EVALUATION OF BIOACTIVITY OF RELEASED VEGF
BY INVESTIGATING OSTEOCLAST PHENOTYPE
5.1. INTRODUCTION

Bone grafting procedures are on the rise in the US, with an estimated 2 million
grafting procedures performed annually.1 Autografts, donor tissues harvested from the patient’s
own body, are considered the gold standard for their optimal biocompatibility, osteoconductivity,
ideal biomechanical properties, biological components and subsequent osteoinductivity, leading
to an 80-90% success rate clinically.2,3 Autografts are typically harvested from the iliac crest for
its porous trabecular bone, relative ease of access, and the high marrow content taken with the
bone because of its abundant cells, blood, and associated proteins. Autograft incorporation follows
a similar sequence of events as typical fracture repair including inflammation, repair, and
remodeling 4. During these three stages multiple cell types including macrophages, monocytes,
lymphocytes, osteoclasts, and fibroblasts infiltrate the autograft from the host bone while
granulation tissue begins to form. Vascularization continues as a collagen matrix is formed and
slowly mineralized. Remodeling of the healed defect, often in response to mechanical loading,
occurs through both bone resorption and subsequent new bone formation.
While autografts are the clinical gold standard for bone grafting the hazard of donor-site
morbidity and a limited supply requires a feasible alternative. Allografts, tissue harvested from a
donor or cadaver, are common alternatives to using autografts but to reduce the likelihood of a
host immune response or disease transmission the donor tissue must be devitalized through a
process that removes cellular and viral components.5 This process removes the cells, blood, and
proteins that are present with autografts, leaving the allograft as a largely structural implant with
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little to no inherent bioactivity and diminished local vascularity. Therefore, in allograft healing
graft incorporation relies only on cells, proteins, and tissues available from host bone and at the
defect site. For trabecular allografts this lack of bioactivity does not prevent adequate healing as
the inherent pore structure of the tissue allows the host to infiltrate the allograft and heal but
devitalization does impact more dense, cortical allografts.6
Large-scale structural allografts (typically cortical bone taken from the diaphysis of long
bones) have limited healing where mineralized tissue usually forms along the cortex of the host
bone and allograft. The lack of osteoclast-mediated allograft resorption or bone remodeling, leaves
large segments of necrotic bone, weakening the defect site over time. The repetitive loading at
these sites makes them vulnerable to destabilization and generation of small microfractures.7,8 As
these allografts become less stable non-unions (27%-34%), late graft fractures (24%-27%), and
infections (9%-16%) occur which ultimately result in clinical failure.9 In the hopes of improving
large scale defect healing we have developed a technique to “revitalize” allografts by incorporating
molecules known to stimulate implant resorption and enhance new bone formation. The literature
reports that delivering bone morphogenetic protein 2 (BMP-2) and vascular endothelial growth
factor (VEGF) simultaneously yields better bone healing over either growth factor alone, and
delivering them sequentially yields even better healing 10-13. The literature also suggests that VEGF
may influence osteoclast precursor differentiation to mature osteoclasts14-17 which, when,
delivered from devitalized allografts may increase the local osteoclast population to facilitate
implant resorption thereby paving the way for subsequent new bone formation. Given this, we
have developed a method through which a thin, polymeric coating capable of retaining and
delivering growth factors is applied to all surfaces of large-scale structural allografts, with the
intention of delivering therapeutic molecules capable of enhancing bone-allograft healing. In the
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previous chapters we have demonstrated the ability to deliver either VEGF or BMP-2 with two
distinct delivery kinetics; short- and long-term.18 Our studies demonstrated that BMP-2 released
from the polymer-coated allograft resulted in robust bone formation in a rat segmental defect.
However, the release of BMP-2 alone failed to show any significant bone resorption in vivo18
substantiating the need to stimulate osteoclastogenesis.
We hypothesized that the delivery of VEGF which is traditionally associated with
angiogenesis would induce differentiation of osteoclast precursors into mature, bone-resorbing
osteoclasts, in vitro.

5.2. MATERIALS AND METHODS
5.2.1. Culture of RAW 264.7 Cells

RAW264.7 cells were obtained from the American Type Culture Collection
(ATCC; Rockville, USA) and cultured in 25 cm2 tissue culture flasks in ATCC-formulated RPMI1640 culture medium with 10% FBS, 1% penicillin/streptomycin at 370C in a humidified
atmosphere containing 5% CO2. After 24–48 h of culture, RAW264.7 cells were detached using a
cell scraper and seeded into 24-well plates at a density of 2.6 x104 cells/cm2 in α-MEM culture
media with 10% FBS, 1% penicillin/streptomycin. Four groups were evaluated in this study: 1)
negative control: cells cultured in α-MEM; no additives, 2) positive control: cells cultured in αMEM with receptor activator of nuclear factor kappa-B ligand (RANKL 50ng/ml) which is
available endogenously and is added to culture to replicate the in vivo environment, 3) cells
cultured in α-MEM treated with RANKL (50 ng/ml) and 10 ng/ml VEGF added directly to the
culture, and 4) cells cultured in α-MEM treated with RANKL (50 ng/ml) and 100 ng/ml VEGF
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added directly to the culture. Cells from each group were cultured for 7 days and then fixed in
3.7% formalin. Cells were then stained with tartrate-resistant acid phosphatase (TRAP) using a
commercial kit (Sigma). Cells that both stained positive for TRAP and contained three or more
nuclei were considered osteoclasts, and were visualized with a Zeiss observer Z.1 light microscope
(Carl Zeiss, USA) and analyzed using NIH ImageJ software.

5.2.2. Isolation of Bone Marrow Macrophages (BMMs) from mice

Primary bone marrow derived mononuclear cells (BMMs) were exposed to VEGF that was
either added to cell culture wells as described above (to assess the functionality of osteoclastprecursors differentiated with VEGF) and eluted directly from coated/loaded allografts (to confirm
the bioactivity of the VEGF after it is released from the coated allograft) (see Figure 5.2.2.1).
BMMs were isolated from long bones of wild type mice aged 4- to 9-week-old, according to
published protocols.10 Briefly, long bones were excised from the mice, cleaned of soft tissue and
stored in PBS. The bone marrow of each bone was flushed out with -MEM media that was
supplemented with 10% FBS and 1% penicillin/streptomycin. Flushed marrow was centrifuged
for 5 minutes at 1200 rpm. Cells were then resuspended in ACK buffer to lyse red blood cells and
the suspension was then centrifuged for 5 minutes at 1200 rpm. Finally cells were resuspended in
complete media. Cells were then seeded on a petri dish (1x108 cells/10 cm dish). Macrophage
colony-stimulating factor (M-CSF) (30ng/ml) was added to the BMM for macrophage
differentiation and cells were cultured for 48 hours in 5% CO2. Cells were then detached and
seeded onto 24-well plates at a concentration of 50,000 cells/well. To support osteoclast
differentiation all cells were cultured in complete -MEM media supplemented with 10% FBS,
1% penicillin/streptomycin and M-CSF (30ng/ml) to assess the following five experimental
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groups: 1) negative control: cells cultured in media (no additional additives), 2) positive control:
cells cultured in media with RANKL added (50ng/ml), 3) cells cultured in media with 100 ng/ml
VEGF added (no RANKL), 4) cells cultured in media with RANKL (50 ng/ml) and VEGF (100
ng/ml) added, and 5) cells cultured in media with RANKL (50 ng/ml) and ~120 ng/ml VEGF
eluted directly from coated/loaded allograft using a transwell with pore size 0.4 μm insert setup
(Figure 5.2.2.1). Each group was cultured for 7 days and numbers of TRAP stained osteoclasts
were counted as described above.

Figure 5.2.2.1: Schematic representation of the cell study to evaluate the bioactivity of VEGF,
adsorbed onto the surface of the PLGA coated allograft. Osteoclast precursors (RAW264.7 and
BMMs) were seeded onto the cell culture plate and the allografts were placed in the corning
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transwell inserts on the permeable membrane. VEGF released from the coated allograft filtered
through the membrane and came in contact with the cells seeded on the plate.

5.2.3. TRAP Staining Assay

TRAP (+) cells were identified as osteoclasts for both RAW264.7 cell studies (on day 7 of
culture) and BMM cell studies (on day 5 of culture) through histochemical staining using a
commercially available kit (Sigma-Aldrich) as per manufacturer’s instruction.

5.2.4. Resorption Assay by Utilizing Osteo-Assay Microplates

Osteoclasts differentiated from BMM cell isolations were assessed for in vitro functionality
using two different methods: quantification of resorbed hydroxyapatite coating, and identification
of resorption pits from bone slices.
Hydroxyapatite Resorption Assay: BMM cells were plated in hydroxyapatite-coated Corning
Osteo-Assay Surface 24-well plates (Corning Life Sciences, USA) using the same culture media
and cell density used in cell culture (see above). After 14 days of culture hydroxyapatite coated
plates were washed with 1.2% sodium hypochlorite solution for 5 min to remove cells, rinsed
with distilled water, and air-dried. For staining, plates were treated in dark at ambient
temperature with 5% (w/v) silver nitrate solution for 30 min. Wells were then aspirated and
washed for 5 min in distilled water. Wells were aspirated again, and 5% (w/v) sodium carbonate
in 10% formalin was added. After a 5-min incubation at ambient temperature plates were
aspirated and air-dried at 370C prior to imaging. The resorption pits were imaged using a light
microscope Zeiss observer Z.1 microscope (Carl Zeiss, USA) and percent resorption area was
calculated using NIH ImageJ software.
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Dentin Resorption Assay: Bovine bone slices were used to assess resorption pits formed by
mature osteoclasts. Briefly, the diaphyses of bovine femurs were cut transversely into 2-3 cm
cylinders with a hacksaw. The cylinder was then cut into three segments and the marrow lifted
out. Any adherent muscle, marrow or periosteum was cleaned with a scalpel. The segments were
then sonicated in warm water. The bone was given a final cleaning of any adherent tissue with a
scalpel. Transverse slices 200 µm thick were made on the Isomet Low Speed Saw (Buehler,
Lake Bluff, IL) with a wafering blade. The bone was then clamped tightly and slices cut at 200
µm intervals using 10% ethanol in Milli-Q water. These 200 µm slices were trimmed to produce
the final 4.4 mm x 4.4 mm x 0.2 mm bone slices. The bone slices were stored in 70% ethanol
until use, then sterilized overnight with UV light in a sterile hood. On the day of experiment,
bone slices were placed in 24 well plates (1 bone slice/well). BMMs (100,000 cells/bone slice)
were plated and cultured according to the 5 different groups described above for 14 days. Culture
medium was changed and every 2-3 days. Bone slices were then fixed with 2.5% glutaraldehyde
in PBS for 30 minutes at RT. Cells were then TRAP stained (Sigma kit #387A-1KT) and
examined microscopically to observe TRAP-positive osteoclasts. Bone slices were sonicated for
5-15 minutes in distilled water to dislodge attached cells and then stained for 30-60 seconds with
1% Toluidine blue in 1% Borax buffer, rinsed in distilled water, air dried, and examined for the
presence of resorption pits using light microscope. The dentin slices were also imaged using
scanning electron microscopy. Allografts were sputter-coated with gold/palladium for 60 sec
using a JEOL JSM-5900LV scanning electron microscope (JEOL USA, Peabody MA) operated
at 10.0 kV and imaged for evidence of resorption pits.

5.2.5. Statistical Analysis
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A student’s t-test (to compare two groups) or one-way analysis of variance with Tukey
post-hoc testing, (for multiple group comparisons) was used to determine statistical significance
with p<0.05. Sample size for cell studies was n=3.

5.3. RESULTS
5.3.1. Effect of VEGF in Formation and Differentiation of Osteoclast: Bioactivity of
VEGF

To assess the efficacy of VEGF as a stimulator of osteoclastogenesis, and to see whether
this effect was dose-dependent, RAW 264.7 cells were cultured in the presence of both RANKL
and a low or high concentration of VEGF. While mononuclear cells can exhibit TRAP-positive
staining, in this study a cell had to stain positive for TRAP and also be multinucleated (three or
more nuclei) to be considered osteoclast-like. There was a statistically significant increase in the
number of multinucleated TRAP-positive cells when comparing cultures with RANKL alone and
RANKL + 10ng/ml VEGF (Figure 5.3.1.1), indicating that combining VEGF and RANKL further
stimulates osteoclastogenesis over RANKL alone. Data showed trend toward a dose-dependent
effect as cultures containing RANKL + 100ng/ml VEGF showed an increase in TRAP-positive
cells over RANKL+ 10ng/ml VEGF cultures (Figure 5.3.1.1).
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Figure 5.3.1.1: Percentage of TRAP positive multinucleated cells in different groups. (*) indicates
statistical significance between groups treated with RANKL alone and groups treated with
RANKL and 100ng/ml VEGF. A dose-dependent trend was observed in osteoclast differentiation
on RAW264.7 cells from VEGF 10 ng/ml to 100 ng/ml (each with RANKL solution (50 ng/ml)
added directly to the media). Data are mean ±SD, n=3 independent experiments. B) Micrograph
of TRAP positive stained cells. Only TRAP positive cells with 3 or more nuclei were considered
osteoclast-like for quantification (circled in red). Scale bar represents 50 μm.

To evaluate the functionality of VEGF-differentiated osteoclasts BMMs were cultured with
VEGF similarly to RAW264.7 cells and then assessed with TRAP staining and for bone resorption
capability. To confirm the bioactivity of eluted VEGF from the allograft BMMs were also placed
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below transwell inserts to allow culture in the VEGF released from the allograft, as depicted in
Figure 5.3.1.1. TRAP assay results confirmed the efficacy of released VEGF to induce osteoclast
formation of BMMs (Figure 5.3.1.1) and showed similar results to that of RAW264.7 cell lines.
Groups treated with VEGF had significantly higher TRAP-positive multinucleated osteoclasts than
those treated without VEGF (figure 5.3.1.8). Further, data demonstrated no significant difference
in the number of TRAP-positive multinucleated cells between the cultures where VEGF was added
directly (100ng/ml) and where it was released from the coating, confirming that the process of
coating and releasing VEGF from coated allografts did not alter its bioactivity.

Figure 5.3.1.2: Micrograph of TRAP positive stained cells. Only TRAP positive cells with 3 or
more nuclei were considered osteoclast-like for quantification.
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Figure 5.3.1.3. BMM cells treated with MCSF. No sign of multinucleated osteoclast was
demonstrated. Scale bar=100 μm.

136

Figure 5.3.1.4: BMM cells treated with VEGF (~140 ng/ml) released from polymer coated
allograft. No multinucleated osteoclast cell was observed. Scale bar=100 μm
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Figure 5.3.1.5: BMM cells treated with RANKL (50ng/ml). In the presence of RANKL BMM
differentiate into TRAP positive multinucleated osteoclasts. Scale bar=100 μm.
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Figure 5.3.1.6: BMM cells treated with RANKL (50 ng/ml) and VEGF (100 ng/ml) added directly
to the cell medium. Multinucleated TRAP positive osteoclasts were observed on day 5 of culture.
Scale bar=100 μm
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Figure 5.3.1.7: BMM cells in the presence of RANKL (50ng/ml) and VEGF (~140 ng/ml) released
from coated allograft. Presence of TRAP positive multinucleated cells verifies the bioactivity of
released VEGF. Scale bar=100 μm.
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Figure 5.3.1.8: Effect of released VEGF on osteoclastogenesis of bone marrow-derived
mononuclear cells as determined by TRAP-positive cell counts. All wells were treated with
MCSF. An increase in cell numbers confirmed the effectiveness of the released protein. There was
a significant increase in osteoclast differentiation between the groups with or without VEGF,
which confirms the bioactivity of the protein. There is no effect of VEGF alone on osteoclastic
141

differentiation. Significance between groups is designated with (*) = p<0.05. Data are mean± SD,
n=3 independent experiments.

5.3.2. Functionality of VEGF induced Osteoclasts: Bioactivity of VEGF

The ability of the osteoclasts differentiated from BMM cells to resorb bone was
confirmed by staining osteo-assay plates with Von Kossa stain. Figure 5.3.2.1 shows
photomicrographs of synthetic hydroxyapatite mineral surfaces as black while white regions are
areas where resorption has occurred due to active acid secretion by differentiated osteoclasts.
Our results showed that the group with VEGF released from the allografts revealed a
significantly (p <0.05) higher percent of resorption area over both positive and negative control
groups (RANKL alone and no RANKL, respectively). These data suggests that the released
VEGF from PLGA coated allograft enhances the differentiation of bone marrow derived
monocytes into functional osteoclasts in vitro (Figure 5.3.2.1).
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Figure 5.3.2.1: Von Kossa staining on hydroxyapatite coated Corning osteo-assay plate. Cells in
culture were treated with MCSF, RANKL, and VEGF that had eluted from coated allografts. The
white regions of the plates indicate osteoclastic resorption, which was quantified using image J
software. Scale bar represents 100 µm
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Figure 5.3.2.2: A significant increase in the resorption activity between the group with and without
VEGF confirms that the released VEGF not only increased osteoclast differentiation but that cells
were functional as well. Significance between groups is designated with (*) = P<0.05. Data are
mean± SD, n=3 independent experiments.
We also tested functionality of BMMs that were differentiated to osteoclasts via released
VEGF on bovine bone chips to assess true bone resorption (fig. 5.3.2.3-5). SEM images revealed
formation of resorption pits on bovine bone surface (fig. 5.3.2.3-4). The bone slices were also
stained with TRAP, to confirm the presence of osteoclasts, and toluidine blue to visualize
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resorption pits. Multinucleated TRAP positive cells were observed on the surface of the bone
slices and the resorption pits developed a blue to purple color (fig. 5.3.2.5). These results
strongly support the notion that incorporating VEGF into coated and loaded allografts will not
only help stimulate angiogenesis and early vascularization11, but also may likely facilitate
allograft resorption via osteoclast precursor differentiation, which may encourage bone
remodeling of the allograft.
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Figure 5.3.2.3: VEGF induced osteoclast resorption activity on bovine bone slices. SEM images
of untouched bone slices at different magnifications, indicate the appearance of bone with no
resorption pits.
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Figure 5.3.2.4: SEM images of bone slices where cells cultured with VEGF released from coated
allograft constructs were seeded for 14 days. Cells were removed from the surfaces and SEM
images were taken at 25x (A), 700x (B) and1800x (C). The resorption lacunae are indicated with
yellow arrows.
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Figure 5.3.2.5: The same bone slices shown in figure 5.3.2.3 were also treated with TRAP and
toluidine blue staining. (A) TRAP staining shows multinucleated osteoclasts on the surface of the
bone slices (red arrows). (B) Toluidine blue staining depicted the presence of resorption pits (red
arrows).

5.4. DISCUSSION

Autografts are still considered the gold standard for bone grafting because of their
biocompatibility and propensity to form bone, but limited supply and donor-site morbidities
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restrict their utility and mandate a viable alternative12. Allografts are either used alone or in
combination with autografts and bone graft substitutes and, depending on the specifics of the
defect site and the nature of the allograft, have a wide range of success. Since allografts are
commonly harvested from cadavers they are traditionally processed before use to remove or
minimize any biological activity, thereby lessening any host immune response but also any
inherent graft bioactivity. So the degree to which the host tissue heals depends more on nonbiological properties of the allograft like defect-size and graft architecture than inherent
biological capabilities it may have possessed prior to processing. It is clear, however, that
devitalizing allografts to render them safer for transplant hinders their functionality and results
in inferior healing8,13. One solution to this has been to add back this functionality or revitalize
the allografts. Different approaches to revitalizing devitalized allografts have included, 1)
creating a synthetic periosteum of cells14, 15, 2) binding and releasing genetic vectors to induce
host cells to overexpress important growth factors for bone repair and remodeling16, 17, 3)
modifying the physical structure of the allograft to encourage better host cell migration 18, 19,
and 4) adding a bioactive ceramic coating to the allograft itself

20, 21

. Each attempt has been

moderately successful but also somewhat complex and challenging when considering scale-up
and the requirements of large-scale manufacturing.
To address these concerns we have developed a novel procedure where a very thin coating
of degradable polymer has been added to the surface of long bone allografts and loaded with
relevant growth factors such that they elute with a temporal precision shown to benefit bone
repair9. By modifying an implant that is clinically viable and currently used in regular practice,
and using materials and molecules that have long track records of safety and efficacy, we
believe our approach may be accepted in the clinic, and by applying this to a known clinical
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challenge by directly addressing the issues at the heart of the challenge we believe this
approach has the potential to be an important tool to the orthopaedic surgeon. This coated
loaded allograft has been shown here to deliver both VEGF and BMP-2 from the surfaces of
the long bone allograft such that the VEGF releases in a burst over the first few days after
implantation and is followed by BMP-2 release over an extended period of time, up to 4 weeks
longer. In the previous chapters we established a methodology to apply a polymer coating
onto the surface of the allograft thin enough to maintain its inherent pore structure (which
facilitates revascularization and bone formation) and still act as a vehicle to deliver growth
factors, VEGF and BMP-2, to the defect site. We examined both the release kinetics of each
growth factor independently from polymer-coated allografts and the osteogenicity of the
allograft through the bioactivity of the released BMP-2 in vitro and in vivo 9. We showed how
VEGF and BMP-2, when loaded individually, and on same coated allograft can be released
with two distinct delivery kinetics depending on how they are loaded onto the allograft.
BMP-2 and VEGF, two of the most commonly studied growth factors in bone repair, are
critically important on their own but also have interconnected roles in the healing process.
However, less well known are the roles of VEGF in regulating both bone formation and resorption
through their respective cell types. VEGF plays a significant role in osteoblast functionality.
Studies have shown that VEGF has a dose-dependent chemoattractive effect on primary human
osteoblasts and human mesenchymal progenitor cells 22, 23 and is responsible for regulating blood
vessel invasion (neovascularization) into hypertrophic cartilage. VEGF also plays a vital role in
osteoclast differentiation and bone resorption14-17. Nakagawa et al., found that VEGF caused a
dose- and time-dependent increase in the area of bone resorption pits excavated by the purified
rabbit mature osteoclast via two distinct VEGF receptors, KDR/Flk- 1 and Flt-1, in osteoclasts at
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the gene and protein levels, and VEGF induced tyrosine phosphorylation of proteins in osteoclasts.
Thus, osteoclastic function and angiogenesis are upregulated by a common mediator, VEGF14.
Helmrich et al. showed that VEGF in a defect site not only improved vascularization but also
increased the recruitment of the TRAP and Cathepsin K-positive osteoclasts15. Kaku et al. showed
in osteopetrotic op/op mice with a severe osteoclast deficiency that injection of VEGF induced
osteoclast formation during experimental tooth movement16. In this study we have substantiated
the osteoclastogenic capacity of VEGF and verified that when released from the coated allograft
its capacity is retained. VEGF released from coated allografts resulted in enhanced differentiation
of osteoclast progenitors in a dose dependent manner, and bone resorption studies verified that the
differentiated osteoclasts were fully functional as bone resorbing cells. While in our studies we
were careful to isolate VEGF release when assessing osteoclastic precursor response, we do
acknowledge that future studies should be done to fully understand how the overlap of VEGF and
BMP-2 delivery that we see may impact this response given the design of our delivery system.
Given that allografts, particularly large scale cortical allografts, have a failure rate of 30-60% at
the 10-year mark9 in part due to lack of vascularization and limited remodeling via creeping
substitution22, it is the belief that the early release of VEGF from the coated allografts will both
encourage neovascularization at the defect site and also differentiate osteoclast precursors to fully
functional osteoclasts so the implanted allograft becomes a temporary strut that is resorbed to make
way for new bone rather than a semi-permanent necrotic tissue that is destined to fail years down
the line.

5.5. CONCLUSIONS & FUTURE DIRECTIONS
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In this study we have demonstrated released VEGF, traditionally tasked with
neovascularization, was shown to effect osteoclast progenitor cells and induce them to mature,
functional osteoclasts capable of resorbing bone. While in our studies we were careful to isolate
VEGF release when assessing osteoclastic precursor response, we do acknowledge that future
studies should be done to fully understand how the overlap of VEGF and BMP-2 delivery that we
see may impact this response given the design of our delivery system.
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6. IN VIVO EVALUATION OF PLGA COATED-GROWTH FACTOR LOADED
ALLOGRAFT FOR BONE REGENERATION IN A RAT FEMORAL SEGMENTAL
MODEL
6.1. INTRODUCTION

The repair and incorporation of bone graft is a regulated process that is very similar to
fracture healing. The initial phase is characterized by inflammation and vascular invasion from
the host, which enables recruitment of mesenchymal stem cells (MSC). These MSCs in the
presence of growth factors like BMPs differentiate into the bone-forming osteoblast cells [1]. In
the case of autografts, both graft and host bones contribute to the migration of osteoprogenitor
cells [2]. In contrast, since allograft does not contain any live cells, healing relies exclusively
upon host cells and tissues. Due to the lack of growth factors that are present in allograft, the host
MSCs fail to receive essential stimuli to contribute in bone formation and overall healing. During
healing process, autografts continue to remodel through osteoclastic resorption of necrotic bone
followed by osteoblastic formation of new woven bone, later remodeled into stronger lamellar
bone. In this way, autografts retain its sustainability through normal bone homeostasis. In
contrast, due to insufficient revascularization, osteoinduction and remodeling of the graft,
allograft tissue often shows limited healing, leaving a large segment of necrotic bone that is
unable to respond to normal mechanical loading. Thus, structural allografts have a limited life
span because microfractures that occur in them over time cannot be remodeled and repaired, and
they demonstrate a 25–35% failure rate from infection, nonunion and fracture [3,4]. Therefore
there is a high demand for revitalizing this devitalized allografts by modulating vascular
ingrowth, osteogenesis, and remodeling. In order to facilitate allograft healing it is imperative to
recognize the growth factors that contribute to autograft healing and are absent in allografts and a
156

method to introduce these factors onto allografts. In the introduction chapter of this thesis we
discussed the important growth factors in bone healing and the two most notable factors were
identified to be vascular endothelial growth factor (VEGF) and bone morphogenetic protein-2
(BMP-2), which are known to dominantly regulate angiogenesis and osteoblastic bone
formation, respectively, during skeletal repair. Our in vitro cell studies indicate that VEGF can
also stimulate osteoclastogenesis in combination with RANKL. In the previous chapters we
developed a polymeric system that can deliver VEGF and BMP-2 simultaneously from structural
cortical allograft. Furthermore, we evaluated the bioactivity of the released growth factors via
cellular assessment.
In our preliminary in vivo study we delivered BMP-2 utilizing short and long term delivery
kinetics. Utilizing the dual delivery method we released approximately 50 µg of BMP-2 in total at
the defect site. The results indicated dense, organized bone formation along the length of the
allograft, fully encapsulating the coated allograft. However, the allograft showed no sign of
resorption, hence no remodeling of the graft. BMP-2 is a very expensive molecule and high dose
of BMP-2 can cause numerous adverse effects including ectopic bone formation, cyst-like bone
void formation, and life-threatening cervical swelling [5,6]. Although proven to be an effective
osteoinducer, the aforementioned adverse effects, along with the possibility of structurally
abnormal and mechanically unstable bone tissue formation, currently limit the overall clinical
efficacy of BMPs. The ability to define upper and lower bounds for BMP doses that would both
form high-quality bone and avoid swelling, void formation, and other side effects would improve
the prospects of BMP as a tissue engineering adjunct and as a clinical product. Therefore, in this
in vivo study we decided to deliver low dose of BMP-2 (at nanograms level) with simultaneous
delivery of VEGF to enhance allograft healing. During normal bone healing, VEGF expression
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was shown to peak during the early days while BMP expression peaked at a later time point [7,8].
Therefore we anticipate that a sequential delivery of VEGF and BMP-2 will show better allograft
resorption and bone formation over BMP-2 alone.
The primary objective of this chapter is to evaluate the efficacy of coated-loaded
bioactive allografts to repair large scale critical sized segmental defects in vivo. The femoral nonunion bone defect is a segmental defect model in which a section of the femur is removed.
Commonly this defect is used to form a critical sized defect (CSD) to ensure non-union, as
critical sized defects will not heal spontaneously and thus are a good measure of the ability of an
implant to promote healing where healing would not otherwise occur [9]. A CSD has been
defined as “the smallest intraosseous wound that would not heal spontaneously throughout the
lifetime of an animal” [10]. For long bones this is defined as those defects having a length
greater than or equal to a distance twice the diameter of the bone itself [11]. In a male SpragueDawley rat weighing 300-325 g, this length is approximately 6mm [12-14]. It is hypothesized
that coated allografts containing BMP-2 will show enhanced bone formation over uncoated
allografts. It is also hypothesized that delivery of both VEGF and BMP-2 in a temporally
controlled way will increase healing over either BMP-2 alone. Specifically, given the nature of
the bone defect to be used, segmental defects, it is anticipated that bone repair will occur via
endochondral ossification. For this reason it is anticipated that an initial release of VEGF will
encourage angiogenesis and osteoclastogenesis, followed by sustained release of BMP-2 will
result in bone formation and overall better bone repair.
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6.2. MATERIALS AND METHODS
6.2.1. In Vivo Femoral Critical-Size Segmental Defect

Allografts were placed in critical size segmental femoral defects in 10 week-old male
Sprague-Dawley rats (weights 300-325 g). All procedures were done in accordance with
approved Institutional Animal Care and Use Committee guidelines. Briefly, the right hindlimb of
the rat were shaved, and prepped with betadine and 70% ethanol. The femur was approached
anterolaterally, the periosteum incised, and then removed circumferentially. A small plate was
fixed to the femur with four Kirschner wires and two surgical steel cerclage wires and a 6mm
critical-sized full-thickness defect was created in the central third of the diaphysis. The allografts
were shaped to final size intraoperatively and placed into the defects to achieve a press-fit, and
maintained in place using a single 4-0 Vicryl (Ethicon, Somerville, NJ) cerclage stitch that was
tied around the graft and plate. A three-layered closure of the muscle, subcutaneous tissue, and
skin was performed with 4-0 Vicryl. After 4 and 8 weeks post-implantation animals were
sacrificed and the femur was harvested, the metals were removed from the limbs and the femurs
were kept fixed in 70% ethanol (fig. 6.2.1.1).
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Figure 6.2.1.1: Steps involved in implantation of allografts into a rat femur bone defect model. (A) The right hindlimb of
the rat is shaved, and prepped with betadine and 70% ethanol. (B) An incision is made in the right hindlimb of the rat and
the surrounding muscle is dissected to expose the femoral bone. (C) A custom made polyethylene plate is placed against
the bone. (D, E) The plate was secured using four Kirschner wires and two surgical steel cerclage wires. (F) A sterile
surgical ruler is used to measure the length of the allograft. (G) A 6 mm defect is created in the bone using a dremel cutting
burr. (H) The construct is secured in the defect by press fit. (I) Graft was maintained in place using a single 4-0 Vicryl and
(J) A three-layered closure of the muscle, subcutaneous tissue, and skin was performed.
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The groups that were evaluated in this study are stated in table 6.2.1.1.
Table 6.2.1.1: Allograft treatment groups for animal study
Healing Time

4 weeks
8 weeks

Rats required to test the treatment method
BMP-2 encapsulated
PLGA coated
allografts
4
4

VEGF surface adsorbed and
BMP-2 encapsulated PLGA
coated allografts
4
4

Uncoated
allografts
4
4

6.2.2. Radiological Analysis

Bone formation on each rat femur was analyzed at 26 kV for 6 seconds using the Faxitron
X-ray machine and the Faxitron DX-Beta SR v1.4 software.
6.2.3. MicroCT Analysis

Limbs harvested at week 4 and 8 weeks were imaged using cone beam micro-focus X-ray
computed tomography to render three-dimensional reconstruction of the defect (μCT40, Scanco
Medical AG, Bassersdorf, Switzerland). Serial tomographic images were acquired at 55 kV and
145 μA with a 300 msec integration time. A set length of the distance between the two proximal
pin holes of the Kirschner wires was analyzed within the defect. Using image J software new
bone area was measured using the radiographs from MicroCT.

6.2.4. Histological Analysis & Histomorphometry

Limbs were embedded in methyl methacrylate using a slow methylmethacrylate (sMMA)
processing, infiltration and embedding techniques as described by Kecena et al., [33] and then
sectioned at 5 μm thickness with a diamond saw microsectioning system., and mounted onto
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glass slides. Undecalcified tissue sections were stained with Goldner’s Trichrome stain to
visualize areas of new osteoid formation (which stains red) and new mineralized tissue (which
stains deep green). It is also possible to visualize red blood cells with the Trichrome stain as they
appear yellow-orange. Toluidine blue stain was used to detect osteoblasts and osteoclasts based
on location of cells and shape, size, and number of nuclei of the cells. All staining was performed
according to protocols described by Kecena et al. [33]. Histomorphomerty analysis was
performed using a Nikon Eclipse E600 microscope (Nikon, Tokyo, Japan) coupled with a digital
camera DN100 NIKON (magnifications of 4, and 10 lens). Osteomeasure software was used to
quantify new bone area in each sample within the region of interest (ROI).

6.2.5. Statistical Analysis

For quantification analysis, a two-way analysis of variance (ANOVA) was preformed to
compare data. Error is reported in figures as the standard deviation (SD) and significance was
determined using a probability value of p < 0.05 (n=4).

6.3. RESULTS
6.3.1. Radiographic and MicroCT Analysis

Radiographs of rats representing each implant type were taken throughout the healing
process. Figure 6.3.1.1 shows healing in the control group (allografts with no growth factor) after
4 weeks. Radiographs show virtually no evidence of callus formation or mineralization. Figure
6.3.1.2 shows progression of healing during 8-week in allografts loaded with BMP-2 alone and
allografts with VEGF and BMP-2. There is radiographic evidence of mineralized callus
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formation in allografts loaded with BMP-2 and VEGF after 4 weeks of healing and at 6 weeks
the grafts demonstrated increased opacity with approaching bridging, suggesting more healing at
this time point. At week 8 almost complete bridging between the ends of the defect is seen along
the length of the graft. Allograft loaded with BMP-2 alone showed less callus formation than
VEGF+BMP-2 group with partial bridging at 8 weeks, indicating loading of dual growth factors
not only show more bone formation over single growth factor but can also accelerate the healing
process.

Figure 6.3.1.1: Healing of the control (allograft without growth factor) after 4 weeks. No visible
healing is evident on the radiograph.
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Figure 6.3.1.2: Sample radiographs taken of limbs at every two weeks demonstrating the
progression in healing within allograft treated with BMP-2 alone and BMP-2 and VEGF. Allograft
treated with dual growth factors showed increased radiopacity within the defect site at week 4 and
approaching complete bridging of the implant at week 8, whereas the group with single growth
factor showed less radiopacity throughout the healing period.

To further confirm our X-ray findings, we performed microCT analysis using samples
from 4- and 8-weeks post-surgery. Micro-CT analyses demonstrated that the size of the external
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callus at the host/allograft junction in both BMP-2 and BMP-2 +VEGF group were larger and
contained more mineralized bone than the allograft alone groups (fig. 6.3.1.3) at 4 and 8 weeks
post-transplantation. MicroCT 3-D rendered images for the entire repair region further
demonstrated that a bony union was achieved only in the BMP-2+VEGF groups at 8 weeks postsurgery , while the gap between allograft and host bone was still visible in both allograft alone
and BMP-2 groups (fig. 6.3.1.4 ).

Figure 6.3.1.3: Representative radiographs (from MicroCT) of the dissected limbs after
sacrificing the animals at 4 and 8 weeks. Groups include allograft with no treatment (control),
BMP-2 encapsulated polymer coated allograft and VEGF surface adsorbed and BMP-2
encapsulated polymer coated allograft. Formation of callus was observed in the VEGF surface
adsorbed and BMP-2 encapsulated coated allograft at 4 weeks and bone union at the host 8
weeks. BMP-2 encapsulated coated allograft showed callus around the defect zone at 8 week but
no callus formation was seen at 4 week. The control group showed the least bone regeneration
among the three groups. Scale bar = 1 mm
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Figure 6.3.1.4: MicroCT analysis of femoral bone defect at 4 and 8 weeks post-implantation.
Representative three-dimensional reconstructed images are shown for control, BMP-2
encapsulated coated allograft and VEGF surface adsorbed and BMP-2 encapsulated coated
allograft. Very limited of new bone growth was detected through the defect site in the control
group, whereas the group treated with VEGF+BMP-2 shows bridging surrounding the defect
site. The group treated with BMP-2 alone shows some union at the host-graft interface but not as
robust as VEGF+BMP-2 group.

6.3.2. Histological Analysis

Histological analysis confirmed the same bone formation trend that was observed in the
microCT scans. The VEGF+BMP-2-loaded allografts showed extensive bone formation around
the defect sites and almost full bridging of the cortices (fig.6.3.2.1 and 6.3.2.2). At 4 weeks there
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was significant difference in bone formation between control group and the groups with growth
factors (fig. 6.3.2.3 a). At 8 weeks BMP-2 + VEGF group showed enhanced bone formation over
the other two groups, however it was not statistically significant (fig. 6.3.2.3 b). Allografts
loaded with no growth factor showed evidence of thin layer of osteoid formation with no
mineralized tissue and fibrotic tissue along the length of the allograft was observed (fig 6.3.2.1,
6.3.2.2, 6.3.2.4). The coated and BMP-2 loaded allograft showed callus formation along the
length of the allograft, however, a closer examination at the allograft revealed that there was no
sign of remodeling on the cortex of the allograft (6.3.2.5). In contrast, the coated and BMP-2 and
VEGF loaded allograft demonstrated not only new bony union between the live host bone and
the allograft surfaces but also partial resorption of the allografts and replacement of the resorbed
dead bone with viable new bone (fig. 6.3.2.6-8). Figure 6.3.2.8 depicted continuing active
resorption of the dead cortical bone with new bone.
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Figure 6.3.2.1: Representative histological images of Goldner’s Trichrome –stained longitudinal
sections 4 weeks post-implantation imaged under 10X magnification. Goldner’s trichrome stain
showed no sign of bridging around uncoated/unloaded allograft. Control and BMP-2 group show
evidence of unmineralized osteoid within the defect site, peripheral to the allograft while there’s
evidence of initiation of callus formation surrounding the defect VEGF +BMP-2 loaded allograft.
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Figure 6.3.2.2: Representative histological images of Goldner’s Trichrome –stained longitudinal
sections 8 weeks post-implantation imaged under 10x magnification. Goldner’s trichrome stain
showed limited healing around uncoated/unloaded allograft. Control group shows evidence of
unmineralized osteoid within the defect site, peripheral to the allograft while there’s evidence of
mineralized bone approaching bridging the defect and surrounding the VEGF +BMP-2 loaded
allograft. The BMP-2 loaded allograft showed some callus formation around the defect site but
no evidence of bridging.
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8 Weeks

4 Weeks

Figure 6.3.2.3: Quantification of new bone area from bridging mineralized calluses of each group.
Bone area was quantified from the histological slides stained with Golder’s trichrome. * indicates
p<0.05.
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Figure 6.3.2.4: Histological section of uncoated/unloaded allograft (A) stained with toluidine blue
shows fibrotic tissue (f) that covered the periosteal surface of necrotic allograft. Image was taken
at 5x.
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Figure 6.3.2.5: Histological section of Allograft (A) encapsulated with BMP-2 alone. Toluidine blue staining showed
callus formation around the defect site, indicated by black arrow (a), however the periosteal surface of the allograft (A)
showed no evidence of remodeling, indicated by * (b). Image (a) was taken at 5x magnification and b) was taken at 20x
magnification and scale bar= 50 µm
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Figure 6.3.2.6: Histological section of allograft (A) loaded with BMP-2 and VEGF stained with
Toluidine blue. Low magnified image of the allograft section stained with toluidine blue showing
formation of new bone around the cortex of the allograft, indicated by black arrow and evidence
of remodeling on the cortex of the allograft is indicated by #. Image was taken 5x magnification.
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Figure 6.3.2.7: Zoom in view of the cortex of the allograft showing cortical bone remodeling is in
progress where space created by osteoclastic bone resorption is being filled by newly synthesized
bone in the presence of osteoblast. Image was taken at 40x magnification and scale bar= 20 μm.
OS=osteoblast, NM= new matrix, A= allograft, OC=osteoclast
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Figure 6.3.2.8: Toluidine blue stained section of the allograft (A) showing resorption pit created
by osteoclast (OC) on the surface of the graft (yellow arrow) and formation of new woven bone in
the resorption lacuna. Image was taken at 40x magnification and scale bar= 20 μm.

6.4. DISCUSSION
Despite the advancement of regenerative medicine to overcome the issues associated with
large segmental defects, effective healing between the host and the allograft implant still remains
a major challenge. Allograft implants do not initiate the repair processes seen in normal fracture
healing due to the lack of biological factors. Five-year follow-up studies have demonstrated
substantial concerns with allograft incorporation into host bone particularly with intact allograft
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tissue [27, 28]. Incorporation is a series of events leading to gradual replacement of the old
necrotic bone by living new bone as a result of creeping substitution, a mechanism of
osteoclastic resorption followed by deposition of new bone. A bone graft is considered to be
incorporated when there is no abrupt histological change between the host bone and the graft.
Stevenson et al defined successful incorporation as the graft uniting with the host, with the grafthost bone construct able to tolerate physiological loads without fracture or pain. From the
perspective of basic science, the complete incorporation is defined as rapid vascularization and
substitution of original graft bone with new host bone without substantial loss of strength. In
short, events that are essential for allograft incorporation are: vascularization, allograft resorption
and new bone formation. Therefore, we have developed a novel procedure where a very thin
coating of degradable polymer has been added to both endosteal and periosteal surfaces of long
bone allografts and loaded with relevant growth factors such that they elute with a temporal
precision shown to benefit bone repair by stimulating vascularization, osteoclastic and
osteoblastic activity.
In the present study, our main objective was to investigate the efficacy of dual delivery of
VEGF and BMP-2 in allograft healing over BMP-2 alone, in vivo. First, we sought to determine
the effect of combined delivery of BMP-2 and VEGF on bone formation. Noteworthy, thought
there is no significant difference in bone formation between BMP-2 +VEGF and BMP-2 alone,
however, a trend is evident that shows more new bone formation in the group treated with BMP2 and VEGF over the other two groups. There was significant difference between the control
group and allograft treated with dual growth factors, however, no significant increase in bone
formation between VEGF+ BMP-2 and BMP-2 alone was noticed. At 8 weeks postimplantation, the amount of newly formed bone tended to be higher in the VEGF+BMP-2 group
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compared with defects treated with BMP-2 alone and control with no statistical difference. The
trend is encouraging and we anticipate by increasing the sample size a significant increase in
bone formation between VEGF+BMP-2 and BMP-2 alone could have been attained. These data
correlate with the results of Young et al.,[15] Patel et al.,[16] and Kempen et al.[17] who found
increase in bone formation by combining BMP-2 with VEGF is more profound at the earlier time
points of the healing. Peng et al., for instance, have shown that VEGF antagonists actually
reduce the induction capacity BMP-2 to form bone, while BMP-2 in the presence of VEGF
showed enhanced bone formation22. Further, the degree of bone formation after exposure to both
factors was partially dependent on the ratio of one to the other, with higher amounts of BMP-2
compared to VEGF eliciting more bone formation than the reverse. Kempen et al. engineered a
composite scaffold consisting of PLGA microspheres loaded with BMP-2, embedded in a
poly(propylene) scaffold, surrounded by a VEGF-loaded gelatin hydrogel. Despite the release of
98% of the VEGF within the first 14 days, the VEGF+BMP-2 group formed more vessels and
bone than the other groups. Patel et al. reported that the sequential delivery of VEGF and BMP-2
accelerates the healing process through a rat cranial critical-size defect model that evaluated the
angiogenic and osteogenic response to porous poly(propylene fumarate) scaffolds with gelatin
microparticles that released VEGF and BMP-2. The experimental constructs that released both
BMP-2 and VEGF showed accelerated bone healing over those releasing BMP-2 or VEGF alone.
In another study of co-release of VEGF and BMP-2 examining the chemotactic role of each
molecule, Ramazanoglu et al. examined expressions of collagen type I, Osteocalcin, and
Osteopontin. Increased collagen I from VEGF+BMP-2 groups confirmed the chemotactic
migration behavior elicited by VEGF on osteoblasts. At week 4, the VEGF+BMP-2 group
showed higher osteopontin expression. Since osteopontin regulates bone remodeling by helping
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osteoclasts bind to bone, an increase in its expression was interpreted as an indication of bone
remodeling [18]. Thus the physiological basis for delivering both VEGF and BMP-2 from the
same allograft is well founded given their traditional roles as vasculogenic and osteogenic
molecules, respectively.
The adverse effects of super-physiological dosage of BMP-2 that are currently being used
clinically is alarming [5,6]. The current therapies utilizing BMP-2, such as INFUSE (contains 1.5
mg/ml rhBMP-2), exceeds physiological levels of the factor (1 µg/kg) by several orders of
magnitude [29,30]. In the present study, we used ~ 300 ng/ml of rhBMP-2 which is several
orders of magnitude lower than what is currently being used clinically (1.5 mg/ml). Using this
low dose of BMP-2, we were able to show enhanced bone formation over the control groups,
however none of the animals showed complete bridging in BMP-2 alone group. Literature
indicates in rodent sub-therapeutic concentrations of BMP-2 with bony nonunion is less than10
µg/mL; therapeutic concentration with robust bony union, normal trabecular architecture, and
marrow cellularity is 10-50 µg/ml; and supra-therapeutic concentrations with bony union
accompanied by cyst-like bone devoid of normal bone structure and cellularity is more than 150
µg/ml [32]. According to this report, we used concentration of BMP-2 lower than sub-optimal,
hence, we observed bone formation around the defect site with no complete bridging. However,
interestingly, in the dual group as we combined low dose of VEGF (~180 ng/ml) with BMP-2
(~300 ng/ml) we noticed almost complete bridging of the allograft. For large critical-sized
defects that cannot heal spontaneously, a burst release of growth factors that recruits progenitor
cells into the scaffold, followed by a sustained release that promotes osteoblastic differentiation
has been suggested as the ideal release strategy[31]. Long-term release of BMP-2 might
stimulate osteoblastic differentiation of osteogenic stem cells or progenitors existing in the
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surrounding of the implants for a longer time period. To attain dense bone formation with
bridging we may need to release more BMP-2 (~10 µg/ml) from the coated allograft. Further
consideration should be taken to study this defect model utilizing a larger defect size, between 710 mm and/or in larger animal models where the distance between the bony ends of the defect
increases and hemostasis is better controlled.
In this study, we sought to improve allograft healing by not only creating bony bridging of the
allograft cortices but also imparting remodeling of the graft. Different approaches to revitalizing
devitalized allografts have included, creating a synthetic periosteum of cells [19,20], binding and
releasing genetic vectors to induce host cells to overexpress important growth factors for bone
repair and remodeling [21,22], modifying the physical structure of the allograft to encourage
better host cell migration [23,24], and adding a bioactive ceramic coating to the allograft itself
[25,26]. Each attempt has been moderately successful but also somewhat complex and
challenging when considering scale-up and the requirements of large-scale manufacturing.
Noteworthy, researchers have attempted to improve the healing of allograft by either enhancing
bone formation or imparting remodeling of the allograft. Our hypothesis is stimulating resorption
of the graft through osteoclast formation and simultaneous induction of new bone formation on
the periosteal and endosteal surface of allografts is a superior method to improve graft
incorporation. Our coated allograft demonstrated higher release of VEGF at earlier time points,
contribute to angiogenesis and osteoclastogenesis followed by sustained release of BMP-2 which
contributes to new bone formation. Ito et al, performed a similar study where they attempted to
treat allograft fracture in mice by utilizing gene therapy to deliver VEGF and RANKL [22]. They
reported, a substantial increase in the release of VEGF at day 4, peaked at day 8 and then started
to plateau and reached the baseline at week 3. The released amount of RANKL couldn’t be
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detected as the amount was always lower than the detection limit (30 pg/ml). The histological
analysis of their study at 4 weeks post-implantation indicated, evidence of continuing
osteoclastic resorption of the cortical dead bone with new bone formation, however, the
resorption and subsequent formation of new bone did not occur uniformly on the allograft
surfaces with parts of some allografts only being resorbed [22]. In the present study, we
emphasized both on bone formation and the remodeling of the allograft implant. Both microCT
and histology analysis indicated that BMP-2 and VEGF loaded allograft demonstrate healing by
stimulating live, vascularized, remodeled graft with bony union. In contrast, BMP-2 loaded
allograft depicted bone formation surrounding the defect zone but failed to show any sign of
bridging or remodeling of the allograft. In the previous chapter we showed VEGF can contribute
to the enhancement of osteoclast formation in the presence of RANKL in vitro. In this study the
presence of osteoclastic resorption activity on the surface of the allograft supports our in vitro
finding. VEGF not only contribute to the invasion of cartilage by blood vessels in endochondral
ossification but also stimulate the cascade of events that lead to remodeling of the graft by
inducing osteoclast resorption. As the old necrotic allograft was resorbed by osteoclastic
activity, new woven bone matrix, synthesized by sustained release of BMP-2, replaced the site to
complete the remodeling process.

6.5. CONCLUSION & FUTURE DIRECTIONS

In this study we have demonstrated the dual release of VEGF and BMP-2 with temporal
precision from polymer-coated cortical allograft can stimulate new bone formation as well as
remodeling of the allograft in a critical-size defect. The combined release of BMP-2 and VEGF
showed more promising result in healing allograft fracture than BMP-2 alone. Released VEGF,
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traditionally tasked with neovascularization, was shown to effect osteoclast progenitor cells and
induce them to mature, functional osteoclasts capable of resorbing bone and sustained release of
BMP-2 can stimulate osteoblastic activity which results in synthesis of woven bone hard callus,
gradually remodeled to lamellar bone. We recognize that vascularization plays a critical role in
healing large scale bone defects. Therefore, future studies should be performed to establish the
technology and protocols for in vivo 3D imaging of vascular ingrowth of allografts for large-animal
preclinical and clinical trials. In this study we showed remodeling of the allograft qualitatively,
however, a quantitative assessment of the osteoclast and resorption lacunae is essential to further
confirm allograft resorption and remodeling. Histological sections should be stained with TRAP
stain and the number of osteoclast present on the surface of the allograft as well as at the graft-host
junction should be counted. Finally, since the primary function of structural bone is to support
loads, the biomechanical properties of coated-loaded allografts must be determined and correlated
with volumetric parameters determined by micro-CT in auto- and allografts after various healing
periods.
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7. SUMMARY AND CONCLUSION

The ultimate goal of a bone tissue engineer is to design a graft that mimics the tissue it is
meant to replace while facilitating the regeneration of a patient’s own bone. In the present
project, we built upon a successful PLGA coated bone allograft design by loading osteogenic
growth factor, BMP-2, and angiogenic growth factor VEGF. Furthermore, we investigated that
VEGF, usually associated with angiogenesis can stimulate mature and functional osteoclasts and
contribute to remodeling of necrotic bone. This study has demonstrated the feasibility of
imparting biofunctionality to devitalize allograft through the addition of a thin factor-loaded
polymer coating while maintaining the inherent structure of the allograft. Furthermore, we were
able to design a polymer coated allograft as a carrier for local and controlled supply of growth
factors that are imperative to enhance bone remodeling process which may improve the loss of
functionality of intact allografts. By utilizing two different loading schemes, namely - surface
adsorption and physical encapsulation, initial burst and gradual release of the growth factors
were achieved. Surface adsorption of VEGF resulted in a burst release with almost all of the
protein being released in the first few days. Physical encapsulation of BMP-2 showed a
sustained release throughout the second and third weeks. Multiple growth factors are able to be
released in a controlled manner with the ability to load any desired concentration while still
maintaining the physical structure of the allograft.
Moving forward, a greater focus needs to be placed on the release of the growth factors and the
factors that affect their release.

More studies need to be done with different polymer

concentrations to better understand the extent of its effect on the release of loaded growth factors.
A protocol must be established to measure the loading efficiency of growth factor. The degree of
initial burst from the polymer coating depends on the ability of the polymer matrix to encapsulate
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the protein, thereby making it unavailable for immediate diffusion. For this reason, efforts to
reduce the initial burst have followed the same track as those that were used to increase
encapsulation efficiency. Although the increase in encapsulation efficiency does not necessarily
lead to reduction of the burst release, developing a protocol to maximize the encapsulation
efficiency will be useful in controlling the release profile. Furthermore, impact of varying
concentration of loaded protein on release kinetics of the growth factors needs to be studied. This
approach of growth factor incorporation is not limited to VEGF and BMP-2. Antibiotics, such as
gentamicin, which may need to be released in a bolus after implantation could be surface adsorbed
to provide both acute and chronic delivery. This continuous release has great potential with
antibiotics like gentamicin, which should be released over a 4-6 week period. Further refinement
of the coating process is also essential to obtain a continuous coating and more consistent release
profile of the growth factors.
In vitro studies demonstrated that both growth factors remained bioactive after being introduced
to the polymer solution and throughout its release. These findings show the ability to deliver
growth factors in a way to mimic the natural healing process of bone in the human body. The
physiological basis for delivering both VEGF and BMP-2 from the same allograft is well
founded given their traditional roles as vasculogenic and osteogenic molecules, respectively. The
additional role of VEGF in stimulating osteoclastogenesis, described in chapter 5 is particularly
beneficial for allograft healing. Allografts show very minimal osteoclast driven remodeling of
the necrotic bone, resulting in microfractures in the graft area. VEGF, turned out to be the
common molecule that has the potential of enhancing allograft healing by inducing angiogenesis
and osteoclastogenesis.
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In future, evaluation of secondary structure of the released protein throughout the study would
further confirm the conformation and denaturation of the protein. In this study, we primarily
focus on the role of VEGF in osteoclastogenesis, using RAW264.7 cells and Bone Marrow
Derived Macrophages (BMMS), both are progenitor cells for osteoclasts. Future studies may
consider evaluating the angiogenesis ability of VEGF, released from the coated allograft.
Utilizing human umbilical vein endothelial cells (HUVECs) or Endothelial progenitor cells
(EPCs), Endothelial progenitor cells (EPCs) display high neovascularization, angiogenic,
proliferative and survival potential in vitro. Detecting antibodies such as vWF, CD31, VECadherin, PECAM-1 as well as DAPI and actin would be critical in confirming endothelial
lineage. To this end, gene expression of Angiopoietin 1, Angiopoietin 2, VEGFA should be
determined using RT-PCR. Moreover, it will be interesting to examine simultaneous effects of
BMP-2 and VEGF released from allografts on osteoblast, osteoclast and endothelial progenitor
cells and depict the crosstalk between growth factor on a cellular level.
Though the use of allograft is the best alternative to autograft by surgeons, allografts demonstrate
reduced incorporation, poor mechanical integrity at the interface, poor mechanical properties of
the allograft as a whole since the tissue is not being remodeled during healing, fracture nonunions, and poor allograft vascularization. Researchers have attempted different approaches to
revitalizing devitalized allografts by creating a synthetic periosteum of cells, binding and
releasing genetic vectors to induce host cells to overexpress important growth factors for bone
remodeling. Each attempt has their own challenges and shortcomings. In our in vivo study we
investigated how simultaneous and sequential delivery of BMP-2 and VEGF can induce not only
bone formation but also graft remodeling which is most essential for overall allograft healing.
Cortical allograft incorporation occurs via reverse creeping substitution, incorporation initiated
188

by osteoclast resorption followed by new bone formation. A method that allowed for the
incorporation and controlled delivery of growth factors implicated in fracture healing and bone
repair would be extremely beneficial in assisting bone-allograft integration and subsequent bone
repair. Given that unstable bone defects (fractures, segmental defects) undergo endochondral
ossification, it may be prudent to develop a factor delivery system that can deliver both BMP-2
and VEGF in temporally controlled patterns specific to that mode of bone repair. To the author’s
knowledge, this is the first account of the simultaneous delivery of VEGF and BMP-2 from
coated allograft to enhance overall healing by stimulating bone formation and remodeling. We
successfully demonstrated that delivering multiple growth factors enhances bone formation over
single growth factor. We also qualitatively assess remodeling of graft and allograft treated with
BMP-2 and VEGF and showed allograft healing by generating remodeled, bony union. Total
number of TRAP positive osteoclasts onto the graft and at graft-host interface would provide us
a quantitative evaluation of remodeling of the graft, since osteoclast resorption initiates the
remodeling and incorporation process in cortical allograft. Additional assessment of mechanical
properties of the structural allografts must be done as these grafts primarily provide immediate
mechanical support.
In conclusion, this simple but effective method of delivering two important molecules with
temporal precision for bone repair may provide the orthopaedic surgeon with a new tool in the
armamentarium for treating large scale bone injuries brought about by tumor resection and
trauma, and may serve to reduce or eliminate the long term complications seen with the
traditional use of devitalized structural allografts
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APPENDIX: PROTOCOL
PROTEIN LOADING PROTOCOL
Encapsulation:
1. Dissolve 50:50 Polylactide-co-glycolide (PLGA) in tetrahydrofuran with a 1:8 w/v ratio.
2. Vortex the solution for 30-45 minutes so that the polymer dissolves completely in the
solvent.
3. Dissolve 500 ug of BMP-2 into 1ml of 20 mM Acetic Acid. Vortex the protein solution
to get a homogenous solution.
4. In order to attain a protein-polymer solution system, add 200 ul of 500 ug/ml
concentrated BMP-2 to the polymer solution dissolved in THF.
NOTE: Do NOT add the full 200 ul of BMP-2 at once to the polymer solution. Add 50 ul
at once and let it dissolve and then add the next aliquot. Adding the full 200 ul protein
solution to the polymer causes precipitation.
5. After adding the 200 ul of protein check the miscibility of the protein-polymer solution, if
it’s homogenous.
6. Coat the allograft samples with BMP-2 encapsulated PLGA coating (following the
coating protocol).
Surface adsorption:
1. Dissolve 50:50 Polylactide-co-glycolide (PLGA) in tetrahydrofuran with a 1:8 w/v ratio.
2. Vortex the solution for 30-45 minutes so that the polymer dissolves completely in the
solvent.
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3. Coat the allografts following the coating protocol.
4. 5 ug of lyophilized protein was provided by sigma.
M= 5 ug = 5 X 10-3 mg
5. The loading concentration of the protein to be surface adsorbed on the allograft was chosen
as 5 ug/ml. In order to attain the concentration add 1 ml of water to the protein vial supplied
by vendor.
6. Place the coated allograft in a centrifuge tube. Add 200 -250 ul of the concentrated protein
solution. Freeze them in -20C freezer for overnight and the lyophilize them.

ELISA PROTOCOL:
1. Prepare all reagents, working standards, control, and samples as directed in the previous
sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch
containing the desiccant pack, and reseal.
3. Add 50 µl of Assay Diluent RD1N to each well.
4. Add 50 µl of Standard, Control, or sample* to each well. Mix by gently tapping the plate
frame for 1 minute. Cover with the adhesive strip provided. Incubate for 2 hours at room
temperature. A plate layout is provided to record standards and samples assayed. Aspirate
each well and wash, repeating the process four times for a total of five washes.
5. Wash by filling each well with Wash Buffer (400 µl) using a squirt bottle, manifold
dispenser, or autowasher. Complete removal of liquid at each step is essential to good
performance. After the last wash, remove any remaining Wash Buffer by aspirating or
decanting. Invert the plate and blot it against clean paper towels.
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6. Add 100 µl of Mouse VEGF Conjugate to each well. Cover with a new adhesive strip.
Incubate for 2 hours at room temperature.
7. Repeat the aspiration/wash as in step 5.
8. Add 100 µl of Substrate Solution to each well. Incubate for 30 minutes at room temperature.
Protect from light.
9. Add 100 µl of Stop Solution to each well. Gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a microplate reader set to
450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength
correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450
nm. This subtraction will correct for optical imperfections in the plate. Readings made
directly at 450 nm without correction may be higher and less accurate.

CELL FEEDING PROTOCOL
1. Turn blower and U.V light on in the hood; make sure all supplies needed are in the hood.
Wait for 15 min.
2. Warm media in 37 C water bath for 20 min.
3. Wipe down hood first with Lysol, then with 70% ethanol
4. Prepare a sterile beaker containing bleach; wipe it down with 70% ethanol.
5. Remove media from the water bath. Wipe off water with paper towel, and then spray with
ethanol.
6. Wipe microscope stand with paper towel spray with 70% ethanol.
7. Remove cell culture flask from incubator, and wipe down with 70% ethanol.
8. Using the microscope examine the confluency/ growth of cells in the culture flask.
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9. Spray ethanol again and place cell culture flask in the hood.
10. Turn vacuum on. Remove a sterile glass pipette and attach to vacuum pump.
11. Place cell culture flask vertically. Remove lid from the cell culture flask, place lid button side
down, and aspirate media. Close cell culture flask.
12. Aspirate bleach with the glass pipette and dispose of the pipette in the glass container.
13. Attach 10ml sterile pipette to the dispenser.
14. Open media, place lid bottom side down, and remove 10ml of media.
15. Close media bottle. Place cell culture flask vertically.
16. Open lid of cell culture flask. Add 10 ml of media to the flask and close lid.
17. Rinse 10 ml pipette by aspirating bleach with it, then dispose the pipette.
18. Place tissue culture flask back in incubator.
19. Remove media, and place back in fridge.
20. Wipe down hood with Lysol and ethanol, turn on U.V light.
21. Rinse vacuum flask with soap and water.
CELL SPLITTING PROTOCOL:
1. Remove cell culture flask from incubator, and wipe down with 70% ethanol.
2. Since the media contains FBS and FBS and trypsin counter attack, all the media should
be suctioned out.
3. Wash the cells with PBS for 2 times.
4. Add 2 ml of trypsin to detach the cells from the surface of the flask.
5. Put the flask in the incubator for 2-1 min depending on how efficiently the cells are being
detached.
6. Look them under the microscope to see the flow of the unattached cells in the flask.
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7. Add 4 ml (2X of trypsin) of media to the flask.
8. Transfer the cell suspension to the centrifuge tube and centrifuge it at 5000 rpm for 10
min.
9. As the cells make pallets, take the media out without interrupting the cell pellet.
10. Add 2 ml of media, vortex it to get a homogenous mixture of cells and media.
11. Take 90 ul of tryphan blue and 10 ul of media with cells. Mix them well.
12. Take 1 ul of the solution (trypan+cell) and count them using hematocytometer.

CELL COUNTING PROTOCOL:

USE OF TRYPAN BLUE STAIN AND THE HEMOCYTOMETER TO DETERMINE TOTAL
CELL COUNTS AND VIABLE CELL NUMBER
1) Prepare a cell suspension in a balanced salt solution (e.g., Hanks= Balanced Salts [HBSS])
2) Transfer 0.5 ml of 0.4% Trypan Blue solution (w/v) to a test tube. Add 0.3 ml of HBSS and
0.2 ml of the cell suspension (dilution factor = 5) and mix thoroughly. Allow to stand for 5 to
15 minutes.
NOTE: If cells are exposed to Trypan Blue for extended periods of time, viable cells, as well as
nonviable cells, may begin to take up dye.
3) With the cover-slip in place, use a Pasteur pipette or other suitable device to transfer a small
amount of Trypan Blue-cell suspension mixture to both chambers of the hemocytometer.
Carefully touch the edge of the cover-slip with the pipette tip and allow each chamber to fill by
capillary action. Do not overfill or underfill the chambers.
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4) Starting with chamber 1 of the hemocytometer, count all the cells in the 1 mm center square
and four 1 mm corner squares. Non- viable cells will stain blue. Keep a separate count of viable
and non-viable cells.
5) Repeat this procedure for chamber 2.
NOTE: If greater than 10% of the cells appear clustered, repeat entire procedure making sure the
cells are dispersed by vigorous pipetting in the original cell suspension as well as the Trypan
Bluecell suspension mixture. If less than 200 or greater than 500 cells (i.e., 20-50 cells/square)
are observed in the 10 squares, repeat the procedure adjusting to an appropriate dilution factor.
6) Withdraw a second sample and repeat count procedure to ensure accuracy.
7) CELL COUNTS: Each square of the hemocytometer, with cover-slip in place, represents a
total volume of 0.1 mm3. Since 1 cm3 is equivalent to approximately 1 ml, the subsequent cell
concentration per ml (and the total number of cells) will be determined using the following
calculations:
CELLS PER ml = the average count per square X dilution factor X 104 (count 10 squares)
TOTAL CELLS = cells per ml x the original volume of fluid from which cell sample was
removed.
8) CELL VIABILITY (%) = total viable cells (unstained) / total cells (stained and unstained)x
100.

MTS ASSAY PROTOCOL:
1. Turn on the plate reader at least 10 minutes before reading results. Use the following settings:
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Wavelength/Bandwidth
Excitation

~480 nm / 20 nm

Emission

~520 nm / 25 nm

2. Thaw the CellTiter 96® AQueous One Solution Reagent.
NOTE: It should take approximately 90 minutes at room temperature on the bench top, or
10 minutes in a water bath at 37°C, to completely thaw the 20 mL size.
3. Remove well plates from incubators at specified time points (d0, d7, d14, d21).
4. Replace each well with 1 mL of fresh basal medium.
5. Pipet 200 µl of CellTiter 96® AQueous One Solution Reagent into each well of the 24-well
assay plate.
6. Incubate the plate for 1 hour at 37°C in a humidified, 5% CO2 atmosphere.
NOTE: To measure the amount of soluble formazan produced by cellular reduction of the
MTS, proceed immediately to Step 8. Alternatively, to measure the absorbance later, add
250 µL of 10% SDS to each well to stop the reaction. Store SDS-treated plates protected
from light in a humidified chamber at room temperature for up to 18 hours. Proceed to
Step 7.
7. In a new 24-well plate, make a 1:4 dilution in dIH2O by adding 0.5 mL of MTS/cell medium
solution from each well to 1.5 mL H2O.
8. Record the absorbance at 492nm using a UV/V is spectrophotometer plate reader.
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ALKALINE PHOSPHATASE QUANTIFICATION (BIORAD):

1. Remove well plates at designated time points and remove medium from each well. Rinse each
well with PBS or Hank’s Balanced Salt Solution and remove.
2. Add 1 mL of 1% Triton-X 100 to lyse cells. Triton is the detergent to break the cell membrane.
If necessary, perform additional freeze-thaw cycles or sonicate well plates to ensure cell lysis.
3. Immediately prior to analysis, mix 1 mL of concentrated diethanolamine buffer and 4 mL of
dIH2O for each p-Nitrophenylphosphate tablet and dissolve completely.
NOTE: Calculate the number of samples to analyze and calculate the total volume of
substrate solution needed. From that, calculate the appropriate number of pNitrophenylphosphate tablets to dissolve.
4. Remove 100 µl of cell lysate from each well and transfer to a new well plate.
5. Add 400 µl of p-Nitrophenylphosphate solution to each well containing cell lysate and
incubate for 30 min at 37°C in a humidified, 5% CO2 atmosphere. Develop until a bright
yellow color of reaction product occurs.
6. Reaction may be stopped by adding 500 µl of 0.4M NaOH to each well.
7. Record the absorbance at 405-420 nm using a UV/Vis spectrophotometer plate reader.
NOTE: Volumes of cell lysate, p-Nitrophenylphosphate substrate solution and NaOH may
be scaled according to the well plate used. For 24-well plates: 100 µl cell lysate + 400 µl
substrate solution + 500 µl NaOH
8. For standard curve: In separate test tubes, prepare a serial dilution of p-Nitrophenol (10
mol/mL) standard solution (from Sigma-Aldrich, #104-1) with 0.02 N NaOH (as below).
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Alkaline
Diluted pTube

Nitrophenyl

#

Solution
(mL)

0.02 N

Phosphatase

NaOH

Activity

(mL)

(Sigma
Units/mL)

1

1

10

1

2

2

9

2

3

4

7

4

4

6

5

6

5

8

3

8

6

10

1

10

9. Take a 1mL aliquot from each tube and place in a new well plate.
10. Record the absorbance at 405-420 nm using a UV/Vis spectrophotometer plate reader using
0.02N NaOH as a reference.
11. Construct a calibration curve of correlating absorbance level with phosphatase activity level
(sigma unit/mL).
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ALIZARIN RED STAINING PROTOCOL
Goal: Calcium deposition
Mineralized matrix synthesis was analyzed with Alizarin Red staining method for calcium
deposition. This technique used a colorimetric analysis based on stabilizing the red matrix
precipitate with Cetylpyridinium Chloride (CPC) to yeild a purple solution.
Material:


4 M Alizarin Red, pH 4.23; add 1.36 g of powder dye to 100 ml of DDI water, use 1N
NaOH to adjust pH.



10% (w/v) Cetylpyridinium Chloride (CPC), pH 7.0; add 10 g of 100 ml of 10 mM
Sodium phospahte Na2PO4. Use 1N HCL to adjust pH [10 mM Na2PO4; dissolve 0.142
in 100 ml]



70% ethanol



PBS w/o Ca or Mg

Procedure:
1. Rinse twice culture/sample with PBS to remove any unattached cells.
2. Rinse culture sample with DDI H2O.
3. Fix in 70% Ethanol for 1 hr @ 4C.
4. Remove ethanol and let air dry for 5-10 minitues.
5. Wash once with DDI H2O.
6. Cover sample in 4M (~500 ul) Alzarin Red and incubate for 10 minutes at RT.
7. Wash samples 5x with DDI H2O (end of stainning assay)
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8. Wash 1x with PBS and store at RT till ready for the test.
9. When ready for the test: place 1 ml of 10% CPC on culture and incubate at RT for 15
mintus. At this point the color will be stable. Samples can be diluted 1:10 in additional
CPC if necessary (if the machine reads “over” you can dilute.)
10. Read on a plate reader at 562 nm.
CULTIVATION OF BONE MARROW MACROPHAGES
1. Sacrifice mice 4-10 weeks old.
2. Dissect the hind limbs and clean the muscle tissue from tibia and femur with a scalpel blade.
3. Separate tibia and femur. Use scalpel blade to chop off the proximal and distal end of each
bone.
4. Using 5 ml syringe and 21g needle, flush marrow with complete media (alpha MEM
supplemented with 10% FBS and 1% pen strep into 50 ml falcon tube.
5. Spin down the marrow for 5 min at 1200 rpm and resuspend then in ACK buffer (1ml/1
mouse).
a. ACK Buffer: Red blood cell lysis buffer:
For 1 liter of RBC (Red Blood Cell) lysing buffer:
>>8.3g NH4Cl (ammonium Chloride)
>>1g NaHCO3 (Sodium bicarbonate)
>>1mL of EDTA (from a stock of 100mM, pH8.2 in miliQ H2O)
>>bring to 1 liter with miliQ H2O
>>filter or autoclave if need sterile
6. Add complete media and spin the cells down.
7. Remove the supernatant and resuspend the cells in complete media.
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8. Seed 100 million of total bone marrow cells in a 10 cm petri dish.
9. Add 30 ng/ml of MCSF to cell culture.
10. Change media the very next day and remove the floating cells.
11. In 3 days the macrophages should form a monolayer of cells and the cells become confluent.
12. Use accutase to lift the cells.
13. Add adequate complete media and spin down the cells to collect a pellet.
14. Resuspend them in complete media.
15. Culture the macrophages in 24 well plate. 150K /well.
16. Add adequate RANKL and MCSF for Osteoclast differentiation.

PREPARATION OF CELLS FOR SEM
1. Fix scaffolds for one hour in 1% (v/v) glutaraldehyde
2. Followed by 3% (v/v) glutaraldehyde for 24 hours
3. Dehydrated in ethanol gradient
a. begin at 10% (v/v)
b. end at 70% (v/v)
4. Air dry for 24 hours
5. Sputter coat with gold/palladium
MODIFIED VON KOSSA FOR HYDROXYAPATITE RESORPTION ASSAY
1. Plates were washed with 1.2% sodium hypochlorite (bleach) solution for 5 min to remove
cells.
a. How to make 1.2% of sodium hypochlorite (bleach) from 10-15% graded sodium
i. 12.5% (avg) -> 12.5 ml in total 100 ml of solution
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To make 1.2% of solution 100X 1.2/12= 10 ml
Take 10 ml from 12.5% v/v sodium hypochlorite solution and add 90 ml
of water.
2. Rinsed with distilled water and air-dried. No PBS.
3. For staining, plates were treated in darkness at ambient temperature with 100 ul/well (400
ul/well in 24 well plates) 5% (w/v) AgNO3 silver nitrate solution for 30 min.
a. How to make 5% (w/v) AgNO3
i. 5% (w/v) AgNO3 solution is 5 g in 100 ml
0.05 g in 1 ml
1 g in 20 ml - 5% (w/v)
4. Wells were then aspirated and washed with distilled water and air-dried. No PBS.
5. Wells were again aspirated, and 100 ul/well 5% (w/v) sodium carbonate in 10% formalin was
added (400 ul/well for 24 well plates).
6. After a 5-min incubation at ambient temperature.
7. The plates were then aspirated and air dried at 500c for 1 hour prior to imaging. Use an
inverted microscope with 20X objective.
Note: we tested this procedure on regular well plates where plates aren’t coated with HA.
The staining procedure doesn’t leave any stains on the regular plates. Therefore under the
microscope the resorption area will show as white as opposed to black staining on HA coated
area.
TRAP assay Protocol:
1. Prewarm sufficient deionized water for a day’s use to 37°C. Check temperature before use.
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2. Bring Fixative Solution to room temperature (18–26°C). Fix slides by immersing in Fixative
Solution for 30 seconds. Rinse thoroughly in deionized water: Do not allow slides to dry.
3. To each of 2 test tubes add 0.5 ml Fast Garnet GBC Base Solution and 0.5 ml Sodium Nitrite
Solution. Mix by gentle inversion for 30 seconds. Let stand 2 minutes.
4. Make the following mixture:
Deionized water prewarmed to 37°C …………………………………………..45 ml
Diazotized Fast Garnet GBC Solution from Step 3………………………..1.0 ml
Naphthol AS-Bl Phosphate Solution……………………………………………. 0.5 ml
Acetate Solution ………………………………………………………………………….2.0 ml
Tartrate Solution……………………………………………………………………….. 1.0 ml
5. Label Coplin jars A and B and transfer solutions from beakers to appropriate Coplin jar. Warm
solutions in jars to 37°C in water bath. Check that temperature is at 37°C before adding slides.
6. Add slides to Coplin jars and incubate 1 hour in 37°C water bath protected from light.
7. After 1 hour, rinse slides thoroughly in deionized water, then counterstain 2 minutes in
Hematoxylin Solution, Gill No. 3.
8. Rinse several minutes in alkaline tap water to blue nuclei.
9. Air dry and evaluate microscopically.
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